Cyclic tetrameric compounds as proprotein convertase subtilisin / kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders

Cyclic tetrameric compounds are developed to address the need for small molecule PCSK9 inhibitors, effectively reducing LDL-C and Lp(a) levels, and treating conditions like hypercholesterolemia and coronary heart disease by modulating PCSK9 activity.

JP7577656B2Active Publication Date: 2024-11-05NOVARTIS AG
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2021529266
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-10-23
Filing Date
2019-11-26
Publication Date
2024-11-05
Estimated Expiration
2039-11-26

AI Technical Summary

Technical Problem

Current treatments for conditions associated with PCSK9, such as hypercholesterolemia and coronary heart disease, rely on anti-PCSK9 antibodies, which can cause side effects, and there is a need for potent small molecule inhibitors.

Method used

Development of cyclic tetrameric compounds that inhibit PCSK9 activity, including their pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers, which can modulate PCSK9 activity and treat associated diseases.

Benefits of technology

The compounds effectively reduce LDL-C levels, lower Lp(a) levels, and inhibit PCSK9 activity, providing therapeutic benefits for conditions like hypercholesterolemia and coronary heart disease without the side effects of antibody treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007577656000001
    Figure 0007577656000001
  • Figure 0007577656000002
    Figure 0007577656000002
  • Figure 0007577656000003
    Figure 0007577656000003
Patent Text Reader

Abstract

The present disclosure provides a compound of formula (I): [Formula 1] or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R1, R1, R1, R1, R1, R1, R1, R1, X1, X2, and X3 are as described herein.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Related Applications This application claims the benefit of and priority to U.S. Provisional Patent Application No. 62 / 772,030, filed November 27, 2018, and U.S. Provisional Patent Application No. 62 / 924,828, filed October 23, 2019, the entire contents of each of which are incorporated herein by reference in their entirety.

[0002] The present disclosure relates to modulators of proprotein convertase subtilisin / kexin type 9 (PCSK9) that are useful in the treatment of diseases or disorders associated with the PCSK9 protease. Specifically, the disclosure relates to compounds and compositions that inhibit PCSK9, methods of treating diseases or disorders associated with PCSK9, and methods of synthesizing these compounds. [Background technology]

[0003] Proprotein convertase subtilisin / kexin type 9 (PCSK9) is a member of the secretory subtilase, subtilisin serine protease family and is expressed in many tissues and cell types. The PCSK9 protein contains a signal sequence, a prodomain, a catalytic domain containing a conserved triad of residues (D186, H226, and S386), and a C-terminal domain. It is synthesized as a soluble 74 kDa precursor that undergoes autocatalytic cleavage in the endoplasmic reticulum. This autocatalytic activity has been shown to be essential for secretion.

[0004] PCSK9 exerts a profound effect on plasma low-density lipoprotein cholesterol (LDL-C) levels through its regulation of the hepatic low-density lipoprotein receptor (LDLR), the primary pathway by which cholesterol is removed from the circulation. PCSK9 binds to LDLR and directs its lysosomal degradation, thereby increasing plasma LDL-C levels and, in turn, increasing the risk of coronary heart disease (CHD) (Maxwell KN, Proc. Natl. Acad. Sci., 101, 2004, 7100-7105; Park, SW, J. Biol. Chem. 279, 2004, 50630-50638; Lagace TA, et. al. J. Clin. Invest. 2006, 116(11):2995-3005). Overexpression of mouse or human PCSK9 in mice has been shown to increase total C and LDL-C levels and dramatically reduce hepatic LDLR protein levels without any discernible effects on mRNA levels, SREBP levels, or the nuclear-to-cytoplasmic ratio of SREBP protein (Maxwell KN, Proc. Natl. Acad. Sci. 101, 2004, 7100-7105). Furthermore, PCSK9 mutations that cause loss of PCSK9 function in mouse models have also been shown to reduce total C and LDL-C levels (Cohen, JC, et al., N. Engl. J. Med., 354, 2006, 1264-1272). Thus, these results indicate that modulation of PCSK9 leads to a reduction in LDLR protein levels.

[0005] Genetic deletion of PCSK9 has also been performed in mice. PCSK9 knockout mice show approximately 50% reduction in plasma cholesterol levels and enhanced sensitivity to statins in lowering plasma cholesterol (Rashid, S., et al., Proc. Natl. Acad. Sci., 2005, 102:5374-5379). Human genetic data strongly support the role of PCSK9 in maintaining LDL homeostasis. The association between PCSK9 and plasma LDL-C levels was initially established by the discovery of a PCSK9 missense mutation in patients with autosomal dominant familial hypercholesterolemia (Abifadel, M., et al., Nature, 2003, 34:154-6). Patients carrying PCSK9 gain-of-function alleles exhibit increased plasma LDL-C levels and premature CHD, whereas patients carrying PCSK9 loss-of-function alleles exhibit significantly reduced plasma LDL-C and are protected from CHD.

[0006] PCSK9 also plays a role in the metabolism of lipoprotein(a) (Lp(a)). Lp(a) is a proatherogenic lipoprotein composed of LDL particles covalently linked to apoLp(a). Human genetic studies have implicated Lp(a) in causal association with CHD risk. PCSK9 therapeutic antibodies have been shown to significantly reduce Lp(a) levels in patients with hypercholesterolemia (Desai, NR, et. al., Circulation. 2013, 128(9):962-969; Lambert, G., et. al., Clin. Sci., 2017, 131, 261-268). Treatment of patients receiving statin therapy with a monoclonal antibody against PCSK9 reduced Lp(a) levels by up to 32% compared to placebo (Desai NR, et.al., Circulation. 2013, 128(9):962-969).

[0007] In addition to its cardiovascular effects, PCSK9 plays an important role in sepsis, a life-threatening condition caused by the body's response to infection. Overexpression of PCSK9 in septic mice has been shown to exacerbate sepsis by increasing inflammation, whereas PCSK9 inhibition has been shown to reduce mortality (Dwivedi, DJ, et al., Shock, 2016, 46(6), 672-680). Furthermore, flow cytometry studies in human HepG2 cells have shown that PCSK9 negatively regulates hepatocyte uptake of Gram-negative lipopolysaccharide (LPS) through an LDL-dependent mechanism, regulating LDLR-mediated uptake of bacterial lipids, including lipoteichoic acid (LTA) and LPS (Grin, PM, et al., Nature, 2018, 8(1):10496). Therefore, PCSK9 inhibition may potentially treat sepsis by reducing the body's immune response to infection. Summary of the Invention [Problem to be solved by the invention]

[0008] Currently, there are no known small molecule PCSK9 inhibitors. The only known commercially available PCSK9 inhibitors are anti-PCSK9 antibodies. Therefore, inhibition of PCSK9 with small molecule inhibitors offers the potential for treating a variety of diseases, including hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral vascular disease, peripheral arterial disease, vascular inflammation, elevated Lp(a), elevated LDL, triglyceride-rich lipoprotein (TRL), elevated triglycerides, sepsis, xanthomas, and other disorders. For these reasons, there remains a need for novel, potent small molecule PCSK9 inhibitors. [Means for solving the problem]

[0009] A first aspect of the present disclosure is a compound of formula (I): [ka] and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof [In formula: X1 and X2 are each independently H or (C1-C6) alkyl, or X1 and X2 together with the carbon atom to which they are attached form =(O); X3 is -CH2- when X1 and X2 are each independently H or (C1-C6) alkyl, or -CH2- when X1 and X2 together with the carbon atom to which they are attached form =(O), or -O-, -NH- or -N(C1-C6) alkyl- when X1 and X2 together with the carbon atom to which they are attached form =(O); R1 is (C6~C 10 ) aryl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are -OR 10 or -NR 21 R 10 and optionally one or more R 11 is replaced by; R2 is H, (C1-C6) alkyl, (C2-C6) alkenyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, (C3-C7)cycloalkenyl, 5- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, (C6-C 10 ) aryl, or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains one or more R 18 and carbocyclyl, cycloalkenyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one or more R 19 is replaced by; R3 is H, D, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, or (C1-C6)hydroxyalkyl, where alkyl is optionally selected from the group consisting of one or more R 14is replaced by; R4 is H or (C1-C6) alkyl; or R3 and R4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1 to 3 heteroatoms selected from N, O, and S; R5 and R7 are each independently H, D, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, or (C1-C6) hydroxyalkyl, wherein the (C1-C6) alkyl is optionally substituted with one or more D; R6 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, or (C1-C6)hydroxyalkyl, wherein the alkyl is optionally substituted with one or more substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl; R8 is H, (C1-C6) alkyl, or (C1-C6) haloalkyl, where alkyl is optionally selected from (C3-C7) carbocyclyl, 4- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, -NR 16 R 17 , and -C(O)NR 16 R 17 substituted with one or more substituents each independently selected from: R9 is halogen, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, -OH, or CN; R 10 (C6~C 10 ) aryl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally joined by one or more R 22 is replaced by; Each R 11is independently at each occurrence halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, —OH, or CN; R 12 and R 13 are each independently H or (C1-C6) alkyl; Each R 14 is independently calculated for each occurrence, D, NR 15 R 15’ , (C3-C7)carbocyclyl, or 3- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more substituents each independently selected from halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, and (C1-C6)haloalkoxy; R 15 and R 15’ are each independently H or (C1-C6) alkyl; R 16 and R 17 are each independently H or (C1-C6) alkyl; R 16 and R 17 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocyclyl ring optionally containing 1-2 additional heteroatoms selected from N, O, and S; Each R 18 is independently selected at each occurrence from (C3-C7)carbocyclyl, 5- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, (C6-C 10 ) aryl, or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein carbocyclyl, heterocyclyl, aryl, and heteroaryl optionally contain one or more R 20 is replaced by; Each R 19is independently at each occurrence halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, —OH, or CN; or The Two R's 19 are together on adjacent atoms, (C6~C 10 ) form an aryl, or a 5- or 6-membered heteroaryl ring containing 1-3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally substituted with one or more substituents each independently selected from halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, —OH, and CN; Each R 20 is independently at each occurrence halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, oxo, —OH, or CN; or R 18 When is carbocyclyl or heterocyclyl, two R 20 When attached to the same carbon atom, they join together to form =(O); R 21 is H or (C1-C6) alkyl; Each R 22 is independently selected at each occurrence from halogen, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, -OH, CN, (C6-C 10 ) aryl, or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally joined by one or more R 23 is replaced by; Each R 23 is independently at each occurrence halogen, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, -CH2(OCH2CH2) 1~3OCH2CH3, -OH, CN, or a 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the heterocyclyl is optionally selected from halogen, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, -OH, -C(O)R 24 , -NR 24 C(O)R 25 , —NH, —NH(C-C)alkyl, and —N((C-C)alkyl) and the alkyl is optionally substituted with one or more substituents each independently selected from —NR 24 R 25 or a 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, optionally substituted with one or more substituents each independently selected from halogen, (C-C)alkyl, (C-C)alkoxy, (C-C)haloalkyl, (C-C)haloalkoxy, —OH, —NH, —NH(C-C)alkyl, and —N((C-C)alkyl); and R 24 and R 25 are each independently H, (C1-C6) alkyl, or (C3-C7) carbocyclyl optionally substituted with 1-2 (C1-C6) alkyls; or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof.

[0010] In another aspect, the present disclosure provides a compound of formula (I), wherein: X1 and X2 are each independently H or (C1-C6) alkyl, or X1 and X2 together with the carbon atom to which they are attached form =(O); X3 is -CH2- when X1 and X2 are each independently H or (C1-C6) alkyl, or -CH2- when X1 and X2 together with the carbon atom to which they are attached form =(O), or -O-, -NH- or -N(C1-C6) alkyl- when X1 and X2 together with the carbon atom to which they are attached form =(O); R1 is (C6~C 10 ) aryl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are -OR 10 or -NR 21 R 10 and optionally one or more R 11 is replaced by; R2 is H, (C1-C6) alkyl, (C2-C6) alkenyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, (C3-C7)cycloalkenyl, 5- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, (C6-C 10 ) aryl, or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains one or more R 18 and carbocyclyl, cycloalkenyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one or more R 19 is replaced by; R3 is H, D, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, or (C1-C6)hydroxyalkyl, where alkyl is optionally selected from the group consisting of one or more R 14 is replaced by; R4 is H or (C1-C6) alkyl; or R3 and R4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1 to 3 heteroatoms selected from N, O, and S; R5 and R7 are each independently H, D, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, or (C1-C6) hydroxyalkyl, wherein the (C1-C6) alkyl is optionally substituted with one or more D; R6 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, or (C1-C6)hydroxyalkyl, wherein the alkyl is optionally substituted with one or more substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl; R8 is H, (C1-C6) alkyl, or (C1-C6) haloalkyl, where alkyl is optionally selected from (C3-C7) carbocyclyl, 4- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, -NR 16 R 17 , and -C(O)NR 16 R 17 substituted with one or more substituents each independently selected from: R9 is halogen, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, -OH, or CN; R 10 (C6~C 10 ) aryl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally joined by one or more R 22 is replaced by; Each R 11 is independently at each occurrence halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, —OH, or CN; R 12 and R 13 are each independently H or (C1-C6) alkyl; Each R14 is independently calculated for each occurrence, D, NR 15 R 15’ , (C3-C7)carbocyclyl, or 3- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more substituents each independently selected from halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, and (C1-C6)haloalkoxy; R 15 and R 15’ are each independently H or (C1-C6) alkyl; R 16 and R 17 are each independently H or (C1-C6) alkyl; R 16 and R 17 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocyclyl ring containing 1-2 additional heteroatoms selected from N, O, and S; Each R 18 is independently selected at each occurrence from (C3-C7)carbocyclyl, 5- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, (C6-C 10 ) aryl, or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein carbocyclyl, heterocyclyl, aryl, and heteroaryl optionally contain one or more R 20 is replaced by; Each R 19 is independently at each occurrence halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, —OH, or CN; or The Two R's 19 are together on adjacent atoms, (C6~C 10) form an aryl, or a 5- or 6-membered heteroaryl ring containing 1-3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally substituted with one or more substituents each independently selected from halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, —OH, and CN; Each R 20 is independently at each occurrence halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, oxo, —OH, or CN; or R 18 When is carbocyclyl or heterocyclyl, two R 20 When attached to the same carbon atom, they join together to form =(O); R 21 is H or (C1-C6) alkyl; Each R 22 is independently selected at each occurrence from halogen, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, -OH, CN, (C6-C 10 ) aryl, or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally joined by one or more R 23 is replaced by; Each R 23 is independently at each occurrence halogen, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, -CH2(OCH2CH2) 1~3 OCH2CH3, -OH, CN, or a 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the heterocyclyl is optionally selected from halogen, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, -OH, -C(O)R 24 , -NR 24 C(O)R 25, —NH, —NH(C-C)alkyl, and —N((C-C)alkyl) and the alkyl is optionally substituted with one or more substituents each independently selected from —NR 24 R 25 or a 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, optionally substituted with one or more substituents each independently selected from halogen, (C-C)alkyl, (C-C)alkoxy, (C-C)haloalkyl, (C-C)haloalkoxy, —OH, —NH, —NH(C-C)alkyl, and —N((C-C)alkyl); and R 24 and R 25 are each independently H, (C1-C6) alkyl, or (C3-C7) carbocyclyl; or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof.

[0011] Another aspect of the present disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment, prevention, amelioration or delay of progression of a PCSK9-mediated disease or disorder, or for use in the treatment, prevention, amelioration or delay of progression of a disease or disorder requiring inhibition of PCSK9 or PCSK9 activity.

[0012] In another aspect, the disclosure relates to the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, for the treatment, prevention, amelioration or delay of progression of a PCSK9-mediated disease or disorder, or for the treatment, prevention, amelioration or delay of progression of a disease or disorder requiring inhibition of PCSK9 or PCSK9 activity.

[0013] Another aspect of the present disclosure relates to the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment, prevention, amelioration or delay of progression of a PCSK9-mediated disease or disorder, or for the treatment, prevention, amelioration or delay of progression of a disease or disorder requiring inhibition of PCSK9 or PCSK9 activity.

[0014] In another aspect, the present disclosure relates to a method for treating, preventing, ameliorating, or delaying the progression of a PCSK9-mediated disease or disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) according to the present disclosure, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof.

[0015] Another aspect of the present disclosure relates to a method of treating, preventing, ameliorating, or delaying progression of a PCSK9-mediated disease or disorder or a disease or disorder requiring inhibition of PCSK9 or PCSK9 activity, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) according to the present disclosure, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof.

[0016] In another aspect, the present disclosure relates to a method for treating, preventing, inhibiting, or removing hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral vascular disease, vascular inflammation, xanthomas, peripheral arterial disease, sepsis, elevated Lp(a), elevated LDL, elevated TRL, or elevated triglycerides, comprising the step of administering a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

[0017] Another aspect of the present disclosure relates to a method of (i) lowering Lp(a), (ii) lowering Lp(a) plasma levels, (iii) lowering Lp(a) serum levels, (iv) lowering serum TRL or LDL levels, (v) lowering serum triglyceride levels, (vi) lowering LDL-C, (vii) lowering total plasma apoB concentration, (viii) lowering LDL apoB, (ix) lowering TRL apoB, or (x) lowering non-HDL-C, comprising administering a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

[0018] In another aspect, the present disclosure also relates to a method of (i) lowering LDL-C, (ii) lowering total apolipoprotein B (apoB), (iii) lowering LDL apoB, (iv) lowering TRL apoB, or (v) lowering non-HDL-C, and combinations thereof, in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0019] Another aspect of the present disclosure relates to a method of lowering the total plasma concentration of a marker selected from (i) LDL-C, (ii) apoB, (iii) LDL apoB, (iv) TRL apoB, and (v) non-HDL-C, and combinations thereof, in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0020] In another aspect, the present disclosure relates to pharmaceutical compositions comprising (e.g., a therapeutically effective amount of) a compound of formula (I), or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients.

[0021] Another aspect of the present disclosure relates to a pharmaceutical composition comprising (e.g., a therapeutically effective amount of) a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients, for use in treating a PCSK9-mediated disease or disorder.

[0022] In another aspect, the present disclosure relates to a method for modulating PCSK9, comprising administering a compound of formula (I), or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

[0023] Another aspect of the present disclosure relates to a method of inhibiting PCSK9, comprising administering to a patient in need thereof a compound of formula (I), or a pharmaceutically acceptable salt thereof. In another aspect, the present disclosure relates to a method of inhibiting PCSK9 activity, comprising administering to a patient in need thereof a compound of formula (I), or a pharmaceutically acceptable salt thereof.

[0024] In another aspect, the present disclosure relates to a method of treating a PCSK9-mediated disease or disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.

[0025] Another aspect of the present disclosure relates to a method of lowering LDL-C in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, thereby lowering the patient's LDL-C.

[0026] In another aspect, the present disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of a PCSK9-mediated disease or disorder.

[0027] Another aspect of the present disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of a PCSK9-mediated disease or disorder selected from hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral vascular disease, peripheral arterial disease, vascular inflammation, elevated Lp(a), elevated LDL, elevated TRL, elevated triglycerides, sepsis, and xanthomas.

[0028] In another aspect, the present disclosure relates to the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a PCSK9-mediated disease or disorder.

[0029] Another aspect of the present disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for the treatment of a disease associated with inhibiting PCSK9 activity.

[0030] In another aspect, the present disclosure relates to the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the treatment of a disease associated with the inhibition of PCSK9 activity.

[0031] In certain embodiments, the PCSK9 modulating or inhibiting compounds of the present disclosure may be administered alone or in combination with other compounds, including other PCSK9 modulating or inhibiting agents, or other therapeutic agents.

[0032] Thus, in another aspect, the disclosure relates to a combination comprising (eg, a therapeutically effective amount of) a compound of formula (I), or a pharmaceutically acceptable salt thereof, and one or more therapeutically active agents.

[0033] Another aspect of the present disclosure is a method for preparing a compound of formula (II), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, N-oxide, or tautomer thereof. [ka] [In the formula, R a1 and R5 are each independently (C1-C6 alkyl), and R9 is as defined above for formula (I); (a) A compound of formula (IIa) or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, N-oxide, or tautomer thereof: [ka] wherein R5 is H and R9 is as defined above for formula (I), Alkylation with an alkyl halide (e.g., methyl iodide, ethyl iodide, etc.) and a base (e.g., NaH) in a solvent (e.g., DMF, acetonitrile, etc.) at low temperature to give a compound of formula (IIb) [ka] wherein R5 is (C1-C6 alkyl) and R9 is as defined above for formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, N-oxide, or tautomer thereof; (b) reacting a compound of formula (IIb), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, N-oxide, or tautomer thereof, with an acid (e.g., trifluoroacetic acid) in a solvent (e.g., dichloromethane), followed by reaction with BocO and a base (e.g., N,N-diisopropylethylamine (DIPEA)) to produce a compound of formula (IIc): [ka] wherein R5 is (C1-C6 alkyl) and R9 is as defined above for formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, N-oxide, or tautomer thereof; (c) alkylating a compound of formula (IIc), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, N-oxide, or tautomer thereof, with an alkylating agent (e.g., methyl iodide, ethyl iodide, etc.) in a solvent (e.g., DMF, acetonitrile, etc.), and optionally a metal oxide (e.g., silver(I) oxide (AgO), etc.) to obtain a compound of formula (IId): [ka] [In the formula, R a1 and R5 are each independently (C1-C6 alkyl), and R9 is as defined above for formula (I)] or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, N-oxide, or tautomer thereof; and (d) deallylating the compound of formula (IId) with a palladium catalyst (e.g., tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4) and N,N-dimethyltrimethylsilylamine in a solvent (e.g., DCM) to provide a compound of formula (II). In one embodiment, the palladium catalyst is tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4).

[0034] In another aspect, the present disclosure provides a method for preparing a compound of formula (II), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, N-oxide, or tautomer thereof. [ka] [In the formula, R a1 is H, R5 is (C1-C6 alkyl), and R9 is as defined above for formula (I), and a compound of formula (IIb): [ka] wherein R5 is (C1-C6 alkyl), and R9 is as defined above for formula (I), with a palladium catalyst (e.g., tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4)) and N,N-dimethyltrimethylsilylamine in a solvent (e.g., DCM) to provide a compound of formula (II). In one embodiment, the palladium catalyst is tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4).

[0035] Unless otherwise defined, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. As used herein, the singular also includes the plural unless the context clearly dictates otherwise. Although methods and materials similar or equivalent to those described herein can be used in the practice and testing of this disclosure, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference. References cited herein are not admitted to be prior art to the claimed disclosure. In case of conflict, the present specification, including definitions, will control. Additionally, the materials, methods, and examples are illustrative only and are not intended to be limiting.

[0036] Other features and advantages of the present disclosure will become apparent from the following detailed description and claims. DETAILED DESCRIPTION OF THE INVENTION

[0037] The present disclosure relates to compounds and compositions capable of modulating the activity of PCSK9. The disclosure features methods for treating, preventing, or ameliorating diseases or disorders in which PCSK9 plays a role by administering a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, to a patient in need thereof. The disclosed methods can be used in the treatment of various PCSK9-dependent diseases and disorders by modulating or inhibiting PCSK9. Inhibition or modulation of PCSK9 provides novel approaches to treating, preventing, or ameliorating diseases, including, but not limited to, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral vascular disease (including aortic disease and cerebrovascular disease), peripheral arterial disease, vascular inflammation, elevated Lp(a), elevated LDL, elevated TRL, elevated triglycerides, sepsis, and xanthomas.

[0038] By inhibiting PCSK9, the compounds of the disclosure have utility in treating hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral vascular disease, peripheral arterial disease, vascular inflammation, elevated Lp(a), elevated LDL, elevated TRL (e.g., elevated VLDL and / or chylomicrons), elevated triglycerides, sepsis, and xanthomas.

[0039] For example, the compound of formula (I) of the present disclosure binds to PCSK9, thereby inhibiting PCSK9 and / or PCSK9 activity, as PCSK9 can no longer bind to low-density lipoprotein receptor (LDLR) or any other target receptor. For example, when PCSK9 is blocked, more LDLR is recycled and present on the surface of cells to remove LDL particles from extracellular fluid. Therefore, blocking PCSK9 can reduce the concentration of LDL particles in the blood.

[0040] As such, the compounds of the present disclosure may in turn be potentially useful in treating, preventing, ameliorating, or delaying progression of PCSK9-mediated diseases or disorders, or diseases or disorders in which PCSK9 plays a role, as well as conditions, diseases and disorders that benefit from modulation of PCSK9 or PCSK9 activity.

[0041] Additionally, compounds of the present disclosure may in turn be potentially useful in treating, preventing, ameliorating, or delaying progression of diseases or disorders requiring inhibition of PCSK9 or PCSK9 activity.

[0042] Such diseases and disorders include diseases or disorders selected from hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral vascular disease, peripheral arterial disease, vascular inflammation, elevated Lp(a), elevated LDL, elevated TRL (e.g., elevated VLDL and / or chylomicrons), elevated triglycerides, sepsis, and xanthomas.

[0043] Various embodiments of the present disclosure are described herein, and it will be recognized that the features specified in each embodiment may be combined with other features specified in other embodiments to provide further embodiments.

[0044] In a first aspect of the present disclosure, a compound of formula (I): [ka] and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, N-oxides, and tautomers thereof (wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X1, X2, and X3 are as described herein above).

[0045] The accompanying description below provides details of the present disclosure. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, exemplary methods and materials are described herein. Other features, objects, and advantages of the present disclosure will become apparent from this description and the claims. In this specification and the appended claims, the singular also includes the plural unless the context clearly dictates otherwise. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. All patents and publications cited herein are incorporated by reference in their entirety.

[0046] Terms and Conventional Definitions Used Terms not specifically defined herein should be given the meaning that one of ordinary skill in the art would give them in light of the present disclosure and the context. However, as used in this specification and the appended claims, unless otherwise specified, the following terms shall have the meaning indicated and shall observe the following conventions.

[0047] Chemical Nomenclature, Terminology, and Usage In the groups, radicals, or moieties defined below, the number of carbon atoms is often specified before the group, e.g., (C1-C 10 ) alkyl means an alkyl group or radical having 1 to 10 carbon atoms. Generally, for groups containing two or more subgroups, the last-named radical is the point of attachment of the radical; for example, "alkylaryl" means a monovalent radical of formula alkyl-aryl-, while "arylalkyl" means a monovalent radical of formula aryl-alkyl-. Furthermore, the use of a term designating a monovalent radical where a divalent radical is appropriate shall be construed to designate the respective divalent radical, and vice versa. Unless otherwise specified, conventional definitions of terms shall prevail, and conventional stable valences are assumed and achieved in all formulas and radicals. The articles "a" and "an" are used in this disclosure to refer to one or more than one (e.g., at least one) of the grammatical referent of the article. By way of example, "an element" means one element or more than one element.

[0048] The term "and / or" is used in this disclosure to mean either "and" or "or," unless otherwise indicated.

[0049] The term "optionally substituted" means that a given chemical moiety (e.g., an alkyl group) may (but need not) be bound to other substituents (e.g., heteroatoms). For example, an optionally substituted alkyl group can be a fully saturated alkyl chain (e.g., pure hydrocarbon). Alternatively, the same optionally substituted alkyl group can have a substituent other than hydrogen. For example, it may be bound at any point along the chain to a halogen atom, a hydroxyl group, or any other substituent described herein. Thus, the term "optionally substituted" means that a given chemical moiety may contain other functional groups, but does not necessarily have any additional functional groups. Suitable substituents used for optional substitution of the described groups include, without limitation, halogen, oxo, -OH, -CN, -COOH, -CHCN, -O-(C-C)alkyl, (C-C)alkyl, (C-C)alkoxy, (C-C)haloalkyl, (C-C)haloalkoxy, -O-(C-C)alkenyl, -O-(C-C)alkynyl, (C-C)alkenyl, (C-C)alkynyl, -OH, -OP(O )(OH)2, —OC(O)(C1-C6)alkyl, —C(O)(C1-C6)alkyl, —OC(O)O(C1-C6)alkyl, —NH2, —NH((C1-C6)alkyl), —N((C1-C6)alkyl)2, —NHC(O)(C1-C6)alkyl, —C(O)NH(C1-C6)alkyl, —S(O)2(C1-C6)alkyl, —S(O)NH(C1-C6)alkyl, and S(O)N((C1-C6)alkyl)2. The substituents themselves may be optionally substituted. "Optionally substituted," as used herein, also refers to substituted or unsubstituted, the meaning of which is defined below.

[0050] The term "substituted" means that the specified group or moiety bears one or more suitable substituents, where the substituents may be linked to the specified group or moiety at one or more positions. For example, an aryl substituted with a cycloalkyl may indicate that the cycloalkyl is linked to an atom of the aryl by a bond or by fusion with the aryl and sharing two or more common atoms.

[0051] The term "unsubstituted" means that the specified group bears no substituents.

[0052] Unless otherwise specifically defined, "aryl" refers to a cyclic aromatic hydrocarbon group having one to three aromatic rings, including monocyclic or bicyclic groups such as phenyl, biphenyl, or naphthyl. When containing two aromatic rings (e.g., bicyclic), the aromatic rings of the aryl group are optionally joined at a single point (e.g., biphenyl) or fused (e.g., naphthyl). Aryl groups are optionally substituted at any point of attachment with one or more substituents, e.g., 1 to 5 substituents. Exemplary substituents include, but are not limited to, -H, -halogen, -CN, -O-(C-C)alkyl, (C-C)alkyl, -O-(C-C)alkenyl, -O-(C-C)alkynyl, (C-C)alkenyl, (C-C)alkynyl, -OH, -O-P(O)(OH), -OC(O)(C-C)alkyl, -C(O)(C-C)alkyl, -OC(O)O(C-C)alkyl, NH, NH((C-C)alkyl), N((C-C)alkyl), -S(O)-(C-C)alkyl, -S(O)NH(C-C)alkyl, and S(O)N((C-C)alkyl). These substituents are themselves optionally substituted. Furthermore, when containing two fused rings, the aryl group optionally has an unsaturated or partially saturated ring fused to a fully saturated ring. Exemplary ring systems of these aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, anthracenyl, phenalenyl, phenanthrenyl, indanyl, indenyl, tetrahydronaphthalenyl, tetrahydrobenzoannurenyl, and the like.

[0053] Unless otherwise specifically defined, "heteroaryl" refers to a monovalent monocyclic aromatic group of 5 to 24 ring atoms or a polycyclic aromatic group containing one or more ring heteroatoms selected from N, O, or S, with the remaining ring atoms being C. Heteroaryl, as defined herein, also refers to a bicyclic heteroaromatic group in which the heteroatoms are selected from N, O, or S. The aromatic group is optionally substituted independently with one or more substituents described herein. Examples include, but are not limited to, furyl, thienyl, pyrrolyl, pyridyl, pyridyl N-oxide, pyrazolyl, pyrimidinyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrazinyl, indolyl, thiophen-2-yl, quinolyl, benzopyranyl, isothiazolyl, thiazolyl, thiadiazole, indazole, benzimidazolyl, thieno[3,2-b]thiophene, triazolyl, thiazolyl, thiadiazole, thiazolyl ...zolyl, thiazolyl, thiazolyl, thiazolyl, thiazolyl, thiazolyl, thiazolyl, thia Zolyl, triazinyl, imidazo[1,2-b]pyrazolyl, furo[2,3-c]pyridinyl, imidazo[1,2-a]pyridinyl, indazolyl, pyrrolo[2,3-c]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrazolo[3,4-c]pyridinyl, thieno[3,2-c]pyridinyl, thieno[2,3-c]pyridinyl, thieno[2,3-b]pyridinyl, benzothiazolyl, indolyl, indolinyl , indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, benzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, dihydrobenzoxanyl, quinolinyl, isoquinolinyl, 1,6-naphthyridinyl, benzo[de]isoquinolinyl, pyrido[4,3-b][1,6]naphthyridinyl, thieno[2,3- b]pyrazinyl, quinazolinyl, tetrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, isoindolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,4-b]pyridinyl, pyrrolo[3,2-b]pyridinyl, imidazo[5,4-b]pyridinyl, pyrrolo[1,2-a]pyrimidinyl, tetrahydropyrrolo[1,2-a]pyrimidinyl, 3,4-dihydro-2H-1Δ 2-pyrrolo[2,1-b]pyrimidine, dibenzo[b,d]thiophene, pyridin-2-one, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, 1H-pyrido[3,4-b][1,4]thiazinyl, benzoxazolyl, benzisoxazolyl, furo[2,3-b]pyridinyl, benzothiophenyl, 1,5-naphthyridinyl, furo[3,2-b]pyridine, [1,2,4]triazolo[l,5-a]pyridinyl, benzo[1,2 ,3]triazolyl, imidazo[1,2-a]pyrimidinyl, [1,2,4]triazolo[4,3-b]pyridazinyl, benzo[c][1,2,5]thiadiazolyl, benzo[c][1,2,5]oxadiazole, 1,3-dihydro-2H-benzo[d]imidazol-2-one, 3,4-dihydro-2H-pyrazolo[1,5-b][1,2]oxazinyl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridinyl, thiazolo[5,4 d]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, thieno[2,3-b]pyrrolyl, 3H-indolyl, and derivatives thereof. Furthermore, when containing two fused rings, an aryl group as defined herein can have an unsaturated or partially saturated ring fused to a fully saturated ring. Exemplary ring systems of these heteroaryl groups include indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, 3,4-dihydro-1H-isoquinolinyl, 2,3-dihydrobenzofuran, indolinyl, indolyl, and dihydrobenzoxanyl.

[0054] "Halogen" or "halo" means fluorine, chlorine, bromine, or iodine.

[0055] "Alkyl" means a straight or branched chain saturated hydrocarbon containing from 1 to 12 carbon atoms. Examples of (C1-C6) alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, and isohexyl.

[0056] "Alkoxy" means a straight or branched chain saturated hydrocarbon containing 1 to 12 carbon atoms including a terminal "O" in the chain, e.g., -O(alkyl). Examples of alkoxy groups include, without limitation, methoxy, ethoxy, propoxy, butoxy, t-butoxy, or pentoxy groups.

[0057] "Alkenyl" refers to a straight-chain or branched-chain unsaturated hydrocarbon containing 2 to 12 carbon atoms. An "alkenyl" group contains at least one double bond in the chain. The double bond of an alkenyl group can be unconjugated or conjugated to another unsaturated group. Examples of alkenyl groups include ethenyl, propenyl, n-butenyl, isobutenyl, pentenyl, or hexenyl. Alkenyl groups can be unsubstituted or substituted and can be straight-chain or branched.

[0058] "Alkynyl" refers to a straight or branched chain unsaturated hydrocarbon containing 2 to 12 carbon atoms. An "alkynyl" group contains at least one triple bond in the chain. Examples of alkenyl groups include ethynyl, propargyl, n-butynyl, isobutynyl, pentynyl, or hexynyl. Alkynyl groups can be unsubstituted or substituted.

[0059] "Cycloalkyl" means a monocyclic or polycyclic saturated carbocyclic ring containing 3 to 18 carbon atoms. Examples of cycloalkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl, cyclooctanyl, norbornanyl, norbornenyl, bicyclo[2.2.2]octanyl, or bicyclo[2.2.2]octenyl and derivatives thereof. A (C3-C8)cycloalkyl is a cycloalkyl group containing 3 to 8 carbon atoms. Cycloalkyl groups may be fused (e.g., decalin) or bridged (e.g., norbornane).

[0060] "Carbocyclyl" refers to a monocyclic or polycyclic saturated or partially unsaturated carbocycle containing 3 to 18 carbon atoms (e.g., cycloalkyl, cycloalkenyl, cycloalkynyl, etc.). Examples of carbocyclyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptanyl, cyclooctanyl, norbornanyl, norbornenyl, bicyclo[2.2.2]octanyl, or bicyclo[2.2.2]octenyl and derivatives thereof. A (C3-C8)carbocyclyl is a carbocyclyl group containing 3 to 8 carbon atoms. Carbocyclyl groups may be fused (e.g., decalin) or bridged (e.g., norbornane).

[0061] The term "cycloalkenyl" refers to a partially unsaturated carbocyclic ring containing 3 to 18 carbon atoms, preferably 4 to 12 carbon atoms, and one or two double bonds. Exemplary cycloalkenyl groups include cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclohexadienyl, and cycloheptadienyl. A (C3-C8)cycloalkenyl is a cycloalkenyl group containing 3 to 8 carbon atoms and at least one double bond.

[0062] "Heterocycloalkyl" means a saturated monocyclic or polycyclic ring containing carbon and at least one heteroatom selected from oxygen, nitrogen, or sulfur (O, N, or S), and lacking delocalized n-electrons (aromaticity) shared between the ring carbons or heteroatoms. The heterocycloalkyl ring structure may be substituted with one or more substituents. The substituents themselves may also be optionally substituted. Examples of heterocycloalkyl rings include, but are not limited to, oxetanyl, azetadinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl, tetrahydropyranyl, dioxalinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, piperazinyl, azepinyl, oxepinyl, diazepinyl, tropanyl, oxazolidinonyl, 1,4-dioxanyl, dihydrofuranyl, 1,3-dioxolanyl, imidazolidinyl, imidazolinyl, dithiolanyl, and homotropanyl.

[0063] "Heterocyclyl" means a saturated (e.g., heterocycloalkyl ring) or partially unsaturated monocyclic or polycyclic ring containing carbon and at least one heteroatom selected from oxygen, nitrogen, or sulfur (O, N, or S), and lacking delocalized n-electrons (aromaticity) shared between the ring carbons or heteroatoms. The heterocyclyl ring structure may be substituted with one or more substituents. The substituents themselves may also be optionally substituted. Examples of heterocyclyl rings include, but are not limited to, oxetanyl, azetadinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, dihydropyrrolidinyl, pyridin-2(1H)-one, dihydropyridinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl, tetrahydropyranyl, dioxalinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, piperazinyl, azepinyl, oxepinyl, diazepinyl, tropanyl, oxazolidinonyl, 1,4-dioxanyl, dihydrofuranyl, 1,3-dioxolanyl, imidazolidinyl, imidazolinyl, dithiolanyl, and homotropanyl.

[0064] "Hydroxyalkyl" means an alkyl group substituted with one or more -OH groups. Examples of hydroxyalkyl groups include HO-CH2-, HO-CH2CH2-, and CH2-CH(OH)-.

[0065] "Haloalkyl" means an alkyl group that is substituted with one or more halogens. Examples of haloalkyl groups include, but are not limited to, trifluoromethyl, difluoromethyl, pentafluoroethyl, trichloromethyl, and the like.

[0066] "Haloalkoxy" means an alkoxy group substituted with one or more halogens. Examples of haloalkyl groups include, but are not limited to, trifluoromethoxy, difluoromethoxy, pentafluoroethoxy, trichloromethoxy, and the like.

[0067] "Cyano" refers to a substituent having a carbon atom joined to a nitrogen atom by a triple bond, eg, C≡N.

[0068] The term "oxo" as used herein means [ka] Refers to the base.

[0069] The term "N-oxide" refers to an oxygen atom (e.g., [ka] ) refers to

[0070] "Amino" means a substituent containing at least one nitrogen atom (eg, NH2).

[0071] Salts, Prodrugs, Derivatives, and Solvates Terminology and Conventions "Prodrug" or "prodrug derivative" means a parent compound or active drug substance covalently bonded to a derivative or carrier that exhibits one or more of its pharmacological effects after at least some biotransformation. Generally, such prodrugs contain metabolically cleavable groups that are rapidly converted in vivo to yield the parent compound, e.g., by hydrolysis in blood, and generally include ester and amide analogs of the parent compound. Prodrugs are formulated for the purposes of improved chemical stability, improved patient acceptance and compliance, improved bioavailability, longer duration of action, improved organ selectivity, improved formulation (e.g., increased water solubility), and / or reduced side effects (e.g., toxicity). Generally, prodrugs themselves have little or no biological activity and are stable under normal conditions.Prodrugs are described in A Textbook of Drug Design and Development, Krogsgaard-Larsen and H. Bundgaard (eds.), Gordon & Breach, 1991, especially Chapter 5: "Design and Applications of Prodrugs"; Design of Prodrugs, H. Bundgaard (ed.), Elsevier, 1985; Prodrugs: Topical and Ocular Drug Delivery, K. B. Sloan (ed.), Marcel Dekker, 1998; Methods in Enzymology, K. Widder, et al. (eds.), Vol. 42, Academic Press, 1985, especially pp. 309-396; and Burger's Medicinal Chemistry and Drug Discovery, 5th Ed., M. Wolff (ed.), John Wiley & Sons, 1989. Sons, 1995, especially Vol. 1 and pp. 172-178 and pp. 949-982; Pro-Drugs as Novel Delivery Systems, T. Higuchi and V. Stella (eds.), Am. Chem. Soc., 1975; Bioreversible Carriers in Drug Design, EB Roche (ed.), Elsevier, 1987 (each of which is incorporated herein by reference in its entirety).

[0072] "Pharmaceutically acceptable prodrug," as used herein, means a prodrug of a compound of the present disclosure that is suitable, within the scope of sound medical judgment, for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit-to-risk ratio, and that is effective for its intended use, and preferably in zwitterionic form.

[0073] "Salt" refers to the reaction product between a parent compound and a suitable acid or base that produces an ionic form of the parent compound or an acid or base salt of the parent compound. Salts of the disclosed compounds can be synthesized from a parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, salts are prepared by reacting the free base or acid parent compound with a stoichiometric or excess amount of the desired salt-forming inorganic or organic acid or base in a suitable solvent or various combinations of solvents.

[0074] "Pharmaceutically acceptable salt" means a salt of a compound of the present disclosure that is generally water-soluble or oil-soluble or dispersible and effective for its intended use, within the scope of sound medical judgment, without undue toxicity, irritation, allergic reaction, etc., and that is suitable for use in contact with the tissues of humans and lower animals, commensurate with a reasonable benefit-risk ratio. This term includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts. Since the compounds of the present disclosure are useful in both free base form and salt form, in practice, use of the salt form is equivalent to use of the base form. For a list of suitable salts, see, for example, S. M. Birge, et al., J. Pharm. Sci., 1977, 66, pp. 1-19 (hereby incorporated by reference in its entirety).

[0075] "Pharmaceutically acceptable acid addition salts" include those with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, nitric acid, phosphoric acid, and the like, as well as those with acetic acid, trichloroacetic acid, trifluoroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 2-acetoxybenzoic acid, butyric acid, camphorsulfonic acid, cinnamic acid, citric acid, digluconic acid, ethanesulfonic acid, glutamic acid, glycolic acid, glycerophosphate, hemisulfonic acid, "Salts" refers to salts formed with organic acids, such as 2-hydroxyethanesulfonic acid (isethionic acid), lactic acid, maleic acid, hydroxymaleic acid, malic acid, malonic acid, mandelic acid, mesitylenesulfonic acid, methanesulfonic acid, naphthalenesulfonic acid, nicotinic acid, 2-naphthalenesulfonic acid, oxalic acid, pamoic acid, pectinic acid, phenylacetic acid, 3-phenylpropionic acid, picric acid, pivalic acid, propionic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, sulfanilic acid, tartaric acid, p-toluenesulfonic acid, undecanoic acid, and the like, which retain the biological effectiveness and properties of the free base and which are not biologically or otherwise undesirable.

[0076] "Pharmaceutically acceptable base addition salts" refers to salts formed with inorganic bases, such as ammonia or ammonium hydroxide, carbonate, or bicarbonate, or metal cations, such as sodium, potassium, lithium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like, which retain the biological effectiveness and properties of the free acids and which are not biologically or otherwise undesirable. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, isopropylamine, tripropylamine, tributylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, Examples of suitable organic non-toxic bases include salts of primary, secondary, and tertiary amines, quaternary amine compounds, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as amines, piperidine, N-ethylpiperidine, tetramethylammonium compounds, tetraethylammonium compounds, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, dibenzylamine, N,N-dibenzylphenethylamine, 1-ephenamine, N,N'-dibenzylethylenediamine, and polyamine resins. Particularly preferred organic non-toxic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.

[0077] "Solvate" refers to a complex of variable stoichiometry formed by a solute, e.g., a compound of Formula (I), with a solvent, e.g., water, ethanol, or acetic acid. This physical association may involve varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances, a solvate is isolable, for example, when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid. Generally, such solvents selected for the purposes of this disclosure do not interfere with the biological activity of the solute. Solvates encompass both solution-phase solvates and isolable solvates. Representative solvates include hydrates, ethanolates, methanolates, and the like.

[0078] "Hydrate" means a solvate in which the solvent molecule or molecules are water.

[0079] The compounds of the present disclosure, as discussed below, including the free base or free acid thereof, salts, solvates, and prodrugs thereof, may contain oxidized sulfur atoms or quaternized nitrogen atoms in their structure, although not expressly stated or shown, particularly pharmaceutically acceptable forms thereof, and such forms, particularly pharmaceutically acceptable forms, are intended to be encompassed by the appended claims.

[0080] Isomers Terms and Conventions "Isomers" mean compounds that have the same number and kind of atoms, and therefore the same molecular weight, but that differ with regard to the arrangement or configuration of the atoms in space. The term includes stereoisomers and geometric isomers.

[0081] "Stereoisomer" or "optical isomer" refers to a stable isomer that has at least one chiral atom or restricted rotation resulting in a perpendicular plane of asymmetry (e.g., certain biphenyls, allenes, and spiro compounds) and is capable of rotating plane-polarized light. Because the compounds of the present disclosure have asymmetric centers and other chemical structures that can give rise to stereoisomerism, the present disclosure contemplates stereoisomers and mixtures thereof. The compounds of the present disclosure and their salts contain asymmetric carbon atoms and therefore can exist as single stereoisomers, racemates, and as mixtures of enantiomers and diastereomers. Typically, such compounds will be prepared as racemic mixtures. However, if desired, such compounds may be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers, or as stereoisomer-enriched mixtures. As discussed in more detail below, individual stereoisomers of the compounds are prepared by synthesis from optically active starting materials containing the desired chiral center, or by preparation of a mixture of enantiomeric products followed by separation or resolution, e.g., conversion to a diastereomeric mixture followed by separation or recrystallization, chromatographic methods, use of chiral resolving agents, or direct separation of enantiomers on a chiral chromatographic column, etc. Starting compounds of precise stereochemistry are either commercially available or made by the methods described below and resolved by techniques well known in the art.

[0082] "Enantiomers" means a pair of stereoisomers that are non-superimposable mirror images of each other.

[0083] "Diastereoisomers" or "diastereomers" mean optical isomers that are not mirror images of one another.

[0084] "Racemic mixture" or "racemate" means a mixture containing equal parts of individual enantiomers.

[0085] "Non-racemic mixture" means a mixture containing unequal parts of individual enantiomers.

[0086] "Geometric isomer" refers to a stable isomer resulting from restricted rotational freedom around a double bond (e.g., cis-2-butene and trans-2-butene) or in a ring structure (e.g., cis-1,3-dichlorocyclobutane and trans-1,3-dichlorocyclobutane). Because carbon-carbon double (olefinic) bonds, C=N double bonds, ring structures, and the like may be present in the compounds of the present disclosure, the present disclosure contemplates each of the various stable geometric isomers and mixtures thereof resulting from the arrangement of substituents around those double bonds and in those ring structures. Substituents and isomers are named using the cis / trans convention or using the E or Z system, where the term "E" refers to higher-order substituents on opposite sides of the double bond and the term "Z" refers to higher-order substituents on the same side of the double bond. A thorough discussion of E and Z isomerism is provided in J. March, Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 4th ed., John Wiley & Sons, 1992, hereby incorporated by reference in its entirety. Some of the examples below represent single E isomers, single Z isomers, and mixtures of E / Z isomers. Determination of E and Z isomers can be performed using techniques such as X-ray crystallography, 1 H NMR, and 13 This can be done by analytical methods such as C NMR.

[0087] Some of the compounds of the present disclosure can exist in more than one tautomeric form, and as stated above, the compounds of the present disclosure include all such tautomers.

[0088] It is well known in the art that the biological and pharmacological activity of a compound is sensitive to the stereochemistry of the compound. Thus, for example, enantiomers often exhibit significant differences in biological activity, including differences in pharmacokinetic properties, including metabolism, protein binding, etc., and pharmacological properties, including the type of activity exhibited, the degree of activity, toxicity, etc. Thus, one skilled in the art will understand that one enantiomer may be more active or may exhibit beneficial effects when enriched or separated from the other enantiomer. In addition, one skilled in the art will know, from this disclosure and knowledge of the prior art, how to separate, enrich, or selectively prepare enantiomers of the compounds of the present disclosure.

[0089] Thus, while a racemic form of a drug may be used, it is often less effective than administering an equal amount of the enantiopure drug; indeed, in some cases, one enantiomer may be pharmacologically inactive and simply serve as a diluent. For example, ibuprofen was previously administered as a racemate, but only the S-isomer of ibuprofen has been shown to be effective as an anti-inflammatory agent. (However, in the case of ibuprofen, while the R-isomer is inactive, it is converted to the S-isomer in vivo, and therefore the immediate effect of this drug in racemic form is slower than that of the pure S-isomer.) Furthermore, the pharmacological activity of enantiomers can exert distinct biological effects. For example, S-penicillamine is a drug for treating chronic arthritis, while R-penicillamine is toxic. Indeed, some purified enantiomers have advantages over their racemates, as purified individual isomers have been reported to have faster transdermal penetration rates compared to the racemic mixture. See U.S. Patent Nos. 5,114,946 and 4,818,541.

[0090] Therefore, if one enantiomer is more pharmacologically active, less toxic, or has more favorable biological properties than the other enantiomer, it may be therapeutically beneficial to administer that enantiomer preferentially, thereby reducing the total drug dose to which the treated patient is exposed and reducing the dose of the enantiomer that may be toxic or an inhibitor of the other enantiomer.

[0091] The preparation of pure enantiomers or mixtures of a desired enantiomeric excess (ee) or enantiopurity is accomplished by one or more of a number of methods: (a) separation or resolution of enantiomers, or (b) enantioselective synthesis, or a combination thereof, known to those skilled in the art. These resolution methods generally rely on chiral recognition and include, for example, chromatography using chiral stationary phases, enantioselective host-guest complexation, resolution or synthesis using chiral auxiliaries, enantioselective synthesis, enzymatic and non-enzymatic kinetic resolution, or spontaneous enantioselective crystallization. Such methods are generally disclosed in Chiral Separation Techniques: A Practical Approach (2nd Ed.), G. Subramanian (ed.), Wiley-VCH, 2000; T.E. Beesley and R.P.W. Scott, Chiral Chromatography, John Wiley & Sons, 1999; and Satinder Ahuja, Chiral Separations by Chromatography, Am. Chem. Soc., 2000. Furthermore, there are likewise well-known methods for quantification of enantiomeric excess or purity, e.g., GC, HPLC, CE, or NMR, and assignment of absolute configuration and conformation, e.g., CD ORD, X-ray crystallography, or NMR.

[0092] In general, all tautomeric and isomeric forms and mixtures of a chemical structure or compound, whether individual geometric or stereoisomers, or racemic or non-racemic mixtures, are intended, unless the specific stereochemistry or isomeric form is specifically indicated in the compound name or structure.

[0093] Pharmaceutical Administration and Treatment Terms and Conventions A "patient" or "subject" is a mammal, such as a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon, or rhesus monkey. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is a human.

[0094] The terms "pharmaceutically effective amount" or "therapeutically effective amount" or "effective amount" refer to an amount of a compound of the present disclosure that, when administered to a patient in need thereof, is sufficient to effect treatment of a disease state, condition, or disorder for which the compound has utility. Such an amount may be sufficient to elicit the biological or medical response in a tissue, system, or patient that is desired by a researcher or clinician. The amount of a compound of the present disclosure that constitutes a therapeutically effective amount will vary depending on factors such as the compound and its biological activity, the composition used for administration, the time of administration, the route of administration, the rate of excretion of the compound, the duration of treatment, the type and severity of the disease state or disorder being treated, drugs used in combination or concomitantly with the compound of the present disclosure, and the patient's age, weight, general health, sex, and diet. Such a therapeutically effective amount can be routinely determined by one of ordinary skill in the art having regard to their own knowledge, the prior art, and this disclosure.

[0095] As used herein, the term "pharmaceutical composition" refers to a compound of the present disclosure, or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, in combination with at least one pharmaceutically acceptable carrier in a form suitable for oral or parenteral administration.

[0096] "Carrier" encompasses carriers, excipients, and diluents and means a material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material, that is involved in carrying or transporting a pharmaceutical agent from one organ or part of the body of a subject to another organ or part of the body.

[0097] A "combination" refers to either a fixed combination in a single dosage unit form, or a combined administration in which a compound of the present disclosure and at least one combination partner (e.g., another drug, as described below, also referred to as a "therapeutic agent" or "co-agent") can be administered independently at the same time or within separate time intervals, particularly where the time intervals are sufficient for the combination partners to exhibit a beneficial effect due to the co-action of such therapeutic agents. Beneficial effects of the combination include, but are not limited to, synergistic, e.g., synergistic, and / or pharmacokinetic or pharmacodynamic co-action resulting from the combination of therapeutic agents, or any combination thereof. In one embodiment, the administration of the combined therapeutic agents occurs over a defined period of time (e.g., minutes, hours, days, or weeks, depending on the combination selected).

[0098] These single components may be packaged in a kit or packaged separately. Prior to administration, one or both of the components (e.g., powder or liquid) may be reconstituted or diluted to the desired dosage. The terms "co-administration" or "administration in combination," etc., as used herein, are meant to encompass the administration of selected combination partners to a single subject (e.g., patient) in need thereof, and are intended to include therapeutic regimens in which the agents are not necessarily administered by the same route of administration or at the same time.

[0099] The term "pharmaceutical combination," as used herein, refers to a product resulting from mixing or combining two or more therapeutic agents, and includes both fixed and non-fixed combinations of therapeutic agents. The term "fixed combination" means that both of the therapeutic agents, e.g., a compound of the present disclosure and a combination partner, are administered to a patient simultaneously in the form of a single entity or dosage. The term "non-fixed combination" means that both of the therapeutic agents, e.g., a compound of the present disclosure and a combination partner, are administered to a patient simultaneously, in parallel, or sequentially, without any particular time limit, as separate entities, where such administration results in therapeutically effective levels of the two compounds in the patient's body. The latter also applies to cocktail therapy, e.g., the administration of three or more therapeutic agents.

[0100] A subject (preferably a human) is "in need of" a treatment if such subject would derive a biological, medical, or quality of life benefit from such treatment.

[0101] The terms "PCSK9" or "proprotein convertase subtilisin / kexin type 9" synonymously refer to a naturally occurring human proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. PCSK9 is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the endoplasmic reticulum and is thought to function as a proprotein convertase. PCSK9 plays a role in cholesterol homeostasis and may have a role in the differentiation of cortical neurons. Mutations in the PCSK9 gene are a cause of autosomal dominant familial hypercholesterolemia (Burnett and Hooper, Clin. Biochem. Rev. (2008) 29(1):11-26).

[0102] As used herein, the terms "inhibit," "inhibition," or "inhibiting" refer to the reduction or suppression of a given condition, symptom, or disorder or disease, or to a significant decrease in the baseline activity of a biological activity or process.

[0103] As used herein, the terms "treat," "treating," or "treatment" of any disease or disorder refers to alleviating or ameliorating the disease or disorder (i.e., slowing or halting the onset of the disease or at least one of its clinical symptoms); or alleviating or ameliorating at least one physical parameter or biomarker associated with the disease or disorder, including those that may not be discernible by the patient.

[0104] As used herein, the terms "prevent," "preventing," or "prevention" of any disease or disorder refers to the prophylactic treatment of the disease or disorder; or the delay in the onset or progression of the disease or disorder.

[0105] "Pharmaceutically acceptable" means that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients comprising the formulation and / or the mammal being treated therewith.

[0106] "Disorder" means, and is used interchangeably with, the terms disease, condition, or illness, unless otherwise indicated.

[0107] "Administer," "administering," or "administration" means either administering a disclosed compound, or a pharmaceutically acceptable salt of a disclosed compound, or a composition directly to a subject, or administering a prodrug derivative or analog of the compound, or a pharmaceutically acceptable salt of the compound, or a composition, which is capable of forming an equivalent amount of the active compound in the subject's body, to a subject.

[0108] "Prodrug" means a compound that is convertible in vivo by metabolic means (eg, by hydrolysis) to a disclosed compound.

[0109] "Compounds of the disclosure," "compounds of Formula (I)," "compounds of this disclosure," and equivalent expressions (unless specifically specified otherwise) refer to compounds of Formula (I), Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), Formula (If), Formula (Ig), Formula (Ih), Formula (Ii), Formula (Ij), Formula (Ik), Formula (Im), and Formula (Io) as described herein, including tautomers, prodrugs, salts, particularly pharmaceutically acceptable salts, and solvates and hydrates thereof, where the context so permits, as well as all stereoisomers (including diastereoisomers and enantiomers), rotamers, tautomers, and isotopically labeled compounds (including deuterium ("D") substitution), and inherently formed moieties (e.g., polymorphs, solvates and / or hydrates). For the purposes of this disclosure, solvates and hydrates are generally considered to be compositions. Generally, and preferably, the compounds of the present disclosure and the formulas specifying the compounds of the present disclosure are understood to include only stable compounds and exclude unstable compounds, even if they may be considered literally included in the compound formula. Similarly, reference to intermediates, regardless of whether they are claimed per se, is intended to include their salts and solvates if the context so permits. For the purpose of clarity, specific examples may be indicated in the text if the context so permits, but these examples are merely illustrative and are not intended to exclude other examples if the context so permits.

[0110] "Intermediates of the disclosure," "intermediates of this disclosure," and equivalent expressions (unless otherwise specifically specified) refer to compounds of Formula (IIIa), Formula (IIIb), Formula (IIIc), Formula (IIId), Formula (IIIe), Formula (IIIf), Formula (IIIg), Formula (IIIh), Formula (IIIi), and Formula (IIIj), as described herein, where the context so permits, including tautomers, prodrugs, salts, particularly pharmaceutically acceptable salts, and solvates and hydrates thereof, as well as all stereoisomers (including diastereoisomers and enantiomers), rotamers, tautomers, and isotopically labeled compounds (including deuterium ("D") substitution), and inherently formed moieties (e.g., polymorphs, solvates, and / or hydrates). For purposes of this disclosure, solvates and hydrates are generally considered to be compositions. Generally, and preferably, the intermediates of the present disclosure and the formulas specifying the intermediates of the present disclosure are understood to include only stable compounds thereof and to exclude unstable compounds, even though they may be considered literally to be included in the compound formula.Similarly, reference to intermediates, whether or not they are claimed per se, is intended to include their salts and solvates, if the context so permits.For the purpose of clarity, specific examples may be indicated in the text if the context so permits, but these examples are merely illustrative and are not intended to exclude other examples if the context so permits.

[0111] By "stable compound" or "stable structure" is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an effective therapeutic or diagnostic agent. For example, compounds that may have "dangling valences" or that are carbanions are not compounds contemplated by the present disclosure.

[0112] In specific embodiments, the term "about" or "approximately" means within 20%, preferably within 10%, and more preferably within 5% of a given value or range.

[0113] As used herein, a "modulator of PCSK9" refers to a compound or molecule capable of modulating the biological activity or function of PCSK9 and / or one or more downstream pathways mediated by PCSK9 activity.

[0114] As used herein, an "inhibitor of PCSK9" refers to a compound or molecule capable of inhibiting the biological activity or function of PCSK9 and / or one or more downstream pathways mediated by PCSK9 signaling. Inhibitors of PCSK9 activity include compounds that block, antagonize, suppress, or reduce (to any extent, e.g., significantly) the biological activity of PCSK9, including downstream pathways mediated by PCSK9 activity.

[0115] As used herein, "disorders or diseases responsive to the inhibition of PCSK9," "disorders and conditions responsive to the inhibition of PCSK9," "disorders and conditions responsive to the inhibition of PCSK9 activity," "disorders responsive to the inhibition of PCSK9," "disorders responsive to the inhibition of PCSK9 activity," "disorders in which PCSK9 plays a role," and similar terms include hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral vascular disease (including aortic disease and cerebrovascular disease), peripheral arterial disease, vascular inflammation, elevated Lp(a), elevated LDL, elevated TRL, elevated triglycerides, sepsis, and xanthomas.

[0116] As used herein, "inhibition of PCSK9 activity" or "inhibition of PCSK9" refers to a decrease in PCSK9 activity, for example, by administration of a compound of the present disclosure.

[0117] The term "hypercholesterolemia" or "dyslipidemia" includes, for example, familial and non-familial hypercholesterolemia. Familial hypercholesterolemia (FH) is an autosomal dominant disorder characterized by elevated serum cholesterol bound to low-density lipoprotein (LDL). Familial hypercholesterolemia includes both heterozygous FH and homozygous FH. Hypercholesterolemia (or dyslipidemia) is the presence of elevated levels of cholesterol in the blood. It is a form of hyperlipidemia (elevated blood lipid levels) and hyperlipoproteinemia (elevated blood lipoprotein levels).

[0118] Hyperlipidemia is an elevation of lipids in the bloodstream. Such lipids include cholesterol, cholesterol esters, phospholipids, and triglycerides. Hyperlipidemia includes, for example, types I, IIa, IIb, III, IV, and V.

[0119] Hypertriglyceridemia refers to high blood triglyceride levels. Elevated triglyceride levels, even in the absence of hypercholesterolemia, are associated with atherosclerosis and predispose to cardiovascular disease.

[0120] "Sitosterolemia" or "phytosterolemia" is a rare autosomal recessive disorder of lipid metabolism characterized by excessive absorption of sitosterol from the gastrointestinal tract and decreased biliary excretion of dietary sterols (i.e., leading to hypercholesterolemia, tendon and tuberous xanthomas, and premature atherosclerosis) and altered cholesterol synthesis.

[0121] "Atherosclerosis" includes the hardening of arteries, involving the deposition of fatty substances, cholesterol, cellular waste products, calcium, and fibrin on the inner walls of arteries. The resulting deposits are called plaques.

[0122] "Atherosclerosis" or "arteriosclerotic vascular disease (ASVD)" is a specific form of arteriosclerosis involving thickening, hardening, and loss of elasticity of the arterial wall as a result of the infiltration and accumulation of leukocytes containing both live, active leukocytes (which cause inflammation) and dead cellular debris, including cholesterol and triglycerides. Atherosclerosis is thus a syndrome that develops in arterial blood vessels due to a chronic inflammatory response of leukocytes in the arterial wall.

[0123] "Coronary heart disease," also known as atherosclerosis, atherosclerotic cardiovascular disease, coronary heart disease, or ischemic heart disease, is the most common type of heart disease and the cause of heart attacks. The disease is caused by plaque that builds up along the inner walls of the heart's arteries, narrowing the arterial lumen and reducing blood flow to the heart.

[0124] "Xanthomas" are a skin manifestation of lipidosis, a buildup of lipids in large foam cells within the skin. Xanthomas are associated with hyperlipidemia.

[0125] The term "elevated Lp(a) concentration," as used herein, refers to a serum Lp(a) concentration greater than 30 mg / dL (75 nmol / L). "Elevated serum Lp(a)" means a serum Lp(a) level greater than about 14 mg / dL. In certain embodiments, a patient is considered to exhibit elevated serum Lp(a) if the serum Lp(a) level measured in the patient is greater than about 15 mg / dL, about 20 mg / dL, about 25 mg / dL, about 30 mg / dL, about 35 mg / dL, about 40 mg / dL, about 45 mg / dL, about 50 mg / dL, about 60 mg / dL, about 70 mg / dL, about 80 mg / dL, about 90 mg / dL, about 100 mg / dL, about 20 mg / dL, about 140 mg / dL, about 150 mgdL, about 180 mg / dL, or about 200 mg / dL. Serum Lp(a) levels may be measured in the patient after a meal. In some embodiments, Lp(a) levels are measured after a period of fasting (e.g., after an 8-hour, 10-hour, 12-hour, or longer fast). Exemplary methods for measuring serum Lp(a) in a patient include, but are not limited to, rate immunonephelometry, ELISA, nephelometry, immunoturbidimetry, and dissociation-enhanced lanthanide fluorescence immunoassay, although any clinically acceptable diagnostic method can be used in the context of this disclosure.

[0126] By "elevated triglyceride levels" or "ETL" is meant any degree of triglyceride levels that are determined to be undesirable or that are subject to regulation.

[0127] "Sepsis" is a systemic response characterized by arterial hypotension, metabolic acidosis, decreased systemic vascular resistance, tachypnea, and organ dysfunction. Sepsis can be caused by septicemia (i.e., organisms in the bloodstream, their metabolic end products, or toxins), including bacteremia (i.e., bacteria in the blood), and toxemia (i.e., toxins in the blood), including endotoxemia (i.e., endotoxins in the blood). The term "sepsis" also encompasses fungemia (i.e., fungi in the blood), viremia (i.e., viruses or virus particles in the blood), and parasitemia (i.e., helminths or protozoan parasites in the blood). Thus, sepsis and septic shock (acute circulatory failure caused by sepsis, often accompanied by multiple organ failure and high mortality) can be caused by several organisms.

[0128] Specific embodiments of compounds of formula (I) The present disclosure relates to compounds capable of modulating PCSK9, or pharmaceutically acceptable salts, hydrates, solvates, stereoisomers, or tautomers thereof, useful for treating diseases and disorders associated with the regulation of the PCSK9 protein or enzyme. In another embodiment, the present disclosure relates to compounds capable of inhibiting PCSK9, or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof, useful for treating diseases and disorders associated with the inhibition of the PCSK9 protein or enzyme. The present disclosure further relates to compounds useful for inhibiting PCSK9, or pharmaceutically acceptable salts, hydrates, solvates, stereoisomers, or tautomers thereof.

[0129] In one embodiment, the compound of formula (I) has the structure of formula (Ia): [ka] and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, N-oxides, and tautomers thereof.

[0130] In another embodiment, the compound of formula (I) has the structure of formula (Ib): [ka] and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, N-oxides, and tautomers thereof.

[0131] In another embodiment, the compound of formula (I) has the structure of formula (Ic): [ka] and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, N-oxides, and tautomers thereof.

[0132] In another embodiment, the compound of formula (I) has the structure of formula (Id): [ka] and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, N-oxides, and tautomers thereof.

[0133] In another embodiment, the compound of formula (I) has the structure of formula (Ie): [ka] and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, N-oxides, and tautomers thereof.

[0134] In another embodiment, the compound of formula (I) has the structure of formula (If): [ka] and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, N-oxides, and tautomers thereof.

[0135] In another embodiment, the compound of formula (I) has the structure of formula (Ig): [ka] and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, N-oxides, and tautomers thereof.

[0136] In another embodiment, the compound of formula (I) has the structure of formula (Ih): [ka] and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, N-oxides, and tautomers thereof.

[0137] In another embodiment, the compound of formula (I) has the structure of formula (Ii): [ka] and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, N-oxides, and tautomers thereof.

[0138] In another embodiment, the compound of formula (I) has the structure of formula (Ij): [ka] wherein x is 0, 1, or 2; and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, N-oxides, and tautomers thereof.

[0139] In another embodiment, the compound of formula (I) has the structure of formula (Ik): [ka] wherein x is 0, 1, or 2; and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, N-oxides, and tautomers thereof.

[0140] In another embodiment, the compound of formula (I) has the structure of formula (Im): [ka] wherein x is 0, 1, or 2; and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, N-oxides, and tautomers thereof.

[0141] In another embodiment, the compound of formula (I) has the structure of formula (Io): [ka] wherein x is 0, 1, or 2; and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, N-oxides, and tautomers thereof.

[0142] In some embodiments of the above formulae (e.g., Formula (I), Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), Formula (If), Formula (Ig), Formula (Ih), Formula (Ii):Formula (Ij), Formula (Ik), Formula (Im), and / or Formula (Io)), X1 and X2 are each independently H or (C1-C6) alkyl, or X1 and X2 together with the carbon atom to which they are attached form =(O); X3 is -CH2- when X1 and X2 are each independently H or (C1-C6) alkyl, or -CH2- when X1 and X2 together with the carbon atom to which they are attached form =(O), or -O-, -NH- or -N(C1-C6) alkyl- when X1 and X2 together with the carbon atom to which they are attached form =(O); R1 is (C6~C 10 ) aryl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are -OR 10 or -NR 21 R 10 and optionally 1 to 4 R 11 is replaced by; R2 is H, (C1-C6) alkyl, (C2-C6) alkenyl, (C1-C6) haloalkyl, -NR 12 R13 , (C3-C7)carbocyclyl, (C3-C7)cycloalkenyl, 5- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, (C6-C 10 ) aryl, or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and carbocyclyl, cycloalkenyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with 1 to 4 R 19 is replaced by; R3 is H, D, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, or (C1-C6) hydroxyalkyl, where alkyl is optionally joined to one to four R 14 is replaced by; R4 is H or (C1-C6) alkyl; or R3 and R4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1 to 3 heteroatoms selected from N, O, and S; R5 and R7 are each independently H, D, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, or (C1-C6) hydroxyalkyl, wherein the (C1-C6) alkyl is optionally substituted with 1 to 4 D; R6 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, or (C1-C6)hydroxyalkyl, wherein the alkyl is optionally substituted with 1 to 4 substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl; R8 is H, (C1-C6) alkyl, or (C1-C6) haloalkyl, where alkyl is optionally selected from (C3-C7) carbocyclyl, 4- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, -NR 16 R 17 , and -C(O)NR 16 R 17 substituted with 1 to 4 substituents each independently selected from: R9 is halogen, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, -OH, or CN; R 10 (C6~C 10 ) aryl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally joined by 1 to 4 R 22 is replaced by; Each R 11 is independently at each occurrence halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, —OH, or CN; R 12 and R 13 are each independently H or (C1-C6) alkyl; Each R 14 is independently calculated for each occurrence, D, NR 15 R 15’ , (C3-C7)carbocyclyl, or 3- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with 1-4 substituents each independently selected from halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, and (C1-C6)haloalkoxy; R 15 and R 15’ are each independently H or (C1-C6) alkyl; R 16 and R 17are each independently H or (C1-C6) alkyl; R 16 and R 17 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocyclyl ring optionally containing 1-2 additional heteroatoms selected from N, O, and S; Each R 18 is independently selected at each occurrence from (C3-C7)carbocyclyl, 5- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, (C6-C 10 ) aryl, or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein the carbocyclyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with 1-4 R 20 is replaced by; Each R 19 is independently at each occurrence halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, —OH, or CN; or The Two R's 19 are together on adjacent atoms, (C6~C 10 ) form an aryl, or a 5- or 6-membered heteroaryl ring containing 1-3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally substituted with 1-4 substituents each independently selected from halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, —OH, and CN; Each R 20 is independently at each occurrence halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, oxo, —OH, or CN; or R 18 When is carbocyclyl or heterocyclyl, two R 20 When attached to the same carbon atom, they join together to form =(O); R 21is H or (C1-C6) alkyl; Each R 22 is independently selected at each occurrence from halogen, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, -OH, CN, (C6-C 10 ) aryl, or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally joined by 1 to 4 R 23 is replaced by; Each R 23 is independently at each occurrence halogen, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, -CH2(OCH2CH2) 1~3 OCH2CH3, -OH, CN, or a 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the heterocyclyl is optionally selected from halogen, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, -OH, -C(O)R 24 , -NR 24 C(O)R 25 , -NH2, -NH(C1-C6)alkyl, and -N((C1-C6)alkyl)2, and alkyl is optionally substituted with 1 to 4 substituents each independently selected from -NR 24 R 25 or a 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, optionally substituted with 1 to 4 substituents each independently selected from halogen, (C-C)alkyl, (C-C)alkoxy, (C-C)haloalkyl, (C-C)haloalkoxy, —OH, —NH, —NH(C-C)alkyl, and —N((C-C)alkyl); and R 24 and R 25 are each independently H, (C1-C6) alkyl, or (C3-C7) carbocyclyl; or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof.

[0143] In some embodiments of the above formula, X1 and X2 are each independently H or (C1-C6) alkyl, or X1 and X2 together with the carbon atom to which they are attached form =(O); X3 is -CH2- when X1 and X2 are each independently H or (C1-C6) alkyl, or -CH2- when X1 and X2 together with the carbon atom to which they are attached form =(O), or -O-, -NH- or -N(C1-C6) alkyl- when X1 and X2 together with the carbon atom to which they are attached form =(O); R1 is (C6~C 10 ) aryl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are -OR 10 or -NR 21 R 10 and optionally 1 to 4 R 11 is replaced by; R2 is H, (C1-C6) alkyl, (C2-C6) alkenyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, (C3-C7)cycloalkenyl, 5- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, (C6-C 10 ) aryl, or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and carbocyclyl, cycloalkenyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with 1 to 4 R 19 is replaced by; R3 is H, D, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, or (C1-C6) hydroxyalkyl, where alkyl is optionally joined to one to four R 14 is replaced by; R4 is H or (C1-C6) alkyl; or R3 and R4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1 to 3 heteroatoms selected from N, O, and S; R5 and R7 are each independently H, D, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, or (C1-C6) hydroxyalkyl, wherein the (C1-C6) alkyl is optionally substituted with 1 to 4 D; R6 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, or (C1-C6)hydroxyalkyl, wherein the alkyl is optionally substituted with 1 to 4 substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl; R8 is H, (C1-C6) alkyl, or (C1-C6) haloalkyl, where alkyl is optionally selected from (C3-C7) carbocyclyl, 4- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, -NR 16 R 17 , and -C(O)NR 16 R 17 substituted with 1 to 4 substituents each independently selected from: R9 is halogen, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, -OH, or CN; R 10 (C6~C 10) aryl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally joined by 1 to 4 R 22 is replaced by; Each R 11 is independently at each occurrence halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, —OH, or CN; R 12 and R 13 are each independently H or (C1-C6) alkyl; Each R 14 is independently calculated for each occurrence, D, NR 15 R 15’ , (C3-C7)carbocyclyl, or 3- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with 1-4 substituents each independently selected from halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, and (C1-C6)haloalkoxy; R 15 and R 15’ are each independently H or (C1-C6) alkyl; R 16 and R 17 are each independently H or (C1-C6) alkyl; R 16 and R 17 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocyclyl ring containing 1-2 additional heteroatoms selected from N, O, and S; Each R 18 is independently selected at each occurrence from (C3-C7)carbocyclyl, 5- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, (C6-C 10) aryl, or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein the carbocyclyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with 1-4 R 20 is replaced by; Each R 19 is independently at each occurrence halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, —OH, or CN; or The Two R's 19 are together on adjacent atoms, (C6~C 10 ) form an aryl, or a 5- or 6-membered heteroaryl ring containing 1-3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally substituted with 1-4 substituents each independently selected from halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, —OH, and CN; Each R 20 is independently at each occurrence halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, oxo, —OH, or CN; or R 18 When is carbocyclyl or heterocyclyl, two R 20 When attached to the same carbon atom, they join together to form =(O); R 21 is H or (C1-C6) alkyl; Each R 22 is independently selected at each occurrence from halogen, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, -OH, CN, (C6-C 10 ) aryl, or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally joined by 1 to 4 R 23 is replaced by; Each R 23is independently at each occurrence halogen, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, -CH2(OCH2CH2) 1~3 OCH2CH3, -OH, CN, or a 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the heterocyclyl is optionally selected from halogen, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, -OH, -C(O)R 24 , -NR 24 C(O)R 25 , -NH2, -NH(C1-C6)alkyl, and -N((C1-C6)alkyl)2, and alkyl is optionally substituted with 1 to 4 substituents each independently selected from -NR 24 R 25 or a 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, optionally substituted with 1 to 4 substituents each independently selected from halogen, (C-C)alkyl, (C-C)alkoxy, (C-C)haloalkyl, (C-C)haloalkoxy, —OH, —NH, —NH(C-C)alkyl, and —N((C-C)alkyl); and R 24 and R 25 are each independently H, (C1-C6) alkyl, or (C3-C7) carbocyclyl; or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof.

[0144] In some embodiments of the above formula, X1 is H or (C1-C6) alkyl. In other embodiments, X1 is H. In yet other embodiments, X1 is (C1-C6) alkyl.

[0145] In some embodiments of the above formula, X2 is H or (C1-C6) alkyl. In other embodiments, X2 is H. In yet other embodiments, X2 is (C1-C6) alkyl.

[0146] In some embodiments of the above formula, X 1 and X 2 together with the carbon atom to which they are attached form =(O).

[0147] In some embodiments of the above formula, X1 is H and X2 is H. In other embodiments, X1 is H and X2 is (C1-C6) alkyl. In yet other embodiments, X1 is (C1-C6) alkyl and X2 is (C1-C6) alkyl.

[0148] In some embodiments of the above formula, when X1 and X2, together with the carbon atoms to which they are attached, form =(O), X3 is -O-, -NH-, or -N(C1-C6)alkyl-. In another embodiment, when X1 and X2, together with the carbon atoms to which they are attached, form =(O), X3 is -N(C1-C6)alkyl-. In yet another embodiment, when X1 and X2, together with the carbon atoms to which they are attached, form =(O), X3 is -O-. In another embodiment, when X1 and X2, together with the carbon atoms to which they are attached, form =(O), X3 is -NH-. In yet another embodiment, X1 and X2 are each independently H or (C1-C6)alkyl, or when X1 and X2, together with the carbon atoms to which they are attached, form =(O), X3 is -CH2-. In another embodiment, when X1 and X2, each independently H or (C1-C6)alkyl, X3 is -CH2-. In yet another embodiment, when X1 and X2 together with the carbon atom to which they are attached form =(O), X3 is -CH2-.

[0149] In some embodiments of the above formula, R1 is (C6-C 10) aryl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are -OR 10 or -NR 21 R 10 and optionally 1 to 3 R 11 In another embodiment, R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are substituted with -OR 10 or -NR 21 R 10 and optionally 1 to 3 R 11 In yet another embodiment, R1 is substituted with (C6-C 10 ) aryl or a 5-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are -OR 10 or -NR 21 R 10 and optionally 1 to 3 R 11 In another embodiment, R1 is phenyl or a 5-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are substituted with -OR 10 or -NR 21 R 10 and optionally 1 to 3 R 11 is replaced by .

[0150] In yet another embodiment, R1 is (C6-C 10 ) aryl or a 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are -OR 10 or -NR 21 R 10 and optionally 1 to 3 R 11In another embodiment, R1 is phenyl or a 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are substituted with -OR 10 or -NR 21 R 10 and optionally 1 to 3 R 11 In another embodiment, R1 is substituted with -OR 10 or -NR 21 R 10 and optionally 1 to 3 R 11 (C6~C 10 ) aryl. In yet another embodiment, R1 is -OR 10 or -NR 21 R 10 and optionally 1 to 3 R 11 In another embodiment, R is phenyl substituted with -OR 10 or -NR 21 R 10 and 1 to 3 R 11 (C6~C 10 ) aryl. In yet another embodiment, R1 is -OR 10 or -NR 21 R 10 and 1 to 3 R 11 is phenyl substituted with

[0151] In another embodiment, R1 is -NR 21 R 10 and optionally 1 to 3 R 11 (C6~C 10 In yet another embodiment, R is -NR 21 R 10 and optionally 1 to 3 R 11 In another embodiment, R is phenyl substituted with -NR 21 R 10 and 1 to 3 R11 (C6~C 10 In yet another embodiment, R is -NR 21 R 10 and 1 to 3 R 11 In another embodiment, R is phenyl substituted with -OR 10 and optionally 1 to 3 R 11 (C6~C 10 ) aryl. In another embodiment, R1 is -OR 10 and optionally 1 to 3 R 11 In yet another embodiment, R is phenyl substituted with -OR 10 and 1 to 3 R 11 (C6~C 10 ) aryl. In another embodiment, R1 is -OR 10 and 1 to 3 R 11 is phenyl substituted with

[0152] In some embodiments of the above formula, R2 is H, (C1-C6) alkyl, (C2-C6) alkenyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, (C3-C7)cycloalkenyl, 5- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, (C6-C 10 ) aryl, or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-3 R 18 and carbocyclyl, heterocyclyl, aryl and heteroaryl are optionally substituted with 1 to 4 R 19 In another embodiment, R2 is substituted with H, (C1-C3) alkyl, (C2-C4) alkenyl, (C1-C6) haloalkyl, -NR 12 R 13, (C3-C7)carbocyclyl, (C3-C7)cycloalkenyl, 5- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, (C6-C 10 ) aryl, or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-3 R 18 and carbocyclyl, heterocyclyl, aryl and heteroaryl are optionally substituted with 1 to 4 R 19 In yet another embodiment, R2 is substituted with H, (C1-C3) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, 5- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, (C6-C 10 ) aryl, or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-3 R 18 and carbocyclyl, heterocyclyl, aryl and heteroaryl are optionally substituted with 1 to 4 R 19 is replaced by .

[0153] In another embodiment, R2 is H, (C1-C3) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or a 5- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1 to 3 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 In another embodiment, R2 is substituted with H, (C1-C6) alkyl, or -NR 12 R 13 wherein the alkyl optionally comprises 1 to 3 R 18 In another embodiment, R2 is substituted with H, (C1-C6) alkyl, (C1-C6) haloalkyl, or -NR12 R 13 In yet another embodiment, R2 is a 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from H, (C1-C3) alkyl, (C1-C6) haloalkyl, (C3-C7) carbocyclyl, N, O, and S, where the alkyl is optionally joined to 1-3 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 In another embodiment, R2 is optionally substituted with 1 to 3 R 18 In yet another embodiment, R2 is (C1-C3) alkyl substituted with 1 to 3 R 18 In another embodiment, R2 is (C1-C3) alkyl substituted with (C3-C7) carbocyclyl or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, where the carbocyclyl and heterocyclyl are optionally substituted with 1-4 R 19 is replaced by .

[0154] In another embodiment, R2 is (C1-C3) alkyl, (C1-C6) haloalkyl, (C3-C7) carbocyclyl, or a 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl is optionally joined to 1-3 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 In another embodiment, R2 is (C1-C3) alkyl, (C1-C6) haloalkyl, (C3-C7) carbocyclyl, 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, where the alkyl is substituted with 1-3 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 is replaced by .

[0155] In some embodiments of the above formula, R3 is H, D, (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl, (C1-C4) haloalkoxy, or (C1-C4) hydroxyalkyl, where alkyl is optionally joined to one to three R 14 In another embodiment, R3 is H, D, (C1-C4) alkyl, (C1-C4) haloalkyl, or (C1-C4) hydroxyalkyl, wherein alkyl is optionally substituted with 1 to 3 R 14 In yet another embodiment, R3 is H, D, (C1-C4) alkyl, or (C1-C4) haloalkyl, where alkyl is optionally substituted with 1 to 3 R 14 In another embodiment, R3 is H, D, or optionally 1 to 3 R 14 In yet another embodiment, R3 is H, D, or optionally one or two R 14 In another embodiment, R3 is H or optionally 1 or 2 R 14 In yet another embodiment, R3 is H. In another embodiment, R3 is optionally substituted with one or two R 14 In yet another embodiment, R3 is H or (C1-C4) alkyl. In another embodiment, R3 is (C1-C4) alkyl.

[0156] In some embodiments of the above formula, R4 is H or (C1-C3) alkyl. In other embodiments, R4 is (C1-C3) alkyl. In yet other embodiments, R4 is H, methyl, ethyl, n-propyl, or i-propyl. In other embodiments, R4 is H, methyl, or ethyl. In yet other embodiments, R4 is H or methyl. In other embodiments, R4 is H.

[0157] In some embodiments of the above formula, R3 and R4, together with the atoms to which they are attached, form a 5- or 6-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S. In another embodiment, R3 and R4, together with the atoms to which they are attached, form a 6- or 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S. In yet another embodiment, R3 and R4, together with the atoms to which they are attached, form a 5-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S. In another embodiment, R3 and R4, together with the atoms to which they are attached, form a 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S. In yet another embodiment, R3 and R4, together with the atoms to which they are attached, form a 6-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S.

[0158] In some embodiments of the above formula, R5 is H, D, (C1-C3)alkyl, (C1-C3)alkoxy, (C1-C3)haloalkyl, (C1-C3)haloalkoxy, or (C1-C3)hydroxyalkyl, where the (C1-C3)alkyl is optionally substituted with one or more (i.e., 1-7) D. In other embodiments, R5 is H, D, (C1-C3)alkyl, (C1-C3)haloalkyl, or (C1-C3)hydroxyalkyl, where the (C1-C6)alkyl is optionally substituted with one or more D. In yet other embodiments, R5 is H, D, (C1-C3)alkyl, (C1-C3)alkoxy, (C1-C3)haloalkoxy, or (C1-C3)hydroxyalkyl, where the (C1-C6)alkyl is optionally substituted with one or more D. In another embodiment, R5 is H, D, (C1-C3)alkyl, or (C1-C3)haloalkyl, where the (C1-C6)alkyl is optionally substituted with one or more D. In yet another embodiment, R5 is H, D, or (C1-C3)alkyl. In another embodiment, R5 is H or (C1-C3)alkyl. In yet another embodiment, R5 is H or (C1-C2)alkyl. In another embodiment, R5 is H, methyl, or ethyl. In yet another embodiment, R5 is H or methyl. In another embodiment, R5 is H. In yet another embodiment, R5 is methyl.

[0159] In some embodiments of the above formula, R6 is (C1-C3)alkyl, (C1-C3)alkoxy, (C1-C3)haloalkyl, (C1-C3)haloalkoxy, or (C1-C3)hydroxyalkyl, wherein the alkyl is optionally substituted with 1 to 3 substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl. In another embodiment, R6 is (C1-C3)alkyl, (C1-C3)alkoxy, (C1-C3)haloalkyl, (C1-C3)haloalkoxy, or (C1-C3)hydroxyalkyl, wherein the alkyl is optionally substituted with 1 to 3 substituents each independently selected from (C1-C3)alkoxy, (C1-C3)haloalkoxy, —C(O)(C1-C3)alkyl, —C(O)OH, and —C(O)O(C1-C3)alkyl. In yet another embodiment, R6 is (C1-C3)alkyl, (C1-C3)haloalkyl, or (C1-C3)hydroxyalkyl, where the alkyl is optionally substituted with 1 to 3 substituents each independently selected from (C1-C3)alkoxy, (C1-C3)haloalkoxy, —C(O)(C1-C3)alkyl, —C(O)OH, and —C(O)O(C1-C3)alkyl. In another embodiment, R6 is (C1-C3)alkyl, (C1-C3)alkoxy, (C1-C3)haloalkoxy, or (C1-C3)hydroxyalkyl, wherein the alkyl is optionally substituted with 1 to 3 substituents each independently selected from (C1-C3)alkoxy, (C1-C3)haloalkoxy, —C(O)(C1-C3)alkyl, —C(O)OH, and —C(O)O(C1-C3)alkyl.

[0160] In another embodiment, R6 is (C1-C3)alkyl, or (C1-C3)haloalkyl, where the alkyl is optionally substituted with 1 to 3 substituents each independently selected from (C1-C3)alkoxy, (C1-C3)haloalkoxy, -C(O)(C1-C3)alkyl, -C(O)OH, and -C(O)O(C1-C3)alkyl. In yet another embodiment, R6 is (C1-C3)alkyl optionally substituted with 1 to 3 substituents each independently selected from (C1-C3)alkoxy, (C1-C3)haloalkoxy, -C(O)(C1-C3)alkyl, -C(O)OH, and -C(O)O(C1-C3)alkyl. In another embodiment, R6 is (C1-C3)alkyl substituted with 1 to 3 substituents each independently selected from (C1-C3)alkoxy, (C1-C3)haloalkoxy, -C(O)(C1-C3)alkyl, -C(O)OH, and -C(O)O(C1-C3)alkyl. In yet another embodiment, R6 is (C1-C3)alkyl optionally substituted with 1 to 3 substituents each independently selected from (C1-C3)alkoxy, (C1-C3)haloalkoxy, -C(O)(C1-C3)alkyl, and -C(O)OH. In another embodiment, R6 is (C1-C3)alkyl substituted with 1 to 3 substituents each independently selected from (C1-C3)alkoxy, (C1-C3)haloalkoxy, -C(O)(C1-C3)alkyl, and -C(O)OH.

[0161] In some embodiments of the above formula, R7 is H, D, (C1-C3)alkyl, (C1-C3)alkoxy, (C1-C3)haloalkyl, (C1-C3)haloalkoxy, or (C1-C3)hydroxyalkyl, where the (C1-C6)alkyl is optionally substituted with one or more D. In other embodiments, R7 is H, D, (C1-C3)alkyl, (C1-C3)haloalkyl, or (C1-C3)hydroxyalkyl, where the (C1-C6)alkyl is optionally substituted with one or more D. In yet other embodiments, R7 is H, D, (C1-C3)alkyl, (C1-C3)alkoxy, (C1-C3)haloalkoxy, or (C1-C3)hydroxyalkyl, where the (C1-C6)alkyl is optionally substituted with one or more D. In another embodiment, R7 is H, D, (C1-C3)alkyl, or (C1-C3)haloalkyl, where the (C1-C6)alkyl is optionally substituted with one or more D. In yet another embodiment, R7 is H, D, or (C1-C3)alkyl. In another embodiment, R7 is H or (C1-C3)alkyl. In yet another embodiment, R7 is H or (C1-C2)alkyl. In another embodiment, R7 is H, methyl, or ethyl. In yet another embodiment, R7 is H or methyl. In another embodiment, R7 is H. In yet another embodiment, R7 is methyl.

[0162] In some embodiments of the above formula, R8 is H, (C1-C5) alkyl, or (C1-C5) haloalkyl, where alkyl is optionally (C3-C7) carbocyclyl, 4- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, -NR 16 R 17 , and -C(O)NR 16 R 17In another embodiment, R8 is H, (C1-C5) alkyl, or (C1-C5) haloalkyl, where alkyl is optionally 4- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, -NR 16 R 17 , and -C(O)NR 16 R 17 In another embodiment, R8 is H, (C1-C5) alkyl, or (C1-C5) haloalkyl, where alkyl is optionally (C3-C7) carbocyclyl, 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, -NR 16 R 17 , and -C(O)NR 16 R 17 In another embodiment, R8 is H, (C1-C5) alkyl, or (C1-C5) haloalkyl, where alkyl is optionally 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, -NR 16 R 17 , and -C(O)NR 16 R 17 is substituted with 1 to 3 substituents each independently selected from

[0163] In some embodiments of the above formula, R9 is halogen, (C1-C3) alkyl, (C1-C3) alkoxy, (C1-C3) haloalkyl, (C1-C3) haloalkoxy, -OH, or CN. In other embodiments, R9 is halogen, (C1-C3) alkyl, (C1-C3) haloalkyl, -OH, or CN. In yet other embodiments, R9 is halogen, (C1-C3) alkoxy, (C1-C3) haloalkoxy, -OH, or CN. In other embodiments, R9 is halogen, (C1-C3) alkyl, (C1-C3) haloalkyl, or (C1-C3) haloalkoxy. In yet other embodiments, R9 is halogen, (C1-C3) alkyl, (C1-C3) haloalkyl, or (C1-C3) haloalkoxy. In still other embodiments, R9 is halogen, (C1-C3) alkyl, or (C1-C3) haloalkyl. In other embodiments, R9 is halogen, or (C1-C3) alkyl. In yet another embodiment, R9 is halogen or (C1-C3)haloalkyl. In another embodiment, R9 is halogen. In yet another embodiment, R9 is F, Cl, or Br. In another embodiment, R9 is F or Cl. In yet another embodiment, R9 is F. In yet another embodiment, R9 is Cl.

[0164] In some embodiments of the above formula, R 10 (C6~C 10 ) aryl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally joined by 1 to 3 R 22 In another embodiment, R 10 is phenyl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, where the phenyl and heteroaryl are optionally joined by 1 to 3 R 22 In yet another embodiment, R 10 (C6~C 10 ) aryl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are each independently selected from 1 to 3 R 22In another embodiment, R 10 is phenyl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, where the phenyl and heteroaryl are selected from 1 to 3 R 22 is replaced by .

[0165] In another embodiment, R 10 (C6~C 10 ) aryl or a 5-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally joined by 1 to 3 R 22 In another embodiment, R 10 (C6~C 10 ) aryl or a 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally joined by 1 to 3 R 22 In yet another embodiment, R 10 (C6~C 10 ) aryl or a 5-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are each independently selected from 1 to 3 R 22 In another embodiment, R 10 (C6~C 10 ) aryl or a 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are each independently selected from 1 to 3 R 22 is replaced by .

[0166] In another embodiment, R 10 is phenyl or a 5-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, where the phenyl and heteroaryl are optionally joined by 1 to 3 R 22 In yet another embodiment, R 10is phenyl or a 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, where the phenyl and heteroaryl are optionally joined by 1 to 3 R 22 In another embodiment, R 10 is phenyl or a 5-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, where the phenyl and heteroaryl are joined by 1 to 3 R 22 In yet another embodiment, R 10 is phenyl or a 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, where the phenyl and heteroaryl are joined by 1 to 3 R 22 is replaced by .

[0167] In another embodiment, R 10 is optionally 1 to 3 R 22 (C6~C 10 ) aryl. In another embodiment, R 10 is 1 to 3 R 22 (C6~C 10 ) aryl. In another embodiment, R 10 is optionally 1 to 3 R 22 In yet another embodiment, R is a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, substituted with 10 is 1 to 3 R 22 In another embodiment, R is a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, substituted with 10 is optionally 1 to 3 R 22 In yet another embodiment, R is a 5-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, substituted with 10 is optionally 1 to 3 R 22 In another embodiment, R is a 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, substituted with 10 is 1 to 3 R22 In yet another embodiment, R is a 5-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, substituted with 10 is 1 to 3 R 22 In another embodiment, R is a 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, substituted with 10 is phenyl or pyridinyl, wherein phenyl and pyridinyl are optionally substituted with 1 to 3 R 22 In yet another embodiment, R 10 is phenyl or pyridinyl, where phenyl and pyridinyl are each independently selected from 1 to 3 R 22 is replaced by .

[0168] In some embodiments of the above formula, each R 11 is independently at each occurrence halogen, (C1-C3) alkyl, (C1-C3) alkoxy, (C1-C3) haloalkyl, (C1-C3) haloalkoxy, —OH, or CN. 11 is independently at each occurrence halogen, (C1-C3) alkyl, (C1-C3) alkoxy, (C1-C3) haloalkyl, or (C1-C3) haloalkoxy. 11 is independently at each occurrence halogen, —OH, or CN. 11 is independently at each occurrence halogen, (C1-C3) alkyl, or (C1-C3) haloalkyl. 11 is independently at each occurrence halogen, (C1-C3) alkyl, (C1-C3) alkoxy, or (C1-C3) haloalkoxy. 11 is independently at each occurrence halogen, (C1-C3) alkyl, (C1-C3) haloalkyl, or (C1-C3) haloalkoxy. 11 is independently at each occurrence halogen, (C1-C3)haloalkyl, or (C1-C3)haloalkoxy. 11is independently at each occurrence a halogen.

[0169] In some embodiments of the above formula, R 12 is H or (C1-C6) alkyl. In another embodiment, R 12 is H or (C1-C3) alkyl. In yet another embodiment, R 12 is H. In another embodiment, R 12 is (C1-C3) alkyl. In yet another embodiment, R 12 is methyl, ethyl, n-propyl, or i-propyl. 12 is methyl or ethyl. In yet another embodiment, R 12 is methyl.

[0170] In some embodiments of the above formula, R 13 is H or (C1-C6) alkyl. In another embodiment, R 13 is H or (C1-C3) alkyl. In yet another embodiment, R 13 is H. In another embodiment, R 13 is (C1-C3) alkyl. In yet another embodiment, R 13 is methyl, ethyl, n-propyl, or i-propyl. 13 is methyl or ethyl. In yet another embodiment, R 13 is methyl.

[0171] In some embodiments of the above formula, R 12 is H, and R 13 is H. In another embodiment, R 12 is H, and R 13 is (C1-C3) alkyl. In yet another embodiment, R 12 is (C1-C3) alkyl, and R 13 is H. In another embodiment, R 12 is (C1-C3) alkyl, and R 13is (C1-C3) alkyl. In yet another embodiment, R 12 is methyl, and R 13 is methyl.

[0172] In some embodiments of the above formula, each R 14 is independently expressed as D, -NR for each occurrence. 15 R 15’ , (C3-C7)carbocyclyl, or a 3- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with 1-3 substituents each independently selected from halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, and (C1-C6)haloalkoxy. 14 is independently expressed as D, -NR for each occurrence. 15 R 15’ , (C3-C7)carbocyclyl, or a 3- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with 1-3 substituents each independently selected from halogen, (C1-C3)alkyl, (C1-C3)alkoxy, (C1-C3)haloalkyl, and (C1-C3)haloalkoxy. 14 is independently expressed as -NR 15 R 15’ , (C3-C7)carbocyclyl, or a 3- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with 1 to 3 substituents each independently selected from halogen, (C1-C3)alkyl, (C1-C3)alkoxy, (C1-C3)haloalkyl, and (C1-C3)haloalkoxy.

[0173] In another embodiment, each R 14 is independently expressed as -NR 15 R 15’or (C3-C7)carbocyclyl optionally substituted with 1 to 3 substituents each independently selected from halogen, (C1-C3)alkyl, (C1-C3)alkoxy, (C1-C3)haloalkyl, and (C1-C3)haloalkoxy. 14 is independently expressed as -NR 15 R 15’ or (C-C)carbocyclyl optionally substituted with 1 to 3 substituents each independently selected from halogen, (C-C)alkyl, and (C-C)haloalkyl. 14 is independently expressed as -NR 15 R 15’ or a (C3-C7)carbocyclyl optionally substituted with 1 to 3 (C1-C3)alkyl.

[0174] In some embodiments of the above formula, R 15 is H or (C1-C6) alkyl. In another embodiment, R 15 is H or (C1-C3) alkyl. In yet another embodiment, R 15 is H. In another embodiment, R 15 is (C1-C3) alkyl. In yet another embodiment, R 15 is methyl, ethyl, n-propyl, or i-propyl. 15 is methyl or ethyl. In yet another embodiment, R 15 is methyl.

[0175] In some embodiments of the above formula, R 15’ is H or (C1-C6) alkyl. In another embodiment, R 15’ is H or (C1-C3) alkyl. In yet another embodiment, R 15’ is H. In another embodiment, R 15’ is (C1-C3) alkyl. In yet another embodiment, R 15’is methyl, ethyl, n-propyl, or i-propyl. 15’ is methyl or ethyl. In yet another embodiment, R 15’ is methyl.

[0176] In some embodiments of the above formula, R 15 is H, and R 15’ is H. In another embodiment, R 15 is H, and R 15’ is (C1-C3) alkyl. In yet another embodiment, R 15 is (C1-C3) alkyl, and R 15’ is H. In another embodiment, R 15 is (C1-C3) alkyl, and R 15’ is (C1-C3) alkyl. In yet another embodiment, R 15 is methyl, and R 15’ is methyl.

[0177] In some embodiments of the above formula, R 16 is H or (C1-C3) alkyl. In another embodiment, R 16 is H. In another embodiment, R 16 is (C1-C3) alkyl. In yet another embodiment, R 16 is H, methyl, ethyl, n-propyl, or i-propyl. 16 is methyl, ethyl, n-propyl, or i-propyl. 16 is H, methyl or ethyl. In another embodiment, R 16 is methyl or ethyl. In yet another embodiment, R 16 is H or methyl. In another embodiment, R 16 is methyl. In yet another embodiment, R 16 is H or (C1-C3) alkyl; or R 16 and R 17are taken together with the nitrogen atom to which they are attached to form a 4- to 7-membered heterocyclyl ring containing 1-2 additional heteroatoms selected from N, O, and S. In yet another embodiment, R 16 is H or (C1-C3) alkyl; or R 16 and R 17 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocyclyl ring optionally containing 1-2 additional heteroatoms selected from N, O, and S.

[0178] In some embodiments of the above formula, R 17 is H or (C1-C3) alkyl. In another embodiment, R 17 is H. In another embodiment, R 17 is (C1-C3) alkyl. In yet another embodiment, R 17 is H, methyl, ethyl, n-propyl, or i-propyl. 17 is methyl, ethyl, n-propyl, or i-propyl. 17 is H, methyl or ethyl. In another embodiment, R 17 is methyl or ethyl. In yet another embodiment, R 17 is H or methyl. In another embodiment, R 17 is methyl.

[0179] In some embodiments of the above formula, R 16 and R 17 are taken together with the nitrogen atom to which they are attached to form a 4- to 7-membered heterocyclyl ring containing 1-2 additional heteroatoms selected from N, O, and S. In another embodiment, R 16 and R 17 are taken together with the nitrogen atom to which they are attached to form a 4- to 6-membered heterocyclyl ring containing 1-2 additional heteroatoms selected from N, O, and S. In yet another embodiment, R 16 and R 17together with the nitrogen atom to which they are attached form a 4- or 5-membered heterocyclyl ring containing 1-2 additional heteroatoms selected from N, O, and S.

[0180] In some embodiments of the above formula, R 16 and R 17 taken together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocyclyl ring optionally containing 1-2 additional heteroatoms selected from N, O, and S. In another embodiment, R 16 and R 17 taken together with the nitrogen atom to which they are attached form a 4- to 6-membered heterocyclyl ring optionally containing 1-2 additional heteroatoms selected from N, O, and S. In yet another embodiment, R 16 and R 17 together with the nitrogen atom to which they are attached form a 4- or 5-membered heterocyclyl ring optionally containing 1-2 additional heteroatoms selected from N, O, and S.

[0181] In some embodiments of the above formula, each R 18 is independently selected at each occurrence from (C3-C7)carbocyclyl, 5- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, (C6-C 10 ) aryl, or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein the carbocyclyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with 1-4 R 20 In another embodiment, each R 18 is independently at each occurrence (C-C)carbocyclyl or 5- to 7-membered heterocyclyl, wherein the carbocyclyl and heterocyclyl are optionally joined by 1 to 4 R 20 In yet another embodiment, each R 18 is independently at each occurrence (C3-C7)carbocyclyl or (C6-C 10) aryl, wherein the carbocyclyl and aryl are optionally substituted with 1 to 4 R 20 In another embodiment, each R 18 is independently at each occurrence a 5- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the heterocyclyl and heteroaryl are optionally joined by 1 to 4 R 20 is replaced by .

[0182] In another embodiment, each R 18 is independently calculated for each occurrence (C6~C 10 ) aryl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are each independently selected from 1 to 3 R 20 In yet another embodiment, each R 18 is independently at each occurrence phenyl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the phenyl and heteroaryl are selected from 1 to 3 R 20 In another embodiment, each R 18 is independently calculated for each occurrence (C6~C 10 ) aryl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally joined by 1 to 3 R 20 In yet another embodiment, each R 18 is independently at each occurrence phenyl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the phenyl and heteroaryl are optionally joined by 1 to 3 R 20 is replaced by .

[0183] In some embodiments of the above formula, R 19is halogen, (C1-C3) alkyl, (C1-C3) alkoxy, (C1-C3) haloalkyl, (C1-C3) haloalkoxy, —OH, or CN. 19 is halogen, (C1-C3) alkyl, (C1-C3) alkoxy, (C1-C3) haloalkyl, or (C1-C3) haloalkoxy. 19 is halogen, (C1-C3) alkyl, (C1-C3) haloalkyl, —OH, or CN. 19 is halogen, (C1-C3) alkyl, (C1-C3) alkoxy, (C1-C3) haloalkyl, (C1-C3) haloalkoxy, or —OH. 19 is halogen, (C1-C3) alkyl, (C1-C3) alkoxy, (C1-C3) haloalkyl, (C1-C3) haloalkoxy, or CN. 19 is halogen, (C1-C3) alkyl, (C1-C3) alkoxy, (C1-C3) haloalkyl, —OH, or CN. 19 is halogen, (C1-C3) alkyl, (C1-C3) alkoxy, (C1-C3) haloalkoxy, —OH, or CN. 19 is halogen, (C1-C3) alkyl, (C1-C3) haloalkyl, (C1-C3) haloalkoxy, —OH, or CN. 19 is halogen, (C1-C3) alkyl, or (C1-C3) haloalkyl. 19 is halogen or (C1-C3) alkyl.

[0184] In some embodiments of the above formula, two R 19 are together on adjacent atoms, (C6~C 10) aryl, or a 5- or 6-membered heteroaryl ring containing 1-3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally substituted with one or more substituents each independently selected from halogen, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, —OH, and CN. In another embodiment, two R 19 taken together, when on adjacent atoms, optionally substituted with one or more substituents each independently selected from halogen, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, —OH, and CN. 10 ) form an aryl. In yet another embodiment, two R 19 are taken together, when on adjacent atoms, to form a 5- or 6-membered heteroaryl ring containing 1 to 3 heteroatoms selected from N, O, and S, optionally substituted with one or more substituents each independently selected from halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, —OH, and CN. In another embodiment, two R 19 when on adjacent atoms, together form a phenyl or a 5- or 6-membered heteroaryl ring containing 1 to 3 heteroatoms selected from N, O, and S, wherein the phenyl and heteroaryl are optionally substituted with one or more substituents each independently selected from halogen, (C-C)alkyl, (C-C)alkoxy, (C-C)haloalkyl, (C-C)haloalkoxy, —OH, and CN.

[0185] In another embodiment, two R 19 are taken together when on adjacent atoms to form a phenyl optionally substituted with one or more substituents each independently selected from halogen, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, -OH, and CN.19 are taken together, when on adjacent atoms, to form a 5-membered heteroaryl ring containing 1 to 3 heteroatoms selected from N, O, and S, optionally substituted with one or more substituents each independently selected from halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, —OH, and CN. In another embodiment, two R 19 taken together, when on adjacent atoms, a 6-membered heteroaryl ring containing 1 to 3 heteroatoms selected from N, O, and S, optionally substituted with one or more substituents each independently selected from halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, —OH, and CN.

[0186] In some embodiments of the above formula, each R 20 is independently at each occurrence halogen, (C1-C3) alkyl, (C1-C3) alkoxy, (C1-C3) haloalkyl, (C1-C3) haloalkoxy, oxo, —OH, or CN. 20 is independently at each occurrence halogen, (C1-C3) alkyl, (C1-C3) haloalkyl, oxo -OH, or CN. 20 is independently at each occurrence halogen, (C1-C3) alkyl, (C1-C3) alkoxy, (C1-C3) haloalkyl, or (C1-C3) haloalkoxy. 20 is independently at each occurrence halogen, (C1-C3) alkyl, oxo, —OH, or CN. 20 is independently at each occurrence halogen, (C1-C3) alkyl, (C1-C3) alkoxy, —OH, or CN. 20 is independently at each occurrence halogen, (C1-C3) alkyl, (C1-C3) alkoxy, (C1-C3) haloalkoxy, —OH, or CN. 20is independently at each occurrence halogen, (C1-C3)alkyl, (C1-C3)alkoxy, (C1-C3)haloalkyl, or (C1-C3)haloalkoxy.

[0187] In another embodiment, each R 20 is independently at each occurrence halogen, (C1-C3) alkyl, or (C1-C3) haloalkyl. 20 is independently at each occurrence halogen, (C1-C3) alkyl, or (C1-C3) alkoxy. 20 is independently at each occurrence halogen, (C1-C3) alkyl, (C1-C3) alkoxy, or (C1-C3) haloalkoxy. 20 is independently at each occurrence halogen, (C1-C3) alkyl, or oxo. 20 is independently at each occurrence halogen or (C1-C3) alkyl. 20 is, independently at each occurrence, (C1-C3) alkyl, (C1-C3) alkoxy, (C1-C3) haloalkyl, or (C1-C3) haloalkoxy. 20 is independently at each occurrence (C1-C3) alkyl or (C1-C3) haloalkyl.

[0188] In some embodiments of the above formula, each R 20 is independently at each occurrence halogen, (C1-C3) alkyl, or oxo; or R 18 When is carbocyclyl or heterocyclyl, two R 20 are attached to the same carbon atom, they are taken together to form =(O). In another embodiment, each R 20 is, independently at each occurrence, halogen or (C1-C3) alkyl; or R 18 When is carbocyclyl or heterocyclyl, two R 20 When attached to the same carbon atom, they combine to form =(O).

[0189] In some embodiments of the above formula, R 18 When is carbocyclyl or heterocyclyl, two R 20 When attached to the same carbon atom, they are taken together to form =(O). 18 When is a carbocyclyl, two R 20 When attached to the same carbon atom, they are taken together to form =(O). 18 When is heterocyclyl, two R 20 When attached to the same carbon atom, they are taken together to form =(O). 18 is 1 to 3 R 20 and two R 20 When attached to the same carbon atom, they are taken together to form =(O). 18 is 1 to 3 R 20 and two R 20 When attached to the same carbon atom, they are taken together to form =(O). 18 is 1 to 3 R 20 and two R 20 When attached to the same carbon atom, they combine to form =(O).

[0190] In some embodiments of the above formula, R 21 is H or (C1-C3) alkyl. In another embodiment, R 21 is H. In another embodiment, R 21 is (C1-C3) alkyl. In yet another embodiment, R 21 is H, methyl, ethyl, n-propyl, or i-propyl. 21 is methyl, ethyl, n-propyl, or i-propyl. 21 is H, methyl or ethyl. In another embodiment, R 21is methyl or ethyl. In yet another embodiment, R 21 is H or methyl. In another embodiment, R 21 is methyl.

[0191] In some embodiments of the above formula, each R 22 is independently selected at each occurrence from halogen, (C1-C3) alkyl, (C1-C3) alkoxy, (C1-C3) haloalkyl, (C1-C3) haloalkoxy, -OH, CN, (C6-C 10 ) aryl, or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally joined by 1 to 3 R 23 In another embodiment, each R 22 is independently selected at each occurrence from halogen, (C1-C3) alkyl, (C1-C3) alkoxy, (C1-C3) haloalkyl, (C1-C3) haloalkoxy, (C6-C 10 ) aryl, or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally joined by 1 to 3 R 23 In yet another embodiment, each R 22 is independently selected at each occurrence from halogen, (C1-C3) alkyl, (C1-C3) haloalkyl, -OH, CN, (C6-C 10 ) aryl, or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally joined by 1 to 3 R 23 In another embodiment, each R 22 is independently selected at each occurrence from halogen, (C1-C3) alkyl, (C1-C3) alkoxy, (C1-C3) haloalkoxy, -OH, CN, (C6-C 10 ) aryl, or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally joined by 1 to 3 R 23 is replaced by .

[0192] In another embodiment, each R 22 is independently selected at each occurrence from halogen, (C1-C3) alkyl, (C1-C3) haloalkyl, (C6-C 10 ) aryl, or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally joined by 1 to 3 R 23 In yet another embodiment, each R 22 is independently selected at each occurrence from halogen, (C1-C3) alkyl, (C1-C3) alkoxy, (C1-C3) haloalkoxy, (C6-C 10 ) aryl, or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally joined by 1 to 3 R 23 In another embodiment, each R 22 is independently selected at each occurrence from halogen, (C1-C3) alkyl, (C6-C 10 ) aryl, or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally joined by 1 to 3 R 23 In yet another embodiment, each R 22 is independently at each occurrence halogen, (C1-C3) alkyl, or 1 to 3 R 23 Optionally substituted with (C6-C 10 ) aryl. In yet another embodiment, each R 22 is independently at each occurrence halogen, (C1-C3) alkyl, or 1 to 3 R 23 In another embodiment, each R 22 is independently at each occurrence halogen, (C1-C3) alkyl, or 1 to 3 R 23is a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, optionally substituted with

[0193] In another embodiment, each R 22 is independently at each occurrence halogen, (C1-C3) alkyl, or 1 to 3 R 23 In yet another embodiment, each R 22 is independently at each occurrence halogen, (C1-C3) alkyl, or 1 to 3 R 23 In another embodiment, each R 22 is independently at each occurrence halogen, (C1-C3) alkyl, or 1 to 3 R 23 In yet another embodiment, each R is a 5-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, substituted with 22 is independently at each occurrence halogen, (C1-C3) alkyl, or 1 to 3 R 23 In another embodiment, each R 22 is independently at each occurrence halogen, (C1-C3) alkyl, or 1 to 3 R 23 In yet another embodiment, each R 22 is independently at each occurrence halogen, (C1-C3) alkyl, or 1 to 3 R 23 and imidazolyl substituted with

[0194] In some embodiments of the above formula, each R 23 is independently at each occurrence halogen, (C1-C3) alkyl, (C1-C3) alkoxy, (C1-C3) haloalkyl, (C1-C3) haloalkoxy, -CH2(OCH2CH2) 1~3OCH2CH3, -OH, CN, or a 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the heterocyclyl is optionally selected from halogen, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, -OH, -C(O)R 24 , -NR 24 C(O)R 25 , -NH2, -NH(C1-C6)alkyl, and -N((C1-C6)alkyl)2, and alkyl is optionally substituted with 1 to 3 substituents each independently selected from -NR 24 R 25 or a 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, optionally substituted by 1 to 3 substituents each independently selected from halogen, (C-C)alkyl, (C-C)alkoxy, (C-C)haloalkyl, (C-C)haloalkoxy, -OH, -NH, -NH(C-C)alkyl, and -N((C-C)alkyl).

[0195] In another embodiment, each R 23 is independently at each occurrence halogen, (C1-C3)alkyl, (C1-C3)alkoxy, (C1-C3)haloalkyl, (C1-C3)haloalkoxy, -OH, CN, or a 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, where heterocyclyl is halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, -OH, -C(O)R 24 , -NR 24 C(O)R 25 , -NH2, -NH(C1-C6)alkyl, and -N((C1-C6)alkyl)2, and alkyl is optionally substituted with 1 to 3 substituents each independently selected from -NR 24 R 25or a 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, optionally substituted by 1 to 3 substituents each independently selected from halogen, (C-C)alkyl, (C-C)alkoxy, (C-C)haloalkyl, (C-C)haloalkoxy, -OH, -NH, -NH(C-C)alkyl, and -N((C-C)alkyl).

[0196] In another embodiment, each R 23 is independently at each occurrence halogen, (C1-C3) alkyl, (C1-C3) haloalkyl, -CH2(OCH2CH2) 1~3 OCH2CH3, -OH, CN, or a 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the heterocyclyl is optionally selected from halogen, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, -OH, -C(O)R 24 , -NR 24 C(O)R 25 , -NH2, -NH(C1-C6)alkyl, and -N((C1-C6)alkyl)2, and alkyl is optionally substituted with 1 to 3 substituents each independently selected from -NR 24 R 25 or a 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, optionally substituted by 1 to 3 substituents each independently selected from halogen, (C-C)alkyl, (C-C)alkoxy, (C-C)haloalkyl, (C-C)haloalkoxy, -OH, -NH, -NH(C-C)alkyl, and -N((C-C)alkyl).

[0197] In another embodiment, each R 23is independently at each occurrence halogen, (C1-C3)alkyl, (C1-C3)haloalkyl, -OH, CN, or a 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, where heterocyclyl is optionally selected from halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, -OH, -C(O)R 24 , -NR 24 C(O)R 25 , -NH2, -NH(C1-C6)alkyl, and -N((C1-C6)alkyl)2, and alkyl is optionally substituted with 1 to 3 substituents each independently selected from -NR 24 R 25 or a 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, optionally substituted by 1 to 3 substituents each independently selected from halogen, (C-C)alkyl, (C-C)alkoxy, (C-C)haloalkyl, (C-C)haloalkoxy, -OH, -NH, -NH(C-C)alkyl, and -N((C-C)alkyl).

[0198] In another embodiment, each R 23 is independently at each occurrence halogen, (C1-C3)alkyl, (C1-C3)alkoxy, (C1-C3)haloalkyl, (C1-C3)haloalkoxy, or 4- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, where heterocyclyl is optionally selected from halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, -OH, -C(O)R 24 , -NR 24 C(O)R 25 , -NH2, -NH(C1-C6)alkyl, and -N((C1-C6)alkyl)2, and alkyl is optionally substituted with 1 to 3 substituents each independently selected from -NR 24 R 25or a 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, optionally substituted by 1 to 3 substituents each independently selected from halogen, (C-C)alkyl, (C-C)alkoxy, (C-C)haloalkyl, (C-C)haloalkoxy, -OH, -NH, -NH(C-C)alkyl, and -N((C-C)alkyl).

[0199] In another embodiment, each R 23 is independently at each occurrence halogen, (C1-C3)alkyl, or 4- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, where heterocyclyl is optionally selected from halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, -OH, -C(O)R 24 , -NR 24 C(O)R 25 , -NH2, -NH(C1-C6)alkyl, and -N((C1-C6)alkyl)2, and alkyl is optionally substituted with 1 to 3 substituents each independently selected from -NR 24 R 25 or a 4- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, optionally substituted with 1-3 substituents each independently selected from halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, -OH, -NH2, -NH(C1-C6)alkyl, and -N((C1-C6)alkyl)2. 23 is independently at each occurrence (C1-C3)alkyl or a 4- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, where heterocyclyl is optionally selected from halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, -OH, -C(O)R 24, -NR 24 C(O)R 25 , -NH2, -NH(C1-C6)alkyl, and -N((C1-C6)alkyl)2, and alkyl is optionally substituted with 1 to 3 substituents each independently selected from -NR 24 R 25 or a 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, optionally substituted by 1 to 3 substituents each independently selected from halogen, (C-C)alkyl, (C-C)alkoxy, (C-C)haloalkyl, (C-C)haloalkoxy, -OH, -NH, -NH(C-C)alkyl, and -N((C-C)alkyl).

[0200] In another embodiment, each R 23 is independently at each occurrence (C1-C3)alkyl or a 4- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, where heterocyclyl is selected from halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, -OH, -C(O)R 24 , -NR 24 C(O)R 25 , -NH2, -NH(C1-C6)alkyl, and -N((C1-C6)alkyl)2, and alkyl is optionally substituted with 1 to 3 substituents each independently selected from -NR 24 R 25 or a 4- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, optionally substituted with 1-3 substituents each independently selected from halogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, -OH, -NH2, -NH(C1-C6)alkyl, and -N((C1-C6)alkyl)2. 23is independently at each occurrence (C1-C3)alkyl or a 4- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, where heterocyclyl is optionally selected from (C1-C6)alkyl, (C1-C6)haloalkyl, -OH, -C(O)R 24 , -NR 24 C(O)R 25 , -NH2, -NH(C1-C6)alkyl, and -N((C1-C6)alkyl)2, and alkyl is optionally substituted with 1 to 3 substituents each independently selected from -NR 24 R 25 or a 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, optionally substituted by 1 to 3 substituents each independently selected from halogen, (C1-C6)alkyl, (C1-C6)haloalkyl, —OH, —NH2, —NH(C1-C6)alkyl, and —N((C1-C6)alkyl)2.

[0201] In another embodiment, each R 23 is independently at each occurrence (C1-C3)alkyl or a 4- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, where the heterocyclyl is optionally substituted with 1-3 substituents each independently selected from (C1-C6)alkyl, (C1-C6)haloalkyl, —OH, —NH2, —NH(C1-C6)alkyl, and —N((C1-C6)alkyl)2, and the alkyl is optionally substituted with —NR 24 R 25 or a 4- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, optionally substituted with 1-3 substituents each independently selected from (C1-C6)alkyl, (C1-C6)haloalkyl, -OH, -NH2, -NH(C1-C6)alkyl, and -N((C1-C6)alkyl)2. 23is independently at each occurrence (C1-C3)alkyl or a 4- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, where the heterocyclyl is optionally substituted with 1-3 substituents each independently selected from (C1-C6)alkyl, —OH, —NH2, —NH(C1-C6)alkyl, and —N((C1-C6)alkyl)2, and the alkyl is optionally substituted with —NR 24 R 25 or a 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, optionally substituted by 1 to 3 substituents each independently selected from (C1-C6)alkyl, —OH, —NH2, —NH(C1-C6)alkyl, and —N((C1-C6)alkyl)2.

[0202] In another embodiment, each R 23 is independently at each occurrence (C1-C3)alkyl or a 4- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the heterocyclyl is optionally substituted with 1-3 (C1-C6)alkyl, and the alkyl is optionally substituted with -NR 24 R 25 or a 4- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, optionally substituted with 1-3 substituents each independently selected from -OH, -NH, -NH(C-C)alkyl, and -N((C-C)alkyl). 23 is independently at each occurrence (C1-C3)alkyl or a 4- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the heterocyclyl is optionally substituted with 1-3 (C1-C6)alkyl, and the alkyl is optionally substituted with -NR 24 R 25or a 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, optionally substituted with 1 to 3 substituents each independently selected from -OH and -N((C1-C6)alkyl)2.

[0203] In some embodiments of the above formula, R 24 is H, (C1-C3) alkyl, or (C3-C7) carbocyclyl optionally substituted with 1-2 (C1-C6) alkyl. 24 is H, (C1-C3) alkyl, or (C3-C7) carbocyclyl optionally substituted with 1-2 (C1-C3) alkyl. 24 is H, (C1-C3) alkyl, or (C3-C7) carbocyclyl. 24 is H, (C1-C3) alkyl, or (C3-C5) carbocyclyl. 24 is H or (C1-C3) alkyl. In another embodiment, R 24 is H. In another embodiment, R 24 is (C1-C3) alkyl. In yet another embodiment, R 24 is (C-C)carbocyclyl optionally substituted with 1-2 (C-C)alkyl. 24 is (C-C)carbocyclyl. 24 is H, methyl, ethyl, n-propyl, or i-propyl. 24 is methyl, ethyl, n-propyl, or i-propyl. 24 is H, methyl, ethyl, cyclopropyl, cyclobutyl, or cyclopentyl, wherein cyclopropyl, cyclobutyl, and cyclopentyl are optionally substituted with 1 to 2 (C1-C3) alkyl. 24is H, methyl, ethyl, cyclopropyl, or cyclobutyl, wherein cyclopropyl and cyclobutyl are optionally substituted with 1 to 2 (C1-C3) alkyl. 24 is H, methyl, ethyl, cyclopropyl, cyclobutyl, or cyclopentyl. 24 is H, methyl, ethyl, cyclopropyl or cyclobutyl. 24 is H, methyl or ethyl. In another embodiment, R 24 is methyl or ethyl. In yet another embodiment, R 24 is H or methyl. In another embodiment, R 24 is methyl.

[0204] In some embodiments of the above formula, R 25 is H, (C1-C3) alkyl, or (C3-C7) carbocyclyl optionally substituted with 1-2 (C1-C6) alkyl. 25 is H, (C1-C3) alkyl, or (C3-C7) carbocyclyl optionally substituted with 1-2 (C1-C3) alkyl. 25 is H, (C1-C3) alkyl, or (C3-C7) carbocyclyl. 25 is H, (C1-C3) alkyl, or (C3-C5) carbocyclyl. 25 is H or (C1-C3) alkyl. In another embodiment, R 25 is H. In another embodiment, R 25 is (C1-C3) alkyl. In yet another embodiment, R 25 is (C-C)carbocyclyl optionally substituted with 1-2 (C-C)alkyl. 25 is (C-C)carbocyclyl. 25is H, methyl, ethyl, n-propyl, or i-propyl. 25 is methyl, ethyl, n-propyl, or i-propyl. 25 is H, methyl, ethyl, cyclopropyl, cyclobutyl, or cyclopentyl, wherein cyclopropyl, cyclobutyl, and cyclopentyl are optionally substituted with 1 to 2 (C1-C3) alkyl. 25 is H, methyl, ethyl, cyclopropyl, or cyclobutyl, wherein cyclopropyl and cyclobutyl are optionally substituted with 1 to 2 (C1-C3) alkyl. 25 is H, methyl, ethyl, cyclopropyl, cyclobutyl, or cyclopentyl. 25 is H, methyl, ethyl, cyclopropyl or cyclobutyl. 25 is H, methyl or ethyl. In another embodiment, R 25 is methyl or ethyl. In yet another embodiment, R 25 is H or methyl. In another embodiment, R 25 is methyl.

[0205] In some embodiments of the above formula, R4 is H or (C1-C6) alkyl. In another embodiment, R4 is H or (C1-C6) alkyl, and R5 is H or (C1-C6) alkyl. In another embodiment, R4 is H or (C1-C6) alkyl, R5 is H or (C1-C6) alkyl, and R7 is H or (C1-C6) alkyl. In another embodiment, R4 is H or (C1-C6) alkyl, R5 is H or (C1-C6) alkyl, R7 is H or (C1-C6) alkyl, and R9 is halogen. In another embodiment, R4 is H or (C1-C6) alkyl, R5 is H or (C1-C6) alkyl, R7 is H or (C1-C6) alkyl, and R9 is chloro. In another embodiment, R4 is H, and R5 is H or (C1-C6) alkyl. In another embodiment, R4 is H, R5 is H or (C1-C6) alkyl, and R7 is H or (C1-C6) alkyl. In another embodiment, R4 is H, R5 is H or (C1-C6) alkyl, R7 is H or (C1-C6) alkyl, and R9 is halogen. In another embodiment, R4 is H, R5 is H or (C1-C6) alkyl, R7 is H or (C1-C6) alkyl, and R9 is chloro.

[0206] In some embodiments of the above formula, R4 is H or (C1-C6) alkyl, and R5 is (C1-C6) alkyl. In other embodiments, R4 is H or (C1-C6) alkyl, R5 is (C1-C6) alkyl, and R7 is H or (C1-C6) alkyl. In other embodiments, R4 is H or (C1-C6) alkyl, R5 is (C1-C6) alkyl, R7 is H or (C1-C6) alkyl, and R9 is halogen. In other embodiments, R4 is H or (C1-C6) alkyl, R5 is (C1-C6) alkyl, R7 is H or (C1-C6) alkyl, and R9 is chloro. In other embodiments, R4 is H, and R5 is (C1-C6) alkyl. In another embodiment, R4 is H, R5 is (C1-C6)alkyl, and R7 is H or (C1-C6)alkyl. In another embodiment, R4 is H, R5 is (C1-C6)alkyl, R7 is H or (C1-C6)alkyl, and R9 is halogen. In another embodiment, R4 is H, R5 is (C1-C6)alkyl, R7 is H or (C1-C6)alkyl, and R9 is chloro.

[0207] In some embodiments of the above formula, R4 is H or (C1-C6) alkyl, R5 is H or (C1-C6) alkyl, and R7 is (C1-C6) alkyl. In other embodiments, R4 is H or (C1-C6) alkyl, R5 is H or (C1-C6) alkyl, R7 is (C1-C6) alkyl, and R9 is halogen. In other embodiments, R4 is H or (C1-C6) alkyl, R5 is H or (C1-C6) alkyl, R7 is (C1-C6) alkyl, and R9 is chloro. In other embodiments, R4 is H, R5 is H or (C1-C6) alkyl, and R7 is (C1-C6) alkyl. In other embodiments, R4 is H, R5 is H or (C1-C6) alkyl, R7 is (C1-C6) alkyl, and R9 is halogen. In another embodiment, R4 is H, R5 is H or (C1-C6) alkyl, R7 is (C1-C6) alkyl, and R9 is chloro.

[0208] In some embodiments of the above formula, R4 is H or (C1-C6) alkyl, R5 is (C1-C6) alkyl, and R7 is (C1-C6) alkyl. In other embodiments, R4 is H or (C1-C6) alkyl, R5 is (C1-C6) alkyl, R7 is (C1-C6) alkyl, and R9 is halogen. In other embodiments, R4 is H or (C1-C6) alkyl, R5 is (C1-C6) alkyl, R7 is (C1-C6) alkyl, and R9 is chloro. In other embodiments, R4 is H, R5 is (C1-C6) alkyl, and R7 is (C1-C6) alkyl. In other embodiments, R4 is H, R5 is (C1-C6) alkyl, R7 is (C1-C6) alkyl, and R9 is halogen. In another embodiment, R4 is H, R5 is (C1-C6) alkyl, R7 is (C1-C6) alkyl, and R9 is chloro.

[0209] In some embodiments of the above formula, R5 is H or (C1-C6) alkyl. In other embodiments, R5 is H or (C1-C6) alkyl, and R7 is H or (C1-C6) alkyl. In other embodiments, R5 is H or (C1-C6) alkyl, R7 is H or (C1-C6) alkyl, and R9 is halogen. In other embodiments, R4 is H or (C1-C6) alkyl, R5 is H or (C1-C6) alkyl, R7 is H or (C1-C6) alkyl, and R9 is chloro.

[0210] In some embodiments of the above formula, R5 is (C1-C6) alkyl. In another embodiment, R5 is (C1-C6) alkyl, and R7 is H or (C1-C6) alkyl. In another embodiment, R5 is (C1-C6) alkyl, R7 is H or (C1-C6) alkyl, and R9 is halogen. In another embodiment, R5 is (C1-C6) alkyl, R7 is H or (C1-C6) alkyl, and R9 is chloro. In another embodiment, R5 is H or (C1-C6) alkyl, and R7 is (C1-C6) alkyl. In another embodiment, R5 is H or (C1-C6) alkyl, R7 is (C1-C6) alkyl, and R9 is halogen. In another embodiment, R5 is H or (C1-C6) alkyl, R7 is (C1-C6) alkyl, and R9 is chloro. In another embodiment, R5 is (C1-C6) alkyl, and R7 is (C1-C6) alkyl. In another embodiment, R5 is (C1-C6) alkyl, R7 is (C1-C6) alkyl, and R9 is halogen. In another embodiment, R5 is (C1-C6) alkyl, R7 is (C1-C6) alkyl, and R9 is chloro.

[0211] In some embodiments of the above formula, R4 is H or (C1-C6) alkyl, and R7 is H or (C1-C6) alkyl. In other embodiments, R4 is H or (C1-C6) alkyl, R7 is H or (C1-C6) alkyl, and R9 is halogen. In other embodiments, R4 is H or (C1-C6) alkyl, R7 is H or (C1-C6) alkyl, and R9 is chloro. In another embodiment, R4 is H, and R7 is H or (C1-C6) alkyl. In another embodiment, R4 is H, R7 is H or (C1-C6) alkyl, and R9 is halogen. In another embodiment, R4 is H, R7 is H or (C1-C6) alkyl, and R9 is chloro. In some embodiments of the above formula, R4 is H or (C1-C6) alkyl, and R7 is (C1-C6) alkyl. In another embodiment, R4 is H or (C1-C6) alkyl, R7 is (C1-C6) alkyl, and R9 is halogen. In another embodiment, R4 is H or (C1-C6) alkyl, R7 is (C1-C6) alkyl, and R9 is chloro. In another embodiment, R4 is H, and R7 is (C1-C6) alkyl. In another embodiment, R4 is H, R7 is (C1-C6) alkyl, and R9 is halogen. In another embodiment, R4 is H, R7 is (C1-C6) alkyl, and R9 is chloro.

[0212] In some embodiments of the above formula, R4 is H or (C1-C6) alkyl, R5 is H or (C1-C6) alkyl, and R9 is halogen. In other embodiments, R4 is H or (C1-C6) alkyl, R5 is H or (C1-C6) alkyl, and R9 is chloro. In other embodiments, R4 is H, R5 is H or (C1-C6) alkyl, and R9 is halogen. In other embodiments, R4 is H, R5 is H or (C1-C6) alkyl, and R9 is chloro. In other embodiments, R4 is H or (C1-C6) alkyl, R5 is (C1-C6) alkyl, and R9 is halogen. In other embodiments, R4 is H or (C1-C6) alkyl, R5 is (C1-C6) alkyl, and R9 is halogen. In other embodiments, R4 is H or (C1-C6) alkyl, R5 is (C1-C6) alkyl, and R9 is chloro. In another embodiment, R4 is H, R5 is (C1-C6) alkyl, and R9 is halogen. In another embodiment, R4 is H, R5 is (C1-C6) alkyl, and R9 is chloro.

[0213] In some embodiments of the above formula, R4 is H or (C1-C6) alkyl, and R9 is halogen. In another embodiment, R4 is H or (C1-C6) alkyl, and R9 is chloro. In another embodiment, R4 is H and R9 is halogen. In another embodiment, R4 is H and R9 is chloro. In another embodiment, R5 is H or (C1-C6) alkyl, and R9 is halogen. In another embodiment, R5 is H or (C1-C6) alkyl, and R9 is chloro. In another embodiment, R5 is (C1-C6) alkyl, and R9 is halogen. In another embodiment, R5 is (C1-C6) alkyl, and R9 is chloro. In another embodiment, R7 is H or (C1-C6) alkyl, and R9 is halogen. In another embodiment, R7 is H or (C1-C6) alkyl, and R9 is chloro. In another embodiment, R7 is (C1-C6) alkyl and R9 is halogen. In another embodiment, R7 is (C1-C6) alkyl and R9 is chloro.

[0214] In some embodiments of the above formula, X1 and X2, together with the carbon atom to which they are attached, form =(O), and X3 is -CH2-. In another embodiment, X1 and X2, together with the carbon atom to which they are attached, form =(O), X3 is -CH2-, and R9 is Cl. In another embodiment, X1 and X2, together with the carbon atom to which they are attached, form =(O), X3 is -CH2-, R9 is Cl, and R4 is H. In yet another embodiment, X1 and X2, together with the carbon atom to which they are attached, form =(O), X3 is -CH2-, R9 is Cl, R4 is H, and R7 is H. In another embodiment, X1 and X2, together with the carbon atom to which they are attached, form =(O), X3 is -CH2-, R9 is Cl, R4 is H, R7 is H, and R5 is H or (C1-C4) alkyl. In yet another embodiment, X1 and X2 together with the carbon atom to which they are attached form =(O), R9 is Cl, R4 is H, R7 is H, R5 is H or (C1-C4) alkyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 is replaced by .

[0215] In another embodiment, X1 and X2 together with the carbon atom to which they are attached form =(O), X3 is -CH2-, R9 is Cl, R4 is H, R7 is H, and R5 is H or (C1-C4)alkyl. In yet another embodiment, X1 and X2 together with the carbon atom to which they are attached form =(O), R9 is Cl, R4 is H, R7 is H, R5 is H or (C1-C4)alkyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R11 In another embodiment, X1 and X2 together with the carbon atom to which they are attached form =(O), X3 is -CH2-, R9 is Cl, R4 is H, R7 is H, R5 is H or (C1-C4) alkyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are substituted with -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, -NR 12 R 13 , (C1-C6)haloalkyl, (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 is replaced by .

[0216] In another embodiment, X1 and X2 together with the carbon atom to which they are attached form =(O), X3 is -CH2-, R9 is Cl, R4 is H, R7 is H, R5 is H or (C1-C4) alkyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19and R3 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl, optionally substituted with 1 to 3 R 14 In yet another embodiment, X1 and X2 together with the carbon atom to which they are attached form =(O), X3 is -CH2-, R9 is Cl, R4 is H, R7 is H, R5 is H or (C1-C4) alkyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 and R3 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl, optionally substituted with 1 to 3 R 14 and R6 is (C1-C6)hydroxyalkyl or (C1-C6)alkyl optionally substituted with 1 to 3 substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl.

[0217] In another embodiment, X1 and X2 together with the carbon atom to which they are attached form =(O), X3 is -CH2-, R9 is Cl, R4 is H, R7 is H, R5 is H or (C1-C4) alkyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 and R3 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl, optionally substituted with 1 to 3 R 14 R6 is (C1-C6)hydroxyalkyl or (C1-C6)alkyl optionally substituted with 1 to 3 substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl; and R8 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl optionally substituted with 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, and —C(O)NR 16 R 17 is alkyl optionally substituted with 1 to 3 substituents each independently selected from:

[0218] In yet another embodiment, X1 and X2 together with the carbon atom to which they are attached form =(O), X3 is -CH2-, R9 is Cl, R4 is H, R7 is H, R5 is H or (C1-C4) alkyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 and R3 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl, optionally substituted with 1 to 3 additional R 14 R6 is (C1-C6)hydroxyalkyl or (C1-C6)alkyl optionally substituted with 1 to 3 substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl; R8 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl optionally substituted with 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, and —C(O)NR 16 R 17 and R 10 is phenyl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, where the aryl and heteroaryl are optionally joined by 1 to 3 R 22 is replaced by .

[0219] In another embodiment, X1 and X2 together with the carbon atom to which they are attached form =(O), X3 is -CH2-, R9 is Cl, R4 is H, R7 is H, and R5 is H or methyl. In another embodiment, X1 and X2 together with the carbon atom to which they are attached form =(O), R9 is Cl, R4 is H, R7 is H, R5 is H or methyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 In yet another embodiment, X1 and X2 together with the carbon atom to which they are attached form =(O), R9 is Cl, R4 is H, R7 is H, R5 is H or methyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are substituted with -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 is replaced by .

[0220] In another embodiment, X1 and X2 together with the carbon atom to which they are attached form =(O), X3 is -CH2-, R9 is Cl, R4 is H, R7 is H, R5 is H or methyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 and R3 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl, optionally substituted with 1 to 3 R 14 In yet another embodiment, X1 and X2 together with the carbon atom to which they are attached form =(O), X3 is -CH2-, R9 is Cl, R4 is H, R7 is H, R5 is H or methyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19and R3 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl, optionally substituted with 1 to 3 R 14 and R6 is (C1-C6)hydroxyalkyl or (C1-C6)alkyl optionally substituted with 1 to 3 substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl.

[0221] In another embodiment, X1 and X2 together with the carbon atom to which they are attached form =(O), X3 is -CH2-, R9 is Cl, R4 is H, R7 is H, R5 is H or methyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 and R3 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl, optionally substituted with 1 to 3 R 14R6 is (C1-C6)hydroxyalkyl or (C1-C6)alkyl optionally substituted with 1 to 3 substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl; and R8 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl optionally substituted with 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, and —C(O)NR 16 R 17 is alkyl optionally substituted with 1 to 3 substituents each independently selected from:

[0222] In yet another embodiment, X1 and X2 together with the carbon atom to which they are attached form =(O), X3 is -CH2-, R9 is Cl, R4 is H, R7 is H, R5 is H or methyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 and R3 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl, optionally substituted with 1 to 3 R 14R6 is (C1-C6)hydroxyalkyl or (C1-C6)alkyl optionally substituted with 1 to 3 substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl; R8 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl optionally substituted with 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, and —C(O)NR 16 R 17 and R 10 is phenyl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, where the aryl and heteroaryl are optionally joined by 1 to 3 R 22 and R 10 is phenyl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, where the aryl and heteroaryl are optionally joined by 1 to 3 R 22 is replaced by .

[0223] In some embodiments of the above formula, X1 is H, X2 is H, and X3 is -CH2-. In another embodiment, X1 is H, X2 is H, X3 is -CH2-, and R9 is Cl. In another embodiment, X1 is H, X2 is H, R9 is Cl, and R4 is H. In yet another embodiment, X1 is H, X2 is H, X3 is -CH2-, R9 is Cl, R4 is H, and R7 is H. In another embodiment, X1 is H, X2 is H, X3 is -CH2-, R9 is Cl, R4 is H, R7 is H, and R5 is H or (C1-C4) alkyl. In yet another embodiment, X1 is H, and X2 is H, X3 is -CH2-, R9 is Cl, R4 is H, R7 is H, R5 is H or (C1-C4) alkyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein aryl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 In another embodiment, X1 is H and X2 is H, X3 is -CH2-, R9 is Cl, R4 is H, R7 is H, R5 is H or (C1-C4) alkyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are substituted with -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 is replaced by .

[0224] In yet another embodiment, X1 is H and X2 is H, X3 is -CH2-, R9 is Cl, R4 is H, R7 is H, R5 is H or (C1-C4) alkyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 and R3 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl, optionally substituted with 1 to 3 R 14 In another embodiment, X1 is H and X2 is H, X3 is -CH2-, R9 is Cl, R4 is H, R7 is H, R5 is H or (C1-C4) alkyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19and R3 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl, optionally substituted with 1 to 3 R 14 and R6 is (C1-C6)hydroxyalkyl or (C1-C6)alkyl optionally substituted with 1 to 3 substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl.

[0225] In yet another embodiment, X1 is H and X2 is H, X3 is -CH2-, R9 is Cl, R4 is H, R7 is H, R5 is H or (C1-C4) alkyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 and R3 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl, optionally substituted with 1 to 3 R 14R6 is (C1-C6)hydroxyalkyl or (C1-C6)alkyl optionally substituted with 1 to 3 substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl; and R8 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl optionally substituted with 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, and —C(O)NR 16 R 17 is alkyl optionally substituted with 1 to 3 substituents each independently selected from:

[0226] In another embodiment, X1 is H and X2 is H, X3 is -CH2-, R9 is Cl, R4 is H, R7 is H, R5 is H or (C1-C4) alkyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 and R3 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl, optionally substituted with 1 to 3 R 14R6 is (C1-C6)hydroxyalkyl or (C1-C6)alkyl optionally substituted with 1 to 3 substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl; R8 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl optionally substituted with 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, and —C(O)NR 16 R 17 and R8 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl, including 4- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and —C(O)NR 16 R 17 and R 10 is phenyl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, where the aryl and heteroaryl are optionally joined by 1 to 3 R 22 and R 10 is phenyl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, where the aryl and heteroaryl are optionally joined by 1 to 3 R 22 is replaced by .

[0227] In some embodiments of the above formula, X1 is H and X2 is H, X3 is -CH2-, R9 is Cl, R4 is H, R7 is H, and R5 is H or methyl. In other embodiments, X1 is H and X2 is H, R9 is Cl, R4 is H, R7 is H, R5 is H or methyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, where phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 In yet another embodiment, X1 is H and X2 is H, R9 is Cl, R4 is H, R7 is H, R5 is H or methyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are substituted with -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 is replaced by .

[0228] In another embodiment, X1 is H and X2 is H, X3 is -CH2-, R9 is Cl, R4 is H, R7 is H, R5 is H or methyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 and R3 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl, optionally substituted with 1 to 3 R 14 In yet another embodiment, X1 is H and X2 is H, X3 is -CH2-, R9 is Cl, R4 is H, R7 is H, R5 is H or methyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 and R3 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl, optionally substituted with 1 to 3 R 14 and R6 is (C1-C6)hydroxyalkyl or (C1-C6)alkyl optionally substituted with 1 to 3 substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl.

[0229] In another embodiment, X1 is H and X2 is H, X3 is -CH2-, R9 is Cl, R4 is H, R7 is H, R5 is H or methyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 and R3 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl, optionally substituted with 1 to 3 R 14 R6 is (C1-C6)hydroxyalkyl or (C1-C6)alkyl optionally substituted with 1 to 3 substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl; and R8 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl optionally substituted with 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, and —C(O)NR 16 R 17 is alkyl optionally substituted with 1 to 3 substituents each independently selected from:

[0230] In yet another embodiment, X1 is H and X2 is H, X3 is -CH2-, R9 is Cl, R4 is H, R7 is H, R5 is H or methyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 and R3 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl, optionally substituted with 1 to 3 R 14 R6 is (C1-C6)hydroxyalkyl or (C1-C6)alkyl optionally substituted with 1 to 3 substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl; R8 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl optionally substituted with 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, and —C(O)NR 16 R 17 and R 10 is phenyl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, where the aryl and heteroaryl are optionally joined by 1 to 3 R 22 and R 10is phenyl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, where the aryl and heteroaryl are optionally joined by 1 to 3 R 22 is replaced by .

[0231] In some embodiments of the above formula, X1 and X2 together with the carbon atoms to which they are attached form =(O), X3 is -CH2-, R9 is Cl, and R3 and R4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S. In other embodiments, X1 and X2 together with the carbon atoms to which they are attached form =(O), X3 is -CH2-, R9 is Cl, R3 and R4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S, and R7 is H. In yet another embodiment, X1 and X2 together with the carbon atoms to which they are attached form =(O), X3 is -CH2-, R9 is Cl, R3 and R4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S, R7 is H, and R5 is H or (C1-C4)alkyl. In another embodiment, X1 and X2 together with the carbon atoms to which they are attached form =(O), X3 is -CH2-, R9 is Cl, R3 and R4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S, R7 is H, R5 is H or (C1-C4)alkyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, where phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 is replaced by .

[0232] In another embodiment, X1 and X2 together with the carbon atoms to which they are attached form =(O), X3 is -CH2-, R9 is Cl, R3 and R4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S, R7 is H, R5 is H or (C1-C4)alkyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, where phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 In yet another embodiment, X1 and X2 together with the carbon atom to which they are attached form =(O), X3 is -CH2-, R9 is Cl, R3 and R4 together with the atom to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S, R7 is H, R5 is H or (C1-C4)alkyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, where phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 and R6 is (C1-C6)hydroxyalkyl or (C1-C6)alkyl optionally substituted with 1 to 3 substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl.

[0233] In another embodiment, X1 and X2 together with the carbon atoms to which they are attached form =(O), X3 is -CH2-, R9 is Cl, R3 and R4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S, R7 is H, R5 is H or (C1-C4)alkyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, where phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19R6 is (C1-C6)hydroxyalkyl or (C1-C6)alkyl optionally substituted with 1 to 3 substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl; and R8 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl optionally substituted with 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, and —C(O)NR 16 R 17 is alkyl optionally substituted with 1 to 3 substituents each independently selected from:

[0234] In yet another embodiment, X1 and X2 together with the carbon atoms to which they are attached form =(O), X3 is -CH2-, R9 is Cl, R3 and R4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S, R7 is H, R5 is H or (C1-C4)alkyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, where phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19R6 is (C1-C6)hydroxyalkyl or (C1-C6)alkyl optionally substituted with 1 to 3 substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl; R8 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl optionally substituted with 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, and —C(O)NR 16 R 17 and R 10 is phenyl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, where the aryl and heteroaryl are optionally joined by 1 to 3 R 22 and R 10 is phenyl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, where the aryl and heteroaryl are optionally joined by 1 to 3 R 22 is replaced by .

[0235] In some embodiments of the above formula, X1 and X2 together with the carbon atoms to which they are attached form =(O), X3 is -CH2-, R9 is Cl, R3 and R4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S, R7 is H, and R5 is H or methyl. In another embodiment, X1 and X2 together with the carbon atoms to which they are attached form =(O), X3 is -CH2-, R9 is Cl, R3 and R4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S, R7 is H, R5 is H or methyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, where phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 is replaced by .

[0236] In yet another embodiment, X1 and X2 together with the carbon atom to which they are attached form =(O), X3 is -CH2-, R9 is Cl, R3 and R4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S, R7 is H, R5 is H or methyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, where phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 In another embodiment, X1 and X2 together with the carbon atom to which they are attached form =(O), X3 is -CH2-, R9 is Cl, R3 and R4 together with the atom to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S, R7 is H, R5 is H or methyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, where phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 and R6 is (C1-C6)hydroxyalkyl or (C1-C6)alkyl optionally substituted with 1 to 3 substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl.

[0237] In another embodiment, X1 and X2 together with the carbon atom to which they are attached form =(O), X3 is -CH2-, R9 is Cl, R3 and R4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S, R7 is H, R5 is H or methyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 R6 is (C1-C6)hydroxyalkyl or (C1-C6)alkyl optionally substituted with 1 to 3 substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl; and R8 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl optionally substituted with 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, and —C(O)NR 16 R 17 is alkyl optionally substituted with 1 to 3 substituents each independently selected from:

[0238] In yet another embodiment, X1 and X2 together with the carbon atom to which they are attached form =(O), X3 is -CH2-, R9 is Cl, R3 and R4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S, R7 is H, R5 is H or methyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, where phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 R6 is (C1-C6)hydroxyalkyl or (C1-C6)alkyl optionally substituted with 1 to 3 substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl; R8 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl optionally substituted with 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, and —C(O)NR 16 R 17 and R 10 is phenyl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, where the aryl and heteroaryl are optionally joined by 1 to 3 R 22 is replaced by .

[0239] In some embodiments of the above formula, X1 is H, and X2 is H, X3 is -CH2-, R9 is Cl, and R3 and R4, together with the atoms to which they are attached, form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S. In other embodiments, X1 is H, and X2 is H, X3 is -CH2-, R9 is Cl, R3 and R4, together with the atoms to which they are attached, form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S, and R7 is H. In yet another embodiment, X1 is H and X2 is H, X3 is -CH2-, R9 is Cl, R3 and R4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S, R7 is H, and R5 is H or (C1-C4)alkyl. In another embodiment, X1 is H and X2 is H, X3 is -CH2-, R9 is Cl, R3 and R4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S, R7 is H, R5 is H or (C1-C4)alkyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, where phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 is replaced by .

[0240] In another embodiment, X1 is H and X2 is H, X3 is -CH2-, R9 is Cl, R3 and R4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S, R7 is H, R5 is H or (C1-C4) alkyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are -OR 10and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 is replaced by .

[0241] In yet another embodiment, X1 is H and X2 is H, X3 is -CH2-, R9 is Cl, R3 and R4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S, R7 is H, R5 is H or (C1-C4) alkyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, where phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 and R6 is (C1-C6)hydroxyalkyl or (C1-C6)alkyl optionally substituted with 1 to 3 substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl.

[0242] In another embodiment, X1 is H and X2 is H, X3 is -CH2-, R9 is Cl, R3 and R4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S, R7 is H, R5 is H or (C1-C4) alkyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 R6 is (C1-C6)hydroxyalkyl or (C1-C6)alkyl optionally substituted with 1 to 3 substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl; and R8 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl optionally substituted with 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, and —C(O)NR 16 R 17 is alkyl optionally substituted with 1 to 3 substituents each independently selected from:

[0243] In yet another embodiment, X1 is H and X2 is H, X3 is -CH2-, R9 is Cl, R3 and R4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S, R7 is H, R5 is H or (C1-C4) alkyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, where phenyl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 R6 is (C1-C6)hydroxyalkyl or (C1-C6)alkyl optionally substituted with 1 to 3 substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl; R8 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl optionally substituted with 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, and —C(O)NR 16 R 17 and R 10 is phenyl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, where the aryl and heteroaryl are optionally joined by 1 to 3 R 22 is replaced by .

[0244] In some embodiments of the above formula, X1 is H, and X2 is H, X3 is -CH2-, R9 is Cl, R3 and R4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S, R7 is H, R5 is H or methyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, where aryl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 In another embodiment, X1 is H and X2 is H, R9 is Cl, R3 and R4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S, R7 is H, R5 is H or methyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, where aryl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 is replaced by .

[0245] In yet another embodiment, X1 is H and X2 is H, X3 is -CH2-, R9 is Cl, R3 and R4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S, R7 is H, R5 is H or methyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, where aryl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 and R6 is (C1-C6)hydroxyalkyl or (C1-C6)alkyl optionally substituted with 1 to 3 substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl.

[0246] In another embodiment, X1 is H and X2 is H, X3 is -CH2-, R9 is Cl, R3 and R4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S, R7 is H, R5 is H or methyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein aryl and heteroaryl are -OR 10 and optionally 1 to 3 R 11and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13 , (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 R6 is (C1-C6)hydroxyalkyl or (C1-C6)alkyl optionally substituted with 1 to 3 substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl; and R8 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl optionally substituted with 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, and —C(O)NR 16 R 17 is alkyl optionally substituted with 1 to 3 substituents each independently selected from:

[0247] In another embodiment, X1 is H and X2 is H, X3 is -CH2-, R9 is Cl, R3 and R4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S, R7 is H, R5 is H or methyl, and R1 is phenyl or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein aryl and heteroaryl are -OR 10 and optionally 1 to 3 R 11 and R2 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -NR 12 R 13, (C3-C7)carbocyclyl, or 5- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains 1-4 R 18 and the carbocyclyl and heterocyclyl are optionally substituted with 1 to 4 R 19 R6 is (C1-C6)hydroxyalkyl or (C1-C6)alkyl optionally substituted with 1 to 3 substituents each independently selected from (C1-C6)alkoxy, (C1-C6)haloalkoxy, —C(O)(C1-C6)alkyl, —C(O)OH, and —C(O)O(C1-C6)alkyl; R8 is H, (C1-C6)haloalkyl, or (C1-C6)alkyl optionally substituted with 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, and —C(O)NR 16 R 17 and R 10 is phenyl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, where the aryl and heteroaryl are optionally joined by 1 to 3 R 22 is replaced by .

[0248] In another embodiment, X1 and X2 together with the carbon atom to which they are attached form =(O), X3 is -CH2-, R9 is Cl, R3 and R4 together with the atom to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S, R7 is H, R5 is H or methyl, and R1 is -OR 10 and optionally 1 to 3 R 11 and R2 is (C1-C6) alkyl, or (C3-C7) carbocyclyl, where the alkyl is optionally substituted with 1 to 4 R 18 and the carbocyclyl is optionally substituted with 1 to 4 R 19wherein R6 is (C1-C6)hydroxyalkyl, R8 is a 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, and —C(O)NR 16 R 17 and R 10 is 1 to 3 R 22 is phenyl substituted with

[0249] Embodiment 1. A compound according to formula (I).

[0250] Embodiment 2. A compound according to embodiment 1, wherein R4 is H or (C1-C6) alkyl.

[0251] Embodiment 3. A compound according to embodiment 1 or 2, wherein R4 is H.

[0252] Embodiment 4. A compound according to embodiment 1, wherein R3 and R4, together with the atoms to which they are attached, form a 5- to 7-membered heterocyclyl ring containing 1-3 heteroatoms selected from N, O, and S.

[0253] Embodiment 5. A compound according to embodiment 1 or 3, wherein R3 and R4, together with the atoms to which they are attached, form a 6-membered heterocyclyl ring containing 1 to 3 heteroatoms selected from N, O, and S.

[0254] Embodiment 6. A compound according to any one of embodiments 1 to 5, wherein R5 is H or (C1-C6) alkyl.

[0255] Embodiment 7. A compound according to any one of embodiments 1 to 6, wherein R5 is (C1-C6) alkyl.

[0256] Embodiment 8. A compound according to any one of embodiments 1 to 7, wherein R7 is H or (C1-C6) alkyl.

[0257] Embodiment 9. A compound according to any one of embodiments 1 to 8, wherein R7 is (C1-C6) alkyl.

[0258] Embodiment 10. A compound according to any one of embodiments 1 to 9, wherein R9 is halogen.

[0259] Embodiment 11. A compound according to any one of embodiments 1 to 10, wherein R9 is chloro.

[0260] Embodiment 12. R8 is (C3-C7)carbocyclyl, 4- to 7-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, -NR 16 R 17 , and -C(O)NR 16 R 17 The compound according to any one of embodiments 1-11, wherein R is (C1-C6) alkyl optionally substituted with 1 to 3 substituents each independently selected from:

[0261] Embodiment 13. A compound according to any one of embodiments 1 to 12, wherein R8 is (C1-C6) alkyl.

[0262] Embodiment 14. A compound according to embodiment 1 having formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (Ii).

[0263] Embodiment 15. R1 is -OR 10 and optionally 1 to 3 R 11 The compound according to any one of embodiments 1 to 14, wherein the compound is phenyl substituted with

[0264] Embodiment 16. R1 is -OR 10 and optionally 1 to 3 R 11 The compound according to any one of embodiments 1 to 14, wherein the compound is pyridinyl substituted with

[0265] Embodiment 17. A compound according to embodiment 1 having formula (Ij), (Ik), (Im), or (Io) wherein x is 0, 1, or 2.

[0266] Embodiment 18.R 10 However, 1 to 3 R 22 The compound according to any one of embodiments 1 to 17, wherein the compound is phenyl substituted with

[0267] Embodiment 19.R 10 However, 1 to 3 R 22 18. The compound according to any one of embodiments 1 to 17, wherein the compound is pyridinyl substituted with

[0268] Embodiment 20. A compound (Cmd) according to embodiment 1 selected from:

[0269] [Table 1]

[0270] [Table 2]

[0271] [Table 3]

[0272] [Table 4]

[0273] [Table 5]

[0274] [Table 6]

[0275] [Table 7]

[0276] [Table 8]

[0277] [Table 9]

[0278] [Table 10]

[0279] [Table 11]

[0280] [Table 12]

[0281] [Table 13]

[0282] [Table 14]

[0283] [Table 15]

[0284] Embodiment 21. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of embodiments 1 to 20, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients.

[0285] Embodiment 22. A combination comprising a compound according to any one of embodiments 1 to 20, or a pharmaceutically acceptable salt thereof, and one or more additional therapeutically active agents.

[0286] Embodiment 23. A combination according to embodiment 22, wherein the additional therapeutically active agent is a statin.

[0287] Embodiment 24. A pharmaceutical composition according to embodiment 21 or a combination according to embodiment 22 or 23 for use in treating, preventing, ameliorating, or delaying the progression of a PCSK9-mediated disease or disorder.

[0288] Embodiment 25. The pharmaceutical composition or combination of embodiment 24, wherein the PCSK9-mediated disease or disorder, or disease or disorder requiring inhibition of PCSK9 activity, is selected from hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral vascular disease, peripheral arterial disease, vascular inflammation, elevated Lp(a), elevated LDL, elevated TRL, elevated triglycerides, sepsis, and xanthomas.

[0289] Embodiment 26. A method of modulating PCSK9, comprising administering to a patient in need thereof a compound of any one of embodiments 1-20, or a pharmaceutically acceptable salt thereof.

[0290] Embodiment 27. A method of inhibiting PCSK9, comprising administering to a patient in need thereof a compound of any one of embodiments 1-20, or a pharmaceutically acceptable salt thereof.

[0291] Embodiment 28. A method of treating, preventing, ameliorating, or delaying the progression of a PCSK9-mediated disease or disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of embodiments 1-20, or a pharmaceutically acceptable salt thereof.

[0292] Embodiment 29. The method of embodiment 28, wherein the PCSK9-mediated disease or disorder is selected from hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral vascular disease, peripheral arterial disease, vascular inflammation, elevated Lp(a), elevated LDL, elevated TRL, elevated triglycerides, sepsis, and xanthomas.

[0293] Embodiment 30. A method for (i) lowering Lp(a), (ii) lowering Lp(a) plasma levels, (iii) lowering Lp(a) serum levels, (iv) lowering serum TRL or LDL levels, (v) lowering serum triglyceride levels, (vi) lowering LDL-C, (vii) lowering total plasma apoB concentration, (viii) lowering LDL apoB, (ix) lowering TRL apoB, or (x) lowering non-HDL-C, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of any one of embodiments 1-20, or a pharmaceutically acceptable salt thereof, thereby lowering LDL-C in the patient.

[0294] Embodiment 31. The method of any one of embodiments 26 to 30, wherein administering is performed orally, parenterally, subcutaneously, by injection, or by infusion.

[0295] Embodiment 32. A compound according to any one of embodiments 1 to 20, or a pharmaceutically acceptable salt thereof, for use in treating a PCSK9-mediated disease or disorder.

[0296] Embodiment 33. A compound according to any one of embodiments 1 to 20, or a pharmaceutically acceptable salt thereof, for use in the treatment, prevention, amelioration or delay of progression, or for use in the treatment, prevention, amelioration or delay of progression of a disease or disorder requiring inhibition of PCSK9.

[0297] Embodiment 34. Use of a compound according to any one of embodiments 1 to 20, or a pharmaceutically acceptable salt thereof, for the treatment, prevention, amelioration or delay of progression of a PCSK9-mediated disease or disorder, or for the treatment, prevention, amelioration or delay of progression of a disease or disorder requiring inhibition of PCSK9.

[0298] Embodiment 35. Use of a compound according to any one of embodiments 1 to 20, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment, prevention, amelioration or delay of progression of a PCSK9-mediated disease or disorder, or for the treatment, prevention, amelioration or delay of progression of a disease or disorder requiring inhibition of PCSK9.

[0299] Embodiment 36. A method of treating, preventing, ameliorating, or delaying progression of a PCSK9-mediated disease or disorder, or a disease or disorder requiring inhibition of PCSK9 or PCSK9 activity, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of embodiments 1-20, or a pharmaceutically acceptable salt thereof.

[0300] Embodiment 37. A compound for use according to embodiment 33, use of a compound according to embodiment 34 or 35, or a method according to embodiment 36, wherein the PCSK9-mediated disease or disorder, or disease or disorder requiring inhibition of PCSK9, is selected from hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral vascular disease, peripheral arterial disease, vascular inflammation, elevated Lp(a), elevated LDL, elevated TRL, elevated triglycerides, sepsis, and xanthomas.

[0301] Embodiment 38. (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7,12-dimethyl-3-(pyridin-2-ylmethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7,12-dimethyl-3-(pyridin-2-ylmethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-3-((S)-2,3-dihydro-1H-inden-1-yl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7,12-dimethyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7,12-dimethyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7,12-dimethyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7,12-dimethyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-fluoro-6-(4-(1-methyl-2-((methylamino)methyl)-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7,12-dimethyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; and (3S,7S,10S,13R)-6-(4-chloro-2-fluoro-6-(4-(1-methyl-2-((methylamino)methyl)-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7,12-dimethyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone The compound according to embodiment 1, selected from: or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof.

[0302] Embodiment 39. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of embodiments 1 to 20 and embodiment 38, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

[0303] Embodiment 40 The pharmaceutical composition of embodiment 39, further comprising at least one additional pharmaceutical agent.

[0304] Embodiment 41. The pharmaceutical composition of embodiment 39 or embodiment 40 for use in treating a PCSK9-mediated disease or disorder.

[0305] Embodiment 42. A method for modulating PCSK9, comprising administering to a patient in need thereof a compound of any one of embodiments 1-20 and embodiment 38, or a pharmaceutically acceptable salt thereof.

[0306] Embodiment 43. A method of inhibiting PCSK9, comprising administering to a patient in need thereof a compound of any one of embodiments 1-20 and embodiment 38, or a pharmaceutically acceptable salt thereof.

[0307] Embodiment 44. A method of inhibiting PCSK9 activity, comprising administering to a patient in need thereof a compound of any one of embodiments 1-20 and embodiment 38, or a pharmaceutically acceptable salt thereof.

[0308] Embodiment 45. A method of treating a PCSK9-mediated disease or disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of embodiments 1-20 and embodiment 38, or a pharmaceutically acceptable salt thereof.

[0309] Embodiment 46. The method of embodiment 45, wherein the PCSK9-mediated disease or disorder is selected from hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral vascular disease, vascular inflammation, and xanthomas.

[0310] Embodiment 47. A method of lowering LDL-C in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of any one of embodiments 1-20 and embodiment 38, or a pharmaceutically acceptable salt thereof, thereby lowering the patient's LDL-C.

[0311] Embodiment 48. The method of any one of embodiments 42 to 47, wherein administering is performed orally, parenterally, subcutaneously, by injection, or by infusion.

[0312] Embodiment 49. A compound according to any one of embodiments 1 to 20 and embodiment 38, or a pharmaceutically acceptable salt thereof, for use in treating a PCSK9-mediated disease or disorder.

[0313] Embodiment 50. A compound according to any one of embodiments 1 to 20 and embodiment 38, or a pharmaceutically acceptable salt thereof, for use in treating a PCSK9-mediated disease or disorder selected from hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral vascular disease, vascular inflammation, and xanthomas.

[0314] Embodiment 51 Use of a compound according to any one of embodiments 1 to 20 and embodiment 38, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a PCSK9-mediated disease or disorder.

[0315] Embodiment 52. The use of claim 51, wherein the PCSK9-mediated disease or disorder is selected from hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral vascular disease, vascular inflammation, and xanthomas.

[0316] Embodiment 53. A compound according to any one of embodiments 1 to 20 and embodiment 38, or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for the treatment of a disease associated with inhibiting PCSK9 activity.

[0317] Embodiment 54. Use of a compound according to any one of embodiments 1 to 20 and embodiment 38, or a pharmaceutically acceptable salt thereof, in the treatment of a disease associated with the inhibition of PCSK9 activity.

[0318] Embodiment 55. The use of embodiment 54, wherein the disease associated with inhibition of PCSK9 activity is selected from hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral vascular disease, vascular inflammation, and xanthomas.

[0319] Embodiment 56. Method for preparing a compound of formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, N-oxide, or tautomer thereof [ka] [In the formula, R a1 and R5 are each independently (C1-C6 alkyl), and R9 is as defined above for formula (I); (d) a compound of formula (IIa), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, N-oxide, or tautomer thereof: [ka] wherein R5 is H and R9 is as defined above for formula (I), Alkylation with alkyl halide and base in a solvent and at low temperature to give the compound of formula (IIb) [ka] wherein R5 is (C1-C6 alkyl) and R9 is as defined above for formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, N-oxide, or tautomer thereof; (e) reacting a compound of formula (IIb), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, N-oxide, or tautomer thereof, with an acid in a solvent, followed by reaction with BocO and a base to produce a compound of formula (IIc): [ka] wherein R5 is (C1-C6 alkyl) and R9 is as defined above for formula (I), forming a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, N-oxide, or tautomer thereof; (f) alkylating a compound of formula (IIc), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, N-oxide, or tautomer thereof, with an alkylating agent in a solvent, and optionally a metal oxide, to obtain a compound of formula (IId): [ka] [In the formula, R a1 and R5 are each independently (C1-C6 alkyl), and R9 is as defined above for formula (I)], or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, N-oxide, or tautomer thereof; and (d) deallylating the compound of formula (IId) with a palladium catalyst and N,N-dimethyltrimethylsilylamine in a solvent to provide a compound of formula (II). A method comprising:

[0320] Embodiment 57 The method of embodiment 56, wherein the solvent in step (a) is DMF.

[0321] Embodiment 58. The method of embodiment 56 or embodiment 57, wherein the temperature in step (a) is about 0°C.

[0322] Embodiment 59. The method of any one of Embodiments 56 through 58, wherein the acid in step (b) is trifluoroacetic acid (TFA).

[0323] Embodiment 60. The method of any one of embodiments 56 to 59, wherein a metal oxide is used in step (c).

[0324] Embodiment 61. The method of embodiment 60, wherein the metal oxide is silver(I) oxide (AgO).

[0325] Embodiment 62. The method of any one of Embodiments 56 to 61, wherein the palladium catalyst in step (d) is tetrakis(triphenylphosphine)palladium(0).

[0326] Embodiment 63. Method for preparing a compound of formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, N-oxide, or tautomer thereof [ka] [In the formula, R a1 is H, R5 is (C1-C6 alkyl), and R9 is as defined above for formula (I), and a compound of formula (IIb): [ka] wherein R5 is (C1-C6 alkyl) and R9 is as defined above for formula (I), with a palladium catalyst and N,N-dimethyltrimethylsilylamine in a solvent to provide a compound of formula (II).

[0327] Embodiment 64 The method of embodiment 63, wherein the solvent is dichloromethane.

[0328] Embodiment 65 The method of Embodiment 63 or Embodiment 64, wherein the palladium catalyst is tetrakis(triphenylphosphine)palladium(0).

[0329] In another embodiment, the compound of formula (I) is (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7,12-dimethyl-3-(pyridin-2-ylmethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7,12-dimethyl-3-(pyridin-2-ylmethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-3-((S)-2,3-dihydro-1H-inden-1-yl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7,12-dimethyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; and (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7,12-dimethyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone is selected from.

[0330] Another aspect of the present disclosure is an intermediate of formula (IIIa): [ka] or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, N-oxide, or tautomer thereof, wherein: cis -NH2, -NH(C1-C6)alkyl, -C(O)NH2, or [ka] where: * represents a chiral center, and R d is H or a nitrogen protecting group (e.g., tert-butyloxycarbonyl (Boc), 9-fluorenylmethyloxycarbonyl (Fmoc), etc.), and R is as defined above for formula (I). d is a nitrogen protecting group. In another embodiment, R d is tert-butyloxycarbonyl (Boc). In another embodiment, R d is H.

[0331] Another aspect of the present disclosure is an intermediate of formula (IIIb): [ka] or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, N-oxide, or tautomer thereof, wherein: d is H or a nitrogen protecting group (e.g., tert-butyloxycarbonyl (Boc), 9-fluorenylmethyloxycarbonyl (Fmoc), etc.), and R e is H or —C(O)OCHCH═CH, R is H, and R, R, and R are as defined above for formula (I). d is a nitrogen protecting group. In another embodiment, R d is tert-butyloxycarbonyl (Boc). In another embodiment, R d is H.

[0332] Another aspect of the present disclosure is an intermediate of formula (IIIc): [ka] or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, N-oxide, or tautomer thereof, wherein: d and R f are each independently H or a nitrogen protecting group (e.g., tert-butyloxycarbonyl (Boc), 9-fluorenylmethyloxycarbonyl (Fmoc), etc.), and R, R, R, R, R, and R are as defined above for formula (I). d is a nitrogen protecting group. In another embodiment, R d is tert-butyloxycarbonyl (Boc). In another embodiment, R d is H. In one embodiment, R f is a nitrogen protecting group. In another embodiment, R f is tert-butyloxycarbonyl (Boc). In another embodiment, R f is H.

[0333] Another aspect of the present disclosure is an intermediate of formula (IIId): [ka] or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, N-oxide, or tautomer thereof, wherein: f is H or a nitrogen protecting group (e.g., tert-butyloxycarbonyl (Boc), 9-fluorenylmethyloxycarbonyl (Fmoc), etc.), and R g is —OH or —O(C1-C6)alkyl, X1 and X2 together with the carbon atom to which they are attached form =(O), X3 is —CH2—, and R1, R2, R5, R6, R7, R8, and R9 are as defined above for formula (I). f is a nitrogen protecting group. In another embodiment, R f is tert-butyloxycarbonyl (Boc). In another embodiment, R f is H.

[0334] Another aspect of the present disclosure is an intermediate of formula (IIIe) or formula (IIIf): [ka] or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, N-oxide, or tautomer thereof, wherein: H is —OH, —O(C1-C6)alkyl, —Otriflate, or halogen, and R 10 and R 11 is as defined above for formula (I).

[0335] Another aspect of the present disclosure is an intermediate of formula (IIIg) or formula (IIIh): [ka] or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, N-oxide, or tautomer thereof, wherein: H is —OH, —O(C1-C6)alkyl, —Otriflate, or halogen, and R 10 and R 11 is as defined above for formula (I).

[0336] Another aspect of the present disclosure is an intermediate of formula (IIIi) or formula (IIIj): [ka] or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, N-oxide, or tautomer thereof, wherein: H is —OH, —O(C1-C6)alkyl, —Otriflate, or halogen, and R 22 is as defined above for formula (I).

[0337] Another aspect of the present disclosure is a method for manufacturing a semiconductor device comprising: [ka] or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, N-oxide, or tautomer thereof.

[0338] In another embodiment of the present disclosure, the compound of formula (I) is an enantiomer. In some embodiments, the compound is an (S)-enantiomer. In other embodiments, the compound is an (R)-enantiomer. In yet other embodiments, the compound of formula (I) may be a (+) or (-) enantiomer.

[0339] In another embodiment of the present disclosure, intermediates (IIIa), (IIIb), (IIIc), and (IIId) are enantiomers. In some embodiments, the intermediates are (S)-enantiomers. In other embodiments, the intermediates are (R)-enantiomers. In still other embodiments, the intermediates may be (+) or (-) enantiomers.

[0340] In another embodiment of the present disclosure, the compounds of formula (I) are diastereomers. In another embodiment of the present disclosure, the intermediates of formula (IIIa), formula (IIIb), formula (IIIc), and formula (IIId) are diastereomers.

[0341] It should be understood that all isomeric forms, including mixtures thereof, are included within the scope of the present disclosure. When a compound contains a double bond, the substituent may be in the E or Z configuration. When a compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis or trans configuration. All tautomeric forms are also intended to be included.

[0342] Compounds and intermediates of the present disclosure, as well as their pharmaceutically acceptable salts, hydrates, solvates, stereoisomers, and prodrugs, may exist in their tautomeric form (for example, as an amide or imino ether), and all such tautomeric forms are contemplated herein as part of the present disclosure.

[0343] The compounds and intermediates of the present disclosure may contain asymmetric or chiral centers and therefore may exist in different stereoisomeric forms. All stereoisomeric forms of the compounds and intermediates of the present disclosure, as well as mixtures thereof, including racemic mixtures, are intended to be part of the present disclosure. In addition, the present disclosure encompasses all geometric and positional isomers. For example, if a compound or intermediate of the present disclosure incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are encompassed within the scope of the present disclosure. Each compound or intermediate disclosed herein includes all enantiomers according to the general structure of that compound or intermediate. The compound or intermediate may be in racemic or enantiopure form, or any other form in terms of stereochemistry. Assay results may reflect data collected for racemic, enantiopure, or any other form in terms of stereochemistry.

[0344] Diastereomeric mixtures can be separated into their individual diastereomers based on their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and / or fractional crystallization. Enantiomers can also be separated by converting the enantiomeric mixture to a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., a chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers, and converting the individual diastereomers to the corresponding pure enantiomers (e.g., by hydrolysis). In addition, some of the compounds of the present disclosure may be atropisomers (e.g., substituted biaryls) and are also considered part of the present disclosure. Enantiomers can also be separated using a chiral HPLC column.

[0345] It is also possible that compounds and intermediates of the present disclosure may exist in different tautomeric forms, and all such forms are encompassed within the scope of the present disclosure, including, for example, all keto-enol and imine-enamine forms of the present compounds.

[0346] All stereoisomers (e.g., geometric isomers, optical isomers, etc.) of the present compounds (including stereoisomers of salts, solvates, esters, and prodrugs of the compounds, as well as salts, solvates, and esters of the prodrugs), such as those that may exist due to asymmetric carbons on various substituents, are contemplated within the scope of the present disclosure, as are enantiomeric forms (which may exist even when there is no asymmetric carbon), rotamer forms, atropisomers, and diastereomeric forms, as well as positional isomers (e.g., 4-pyridyl, 3-pyridyl, etc.). (For example, when a compound of Formula (I) incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are encompassed within the scope of the present disclosure. Also included in the present disclosure are, for example, all keto-enol and imine-enamine forms of the present compounds.) Individual stereoisomers of the compounds of the present disclosure may be, for example, substantially free of other isomers, or may be mixed, for example, as a racemate or with all or selected other stereoisomers. The chiral centers of the present disclosure can have the S or R configuration as defined by the IUPAC Recommendations of 1974. Use of the terms "salts," "solvates," "esters," "prodrugs," and the like are intended to apply equally to salts, solvates, esters and prodrugs of the enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the compounds of the present invention.

[0347] Compounds of formula (I) may form salts, and such salts are also within the scope of this disclosure. Reference to compounds of formula (I) herein is understood to include reference to salts thereof, unless otherwise indicated.

[0348] The present disclosure relates to compounds that are modulators of PCSK9. In one embodiment, the compounds of the disclosure are inhibitors of PCSK9.

[0349] The present disclosure relates to compounds as described herein and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof, and pharmaceutical compositions comprising one or more compounds as described herein or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof.

[0350] Compound activity The activity of compounds of the present disclosure as PCSK9 inhibitors can be assessed using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay, which measures the ability of compounds of the present disclosure to interfere with the binding of human PCSK9 to human LDLR, and provides a measure of both potency (IC50) and efficacy (Amax).

[0351] Solutions of various concentrations of compounds of the present disclosure are prepared by diluting them in dimethyl sulfoxide (DMSO), and the resulting solutions are pipetted into the plate. DMSO is used as a negative control. An intermediate plate is prepared by transferring known amounts of each compound solution and control from the compound plate to corresponding wells containing assay buffer and mixing thoroughly. A third plate to be used in the assay is then prepared by adding human PCSK9 Alexa Fluor 647, followed by a known amount of each solution from the intermediate plate. Unlabeled human PCSK9 in assay buffer containing DMSO is used as a positive control for this assay. After incubation, human LDLR extracellular domain-Europium Cryptate is added to each well of the assay plate, and the resulting mixture is incubated for an additional period of time. The TR-FRET signal is measured, and the FRET ratio (FRET / Europium) is used to determine the IC of the compound. 50 and Amax are calculated.

[0352] Compound synthesis method The compounds of the present disclosure may be made by a variety of methods, including standard chemistry. The schemes provided below illustrate suitable synthetic routes.

[0353] Compounds of formula (I) may be prepared by methods known in the art of organic synthesis, as illustrated in part by the following synthetic schemes. In the schemes described below, it is well understood that protecting groups for sensitive or reactive groups are utilized where necessary in accordance with general principles or chemistry. Protecting groups are manipulated according to standard organic synthesis methods (T.W. Greene and P.G.M. Buts, "Protective Groups in Organic Synthesis," Third Edition, Wiley, New York 1999). Such groups are removed at a convenient stage in the compound synthesis using methods readily apparent to those skilled in the art. The selected processes, as well as the reaction conditions and order of their execution, shall be consistent with the preparation of compounds of formula (I).

[0354] Those skilled in the art will recognize whether a stereocenter exists in compounds of formula (I). Accordingly, the present disclosure includes both possible stereoisomers (unless specified in the synthesis), including not only racemates but also individual enantiomers and / or diastereomers as well. When a compound is desired as a single enantiomer or diastereomer, it may be obtained by stereospecific synthesis or by resolution of the final product or any convenient intermediate. Resolution of the final product, intermediate, or starting material may be affected by any suitable method known in the art. See, for example, "Stereochemistry of Organic Compounds" by EL Eliel, SH Wilen, and LN Mander (Wiley-Interscience, 1994).

[0355] The compounds described herein may be made from commercially available starting materials or may be synthesized using known organic, inorganic, and / or enzymatic methods.

[0356] Preparation of compounds The compounds of the present disclosure can be prepared by several methods well known to those skilled in the art of organic synthesis. For example, the compounds of the present disclosure can be synthesized using the methods described below, in combination with synthetic methods known in the art of synthetic organic chemistry, or variations thereof as understood by those skilled in the art. Preferred methods include, but are not limited to, the methods described below. The compounds of the present disclosure can be synthesized according to the steps outlined in General Schemes 1 and 2, which include the construction of various intermediates 1-a, 1-b, 1-c, 1-d, 1-e, 1-f, 1-g, 1-h, 1-i, 2-a, 2-b, 2-c, 2-d, and 2-e. Starting materials are either commercially available or prepared by known procedures in the published literature or as illustrated.

[0357] General Scheme 1 [ka] wherein R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in formula (I), X3 is CH2, X1 and X2 together with the carbon atom to which they are attached form =(O), and P is an amine protecting group (e.g., tert-butyloxycarbonyl (Boc), 9-fluorenylmethyloxycarbonyl (Fmoc), etc.).

[0358] A general method for preparing compounds of formula (I) by using intermediates 1-a, 1-b, 1-c, 1-d, 1-e, 1-f, 1-g, 1-h, and 1-i is outlined in General Scheme 1. Treatment of 1-a with PS-2-chlorotrityl chloride resin in a solvent (e.g., dichloromethane (DCM), dimethylformamide (DMF), etc.) in the presence of a base (e.g., triethylamine (TEA), N,N-diisopropylethylamine (DIPEA), etc.) provides 1-b. Synthesis of intermediate 1-d can be achieved by coupling 1-b with 1-c under standard coupling conditions using an amide coupling reagent (e.g., 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU), O-(1H-6-chlorobenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU), or O-(7-azobenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), etc.) on a resin (e.g., TentaGel™ S RAM resin) in a solvent (e.g., N-methylpyrrolidine (NMP) or DMF) and optionally a base (e.g., TEA, DIPEA, etc.), followed by removal of the amine protecting group P (e.g., treatment with 4-methylpiperidine / DMA to remove the Fmoc group). Coupling of 1-d with acid 1-e using an amide coupling reagent (e.g., TBTU, HCTU, HATU, etc.) and optionally a base (e.g., TEA, DIPEA, etc.), followed by deprotection (e.g., treatment with 4-methylpiperidine / DMA to remove the Fmoc group or TFA to remove the Boc group) provides 1-f.

[0359] Cleavage of 1-f from the resin by repeated treatment with 1,1,1,3,3,3-hexafluoropropan-2-ol (HFIP) in a solvent (e.g., DCM) provides 1-g. Reductive amination of amine 1-g and aldehyde 1-h in a solvent (e.g., methanol (MeOH) and / or DCM) in the presence of a reducing agent (e.g., sodium triacetoxyborohydride, sodium cyanoborohydride, sodium borohydride, etc.), optionally with an acid (e.g., acetic acid (AcOH)), provides 1-i. Cyclization of 1-i using standard coupling conditions, such as amide coupling reagents (e.g., HATU, HOAt, TBTU, and / or HCTU) in a solvent (e.g., DCM, NMP, DMF, etc.), optionally with a base (e.g., 2,6-lutidine, TEA, DIPEA, etc.), provides the desired compound of Formula (I).

[0360] General Scheme 2 [ka] wherein R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in formula (I), X3 is CH2, X1 and X2 together with the carbon atom to which they are attached form =(O), R' is an alkyl group, and P is an amine protecting group (e.g., tert-butyloxycarbonyl (Boc), 9-fluorenylmethyloxycarbonyl (Fmoc), etc.).

[0361] Alternatively, compounds of formula (I) may be prepared by using intermediates 1-c, 1-e, 1-h, 1-i, 2-a, 2-b, 2-c, 2-d, and 2-e as outlined in General Scheme 2. Synthesis of intermediate 2-c may be achieved by coupling 2-a with 2-b under standard coupling conditions using an amide coupling reagent (e.g., TBTU, HCTU, HATU, etc.) and optionally a base (e.g., TEA, DIPEA, etc.) in a solvent (e.g., NMP, DMF, etc.), followed by removal of the amine protecting group P (e.g., treatment with 4-methylpiperidine / DMA to remove the Fmoc group). Coupling of amine 2-c with acid 1-c using an amide coupling reagent (e.g., TBTU, HCTU, HATU, etc.) and optionally a base (e.g., TEA, DIPEA, etc.), followed by deprotection (e.g., treatment with 4-methylpiperidine / DMA to remove the Fmoc group or TFA to remove the Boc group) provides 2-d. In step 3, repeating the coupling and deprotection steps using standard coupling conditions described above provides intermediate 2-e. Reductive amination of amine 2-e and aldehyde 1-h in a solvent (e.g., MeOH and / or DCM) in the presence of a reducing agent, such as sodium triacetoxyborohydride, sodium cyanoborohydride, or sodium borohydride, and optionally an acid (e.g., AcOH), followed by hydrolysis of the ester using an acid (e.g., TFA) in a solvent (e.g., DCM) provides 1-i. Cyclization of 1-i using standard coupling conditions, such as an amide coupling reagent (e.g., HATU, HOAt, TBTU, and / or HCTU) in a solvent (e.g., DCM, NMP, or DMF), optionally with a base (e.g., 2,6-lutidine, TEA, or DIPEA), provides the desired compound of formula (I).

[0362] In the descriptions and formulas set forth above, it should be understood that the various groups X, X, X, R, R, R, R, R, R, R, R, R, R, R, and R, and other variables, are as defined above unless otherwise indicated. Furthermore, for synthetic purposes, the compounds of General Schemes 1 and 2 are merely representative, with selected groups intended to illustrate the general synthetic methodology for compounds of Formula (I), as defined herein.

[0363] Methods of Use of the Disclosed Compounds Another aspect of the present disclosure relates to a method for modulating PCSK9, comprising administering to a patient in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier.

[0364] In another aspect, the present disclosure relates to a method of inhibiting PCSK9, the method involving administering to a patient in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier.

[0365] Another aspect of the present disclosure relates to a method for treating, preventing, inhibiting, or eliminating a disease or disorder in which PCSK9 plays a role, comprising administering to a patient in need of treatment for the disease or disorder in which PCSK9 plays a role an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier.

[0366] Another aspect of the present disclosure relates to a method for treating, preventing, inhibiting, or eliminating a disease or disorder in a patient associated with inhibition of PCSK9, comprising administering to a patient in need thereof an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier.

[0367] In another aspect, the present disclosure relates to a method for treating, preventing, inhibiting, or eliminating a PCSK9-mediated disease or disorder, the method comprising administering to a patient in need of treatment for a PCSK9-mediated disease or disorder an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier.

[0368] Another aspect of the present disclosure relates to a method for treating, preventing, inhibiting, or removing hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral vascular disease, vascular inflammation, xanthomas, peripheral arterial disease, sepsis, elevated Lp(a), elevated LDL, elevated TRL, or elevated triglycerides, comprising administering to a patient in need of treatment an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier.

[0369] In another aspect, the disclosure relates to a method of lowering Lp(a), lowering Lp(a) plasma levels, lowering Lp(a) serum levels, lowering serum TRL or LDL levels, lowering serum triglyceride levels, lowering LDL-C, lowering total plasma apoB concentration, lowering LDL apoB, lowering TRL apoB, or lowering non-HDL-C, comprising administering to a patient in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier.

[0370] In another aspect, the disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, for use in the treatment, prevention, inhibition, or elimination of a disease or disorder in which PCSK9 plays a role.

[0371] Another aspect of the present disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, for use in the treatment, prevention, inhibition, or elimination of diseases associated with inhibiting PCSK9.

[0372] Another aspect of the present disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, for use in the treatment, prevention, inhibition, or elimination of hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral vascular disease, vascular inflammation, xanthomas, peripheral arterial disease, sepsis, elevated Lp(a), elevated LDL, elevated TRL, or elevated triglycerides.

[0373] In another aspect, the disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, for use in lowering Lp(a), lowering Lp(a) plasma levels, lowering Lp(a) serum levels, lowering serum TRL or LDL levels, lowering serum triglyceride levels, lowering LDL apoB, lowering TRL apoB, or lowering non-HDL-C.

[0374] Another aspect of the present disclosure relates to the use of a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, for treating, preventing, inhibiting, or eliminating a disease or disorder in which PCSK9 plays a role.

[0375] In another aspect, the disclosure relates to the use of a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, in the manufacture of a medicament for the inhibition of PCSK9.

[0376] In another aspect, the disclosure relates to the use of a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, in the manufacture of a medicament for the treatment, prevention, inhibition, or removal of hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral vascular disease, vascular inflammation, xanthomas, peripheral arterial disease, sepsis, elevated Lp(a), elevated LDL, elevated TRL, or elevated triglycerides.

[0377] Another aspect of the present disclosure relates to the use of a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, in the manufacture of a medicament for lowering Lp(a), lowering Lp(a) plasma levels, lowering Lp(a) serum levels, lowering serum TRL or LDL levels, lowering serum triglyceride levels, lowering LDL apoB, lowering TRL apoB, or lowering non-HDL-C.

[0378] In another aspect, the present disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, for use in the manufacture of a medicament for the treatment of a disease associated with inhibiting PCSK9.

[0379] Another aspect of the present disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, for use in the manufacture of a medicament for the treatment of a disease in which PCSK9 plays a role.

[0380] In another aspect, the present disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, for use in the manufacture of a medicament for the treatment, prevention, inhibition, or removal of hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral vascular disease, vascular inflammation, xanthomas, peripheral arterial disease, sepsis, elevated Lp(a), elevated LDL, elevated TRL, or elevated triglycerides.

[0381] Another aspect of the present disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, for use in the manufacture of a medicament for lowering Lp(a), lowering Lp(a) plasma levels, lowering Lp(a) serum levels, lowering serum TRL or LDL levels, lowering serum triglyceride levels, lowering LDL apoB, lowering TRL apoB, or lowering non-HDL-C.

[0382] In another aspect, the disclosure relates to the use of a PCSK9 inhibitor for the preparation of a medicament for use in the treatment, prevention, inhibition, or removal of hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral vascular disease, peripheral arterial disease, vascular inflammation, elevated Lp(a), elevated LDL, elevated TRL, elevated triglycerides, sepsis, or xanthomas.

[0383] Another aspect of the present disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, for use in the treatment of a PCSK9-mediated disease or disorder.

[0384] Another aspect of the present disclosure relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, for use in the treatment of a PCSK9-mediated disease or disorder selected from hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral vascular disease, peripheral arterial disease, vascular inflammation, elevated Lp(a), elevated LDL, elevated TRL, elevated triglycerides, sepsis, and xanthomas.

[0385] In another aspect, the disclosure relates to the use of a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, in the manufacture of a medicament for the treatment of a PCSK9-mediated disease or disorder.

[0386] Another aspect of the present disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, for use in the manufacture of a medicament for the treatment of a PCSK9-mediated disease or disorder.

[0387] In another aspect, the present disclosure relates to the use of a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, for use as a medicament.

[0388] The present disclosure also relates to the use of a PCSK9 inhibitor for the preparation of a medicament for use in the treatment, prevention, inhibition, or elimination of a disease or condition in which PCSK9 plays a role, wherein the medicament comprises a compound of formula (I).

[0389] In another aspect, the disclosure relates to a method for making a medicament for treating, preventing, inhibiting, or eliminating a disease or condition mediated by PCSK9, wherein the medicament comprises a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier.

[0390] In some embodiments of the above methods, the PCSK9-mediated disease or disorder, the disease or disorder in which PCSK9 plays a role, the disease or disorder in a patient associated with inhibition of PCSK9, and the disease associated with inhibiting PCSK9 is selected from hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral vascular disease, peripheral arterial disease, vascular inflammation, elevated Lp(a), elevated LDL, elevated TRL, elevated triglycerides, sepsis, and xanthomas.

[0391] The compounds of the present disclosure find use in lowering or reducing low-density lipoprotein cholesterol (LDL-C) in individuals in need thereof. The individual may exhibit persistently elevated LDL-C levels. In some embodiments, the individual has LDL-C plasma levels consistently greater than 70 mg / dL, e.g., greater than or equal to 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, or 190 mg / dL. The compounds of the present disclosure may also be used to lower or reduce non-high-density lipoprotein cholesterol (non-HDL-C) or total cholesterol in individuals in need thereof.

[0392] The present disclosure also relates to methods for improving blood cholesterol markers associated with increased risk of heart disease. Such markers include high total cholesterol, high LDL, high total cholesterol-to-HDL ratio, and high LDL-to-HDL ratio. Total cholesterol below 200 mg / dL is considered ideal, 200-239 mg / dL is considered borderline high, and 240 mg / dL or higher is considered high.

[0393] In a further aspect, the present disclosure provides a method of lowering LDL-C, non-HDL-C and / or total cholesterol in an individual in need thereof, the method comprising administering to the individual a therapeutically effective amount of a compound or a pharmaceutical composition comprising a compound disclosed herein and a pharmaceutically acceptable carrier as described herein.

[0394] In another embodiment, the present disclosure relates to a compound of formula (I) of the present disclosure, or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, for use in the treatment of diseases including, but not limited to, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral vascular disease, peripheral arterial disease, vascular inflammation, elevated Lp(a), elevated LDL, elevated TRL, elevated triglycerides, sepsis, and xanthomas.

[0395] In one embodiment, there is provided a method for treating a disease or disorder in which PCSK9 plays a role, including hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral vascular disease, peripheral arterial disease, vascular inflammation, elevated Lp(a), elevated LDL, elevated TRL, elevated triglycerides, sepsis, and xanthomas, comprising administering to a patient suffering from at least one of said diseases or disorders a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier.

[0396] The disclosed compounds of the present disclosure can be administered in an amount effective to treat or prevent and / or prevent the onset of a disorder in a subject.

[0397] The disclosed compounds of the present disclosure can be administered in an amount effective to treat or prevent and / or prevent the onset of a disorder in a subject.

[0398] Administration, Pharmaceutical Compositions, and Dosing of the Disclosed Compounds Administration of the disclosed compounds can be achieved via any mode of administration for therapeutic agents, including systemic or local administration, such as oral, nasal, parenteral, transdermal, subcutaneous, intravaginal, buccal, rectal, or topical modes of administration.

[0399] Depending on the intended mode of administration, the disclosed compositions may be in solid, semi-solid, or liquid dosage form, sometimes in unit dosage amounts, and consistent with conventional pharmaceutical practice, such as, for example, injectable solutions, tablets, suppositories, pills, sustained-release capsules, elixirs, tinctures, emulsions, syrups, powders, liquids, suspensions, etc. Likewise, the compositions may also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous, or intramuscular form, and all using forms well known to those of ordinary skill in the pharmaceutical arts.

[0400] Another aspect of the present disclosure relates to a pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers may further include excipients, diluents, or surfactants. In a further embodiment, the composition comprises at least two pharmaceutically acceptable carriers, such as those described herein. The pharmaceutical composition may be formulated for a specific route of administration, such as oral administration, parenteral administration (e.g., by injection, infusion, transdermal, or topical administration), and rectal administration. Topical administration may also involve inhalation or intranasal application. The pharmaceutical compositions of the present disclosure may be made in solid form (including, without limitation, capsules, tablets, pills, granules, powders, or suppositories) or liquid form (including, without limitation, solutions, suspensions, or emulsions). Tablets may be either film-coated or enteric-coated by methods known in the art. Typically, the pharmaceutical composition is a tablet or gelatin capsule containing the active ingredient together with one or more of the following: a) diluents, such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and / or glycine; b) lubricants, such as silica, talc, stearic acid, its magnesium or calcium salts and / or polyethylene glycol; for tablets also c) binders, such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and / or polyvinylpyrrolidone; optionally d) disintegrating agents, such as starch, agar, alginic acid or its sodium salt, or effervescent mixtures; and e) Absorbents, colourings, flavourings and sweeteners.

[0401] Liquid compositions, particularly injectable compositions, can be prepared, for example, by dissolving, dispersing, etc. For example, the disclosed compounds are dissolved in or mixed with a pharmaceutically acceptable solvent, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, etc., to form an injectable isotonic solution or suspension. Proteins such as albumin, chylomicron particles, or serum proteins can be used to solubilize the disclosed compounds.

[0402] The disclosed compounds may also be formulated as suppositories from fatty emulsions or suspensions; using polyalkylene glycols, such as propylene glycol, as the carrier.

[0403] Parenteral injectable administration is generally used for subcutaneous, intramuscular, or intravenous injections and infusions. Injectable solutions can be prepared in conventional forms, either as liquid solutions or suspensions, or as solid forms suitable for dissolving in liquid prior to injection.

[0404] The compositions can be prepared by conventional mixing, granulating, or coating methods, respectively, and the pharmaceutical compositions can contain about 0.1% to about 99%, about 5% to about 90%, or about 1% to about 20% of the disclosed compounds by weight or volume.

[0405] Dosage regimens utilizing the disclosed compounds are selected based on a variety of factors, including the type, species, age, weight, sex, and medical condition of the patient; the severity of the condition being treated; the route of administration; the patient's renal or hepatic function; and the particular disclosed compound being used. A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the condition.

[0406] Effective dosages of the disclosed compounds, pharmaceutical compositions, or combinations, when used for the indicated effect, range from about 0.5 mg to about 5,000 mg of the disclosed compounds as needed to treat a condition. Compositions for in vivo or in vitro use may contain about 0.5, 5, 20, 50, 75, 100, 150, 250, 500, 750, 1,000, 1,250, 2,500, 3,500, or 5,000 mg of the disclosed compounds, or any range from one amount to another listed in the dosage list. In one embodiment, the composition is in the form of a tablet, which may be scored. The therapeutically effective dosage of the compound, pharmaceutical composition, or combination thereof depends on the species, weight, age, and individual condition of the subject, and the disorder or disease being treated or its severity. A physician, clinician, or veterinarian skilled in the art can readily determine the effective amount of each active ingredient required to prevent, treat, or arrest the progression of a disorder or disease.

[0407] The above-cited dosage characteristics are demonstrable in vitro and in vivo tests, preferably using mammals, e.g., mice, rats, dogs, monkeys, or isolated organs, tissues, and preparations thereof. The compounds of the present disclosure can be applied in vitro in the form of solutions, e.g., aqueous solutions, and in vivo enterally, parenterally, advantageously intravenously, e.g., as a suspension or in aqueous solution. In vitro dosages can range from about 10-3 molar to 10-9 molar. In vivo therapeutically effective amounts can range from about 0.1 to 500 mg / kg, or from about 1 to 100 mg / kg, depending on the route of administration.

[0408] Combination therapy The compounds of the present disclosure can be administered in therapeutically effective amounts in combination therapy with one or more therapeutic agents (pharmaceutical combinations) or modalities, e.g., non-pharmacologic therapies. For example, synergistic effects may occur with other cardiovascular drugs, antihypertensives, coronary vasodilators, and diuretics. When the compounds of the present disclosure are administered in conjunction with other therapies, the dosage of the co-administered compound will, of course, vary depending on the type of codrug used, the specific drug used, the condition being treated, etc.

[0409] The compounds of the present disclosure may be administered simultaneously with, before, or after one or more other therapeutic agents. The compounds of the present disclosure may be administered separately from the other agents, by the same or different administration route, or together in the same pharmaceutical composition. The therapeutic agent may be, for example, a chemical compound, peptide, antibody, antibody fragment, or nucleic acid, which has therapeutic activity or enhances therapeutic activity when administered to a patient in combination with a compound of the present disclosure.

[0410] In one embodiment, the present disclosure provides a product comprising a compound of the present disclosure and at least one other therapeutic agent as a combined preparation for simultaneous, separate, or sequential use in therapy. In one embodiment, the therapy is the treatment of a disease or condition mediated by PCSK9. The product provided as a combined preparation includes a composition comprising a compound of the present disclosure and one or more other therapeutic agents together in the same pharmaceutical composition, or a compound of the present disclosure and one or more other therapeutic agents in separate forms, for example, in the form of a kit.

[0411] In another aspect, the disclosure includes a compound of Formula (I), Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), Formula (If), Formula (Ig), Formula (Ih), Formula (Ii), Formula (Ij), Formula (Ik), Formula (Im), Formula (Io), any one of Embodiments 1-20 or Embodiment 38, or a compound according to any embodiment of Formula (I), Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), Formula (If), Formula (Ig), Formula (Ih), Formula (Ii), Formula (Ij), Formula (Ik), Formula (Im), and / or Formula (Io) described herein, or a pharmaceutically acceptable salt thereof, for use in combination therapy. The compounds, compositions, medicaments and compounds for use of Formula (I), Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), Formula (If), Formula (Ig), Formula (Ih), Formula (Ii), Formula (Ij), Formula (Ik), Formula (Im), Formula (Io), any one of Embodiments 1-20 or Embodiment 38, or any embodiment of Formula (I), Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), Formula (If), Formula (Ig), Formula (Ih), Formula (Ii), Formula (Ij), Formula (Ik), Formula (Im), and / or Formula (Io) described herein, or pharmaceutically acceptable salts thereof, may also be used to advantage in combination with one or more other therapeutic agents.

[0412] Another aspect of the present disclosure relates to a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, a pharmaceutically acceptable carrier, and one or more therapeutic agents. The pharmaceutically acceptable carrier may further comprise an excipient, diluent, or surfactant.

[0413] Combination therapy includes the administration of the subject compounds further in combination with other biologically active ingredients (such as, but not limited to, a second drug, for example, but not limited to, a cardiovascular drug, an adrenergic blocking agent, an antihypertensive agent, an angiotensin system inhibitor, an angiotensin-converting enzyme (ACE) inhibitor, a coronary vasodilator, a diuretic, or an adrenergic stimulant, or a second drug targeting PCSK9) and non-drug therapies (such as, but not limited to, surgery or radiation therapy). For example, the compounds of the present application can be used in combination with other pharmaceutically active compounds, preferably compounds that can enhance the effects of the compounds of the present application. The compounds of the present application can be administered simultaneously (as a single formulation or separate formulations) or sequentially with other drug therapies or treatment modalities. Generally, combination therapy contemplates the administration of two or more drugs within a single therapeutic cycle or course.

[0414] In some embodiments, the compounds of the present application can be used in combination with agents known to have cholesterol (including LDL-C, non-HDL-C, triglyceride-lowering agents) and total cholesterol-lowering benefit and / or HDL-C-raising benefit.

[0415] Exemplary therapeutic agents that may be used in combination with the compounds of the present disclosure include, but are not limited to, lipid-lowering agents, niacin and its analogs, bile acid sequestrants, thyromimetics, thyroid hormone receptor (THR) β-selective agonists, microsomal triglyceride transfer protein (MTP) inhibitors, acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) inhibitors, Niemann-Pick C1-like 1 (NPC1-L1) inhibitors, ATP-binding cassette (ABC) protein G5 or G8 agonists, inhibitory nucleic acids targeting PCSK9, inhibitory nucleic acids targeting apoB100, apoA-I upregulators / inducers, ABCA1 stabilizers or inducers, phospholipid transfer protein (PLTP) inhibitors, fish oil, antidiabetic agents, antiobesity agents, peroxisome proliferator-activated receptor agonists, ATP citrate lyase (ACL) inhibitors, and antihypertensive agents.

[0416] Examples of lipid-lowering agents that may be used in combination with the compounds of the present disclosure include, but are not limited to, HMG-CoA reductase inhibitors, squalene synthase inhibitors, LXR agonists, FXR agonists, fibrates, cholesterol absorption inhibitors, nicotinic acid bile acid binding resins, nicotinic acid and other GPR109 agonists, and aspirin.

[0417] HMG-CoA reductase inhibitors (i.e., statins) are a class of drugs used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, which plays a central role in cholesterol production in the liver. Increased cholesterol levels are associated with cardiovascular disease, and therefore statins are used to prevent these diseases. Exemplary statins include, but are not limited to, atorvastatin, cerivastatin, compactin, dalvastatin, dihydrocompactin, fluindostatin, fluvastatin, lovastatin, pitavastatin, mevastatin, pravastatin, rivastatin, simvastatin, and velostatin, or pharmaceutically acceptable salts thereof.

[0418] Fibrates or fibric acid derivatives lower triglycerides and increase HDL cholesterol. They may have only a slight effect on LDL cholesterol. For example, gemfibrozil or fenofibrate is prescribed for people with extremely high triglycerides or people with low HDL and high triglycerides. Gemfibrozil can be used to reduce the risk of heart attack in people with coronary artery disease (CAD) with low HDL and high triglycerides. Examples of fibrates include, but are not limited to, clofibrate, gemfibrozil, fenofibrate, ciprofibrate, and bezafibrate.

[0419] Cholesterol absorption inhibitors are a class of compounds that prevent cholesterol from being absorbed into the circulatory system from the small intestine, thereby reducing plasma LDL-C levels. Increased cholesterol levels are associated with increased CVD risk; therefore, cholesterol absorption inhibitors are used to reduce CVD risk. A non-limiting example of a cholesterol absorption inhibitor is ezetimibe, formerly known as "Sch-58235." Another example is Sch-48461. Both compounds are being developed by Schering-Plough.

[0420] Examples of bile acid sequestrants that may be used in combination with the compounds of the present disclosure include, but are not limited to, cholestyramine, colestipol, and colesevelam.

[0421] A non-limiting example of a thyromimetic that may be used in combination with the compounds of the present disclosure is the compound KB2115.

[0422] A non-limiting example of a thyroid hormone receptor (THR) β selective agonist that may be used in combination with the compounds of the present disclosure is MGL-3196.

[0423] DGAT is an enzyme that catalyzes the final step in triacylglycerol biosynthesis. DGAT catalyzes the coupling of 1,2-diacylglycerol with fatty acyl-CoA, resulting in coenzyme A and triacylglycerol. Two enzymes exhibiting DGAT activity have been identified: DGAT1 (acyl-coA-diacylglycerol acyltransferase 1; see Cases et al., Proc. Natl. Acad. Sci. 95:13018-13023, 1998) and DGAT2 (acyl-coA-diacylglycerol acyltransferase 2; see Cases et al., J. Biol. Chem. 276:38870-38876, 2001). DGAT1 and DGAT2 do not share significant protein sequence homology. Importantly, DGAT1 knockout mice are protected from high-fat diet-induced weight gain and insulin resistance (Smith et al., Nature Genetics 25:87-90, 2000). The phenotype of DGAT1 knockout mice suggests that DGAT1 inhibitors may be useful in treating obesity and obesity-related complications. DGAT1 inhibitors useful in the combination are, for example, the subject of the compounds and analogs, end products, pharmaceutical formulations and claims generally and specifically disclosed in WO 2007 / 126957 and WO 2009 / 040410, particularly the compound claims and end products in the examples.

[0424] Examples of suitable DGAT1 inhibitors for use in combination with the compounds of the present disclosure include, but are not limited to, {4-[4-(3-methoxy-5-phenylamino-pyridin-2-yl)-phenyl]-cyclohexyl}-acetic acid, (4-{4-[5-(1-methyl-1H-pyrazol-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid, (4-{4-[5-(5-fluoro-6-methoxy-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid, (4-{5-[5-(6- trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-spirocyclohexylidenyl-1,1'-indanyl}-acetic acid, (4-{4-[5-(benzoxazol-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid, 4-(4-{4-[2-(3-chlorophenylamino)-oxazol-5-yl]-phenyl}-cyclohexyl)-butyric acid, (4-{4-[5-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid, (6-{4-[4-(2H-tetrazol-5-ylmethyl)-cyclohexyl]-phenyl}-pyridazin-3-yl)-(6-trifluoromethyl-pyridin-3-yl)-amine, 3-(4-{4-[6-(6-trifluoromethyl-pyridin-3-ylamino)-pyridazin-3-yl]-phenyl}-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one, (1-{4-[6-(3-trifluoromethyl-phenylamino)-pyridazin-3-yl]-phenyl}-piperidin-4-yl)-acetic acid, (4-{ 4-[4-Methyl-6-(6-trifluoromethyl-pyridin-3-ylamino)-pyridazin-3-yl]-phenyl}-cyclohexyl)-acetic acid, (4-{4-[5-(6-trifluoromethyl-pyridin-3-ylamino)-pyrazin-2-yl]-phenyl}-cyclohexyl)-acetic acid, 6-[5-(4-chloro-phenyl)-[1,3,4]oxadiazol-2-yl]-2-(2,6-dichloro-phenyl)-1H-benzimidazole, 6-(5-cyclohexyl-[1,3,4]oxadiazol-2-yl)-2-(2,6-dichloro-phenyl)-1H-benzimidazole, 6-(5-butyl-[1,3,4]oxadiazol-2-yl)-2-(2,6-dichloro-phenyl)-1H-benzimidazole, 2-(2,6-dichloro-phenyl)-6-[5-(5-methyl-pyridin-3-yl)-[1,3,4]oxadiazol-2-yl]-1H-benzimidazole, 6-[5-(4-chloro-phenyl)-[1,3,4]oxadiazol-2-yl]-2-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-1H-benzimidazole, 6-[5-(4-chloro-phenyl)-[1,3,4]oxadiazol-2-yl]-2-(3,5-dichloro-pyridin-4-yl)-1H-benzimidazole, 3-(4-{5-[5-(4-methoxy-phenyl)-[1,3,4]oxadiazol-2-yl]-1H-benzimidazol-2-yl}-3,5-dimethyl-phenyl)-2,2-dimethyl-propionic acid, 3-(4-{6-[5-(4-methoxy-phenyl)-[1,3,4]oxadiazol-2-yl]-1H-benzimidazol-2-yl}-3,5-dimethyl- phenyl)-propionic acid, 3-(4-{6-[5-(4-methoxyphenylamino)-[1,3,4]oxadiazol-2-yl]-1H-benzimidazol-2-yl}-3,5-dimethylphenyl)-propionic acid, [3-(4-{6-[5-(4-chloro-phenyl)-[1,3,4]oxadiazol-2-yl]-1H-benzimidazol-2-yl}-3,5-dimethyl-phenyl)-propyl]-phosphonic acid, 2-(2,6-dichloro-phenyl)-6-(4,5-diphenyl-oxazol-2-yl)-1H-benzimidazol-2-yl azole, (4-{6-[5-(4-chloro-phenyl)-[1,3,4]oxadiazol-2-yl]-1H-benzimidazol-2-yl}-3,5-dimethyl-phenoxy)-acetic acid, 2-(2,6-dichloro-phenyl)-6-(5-pyrrolidin-1-yl-[1,3,4]oxadiazol-2-yl)-1H-benzimidazole, and 3,5-dimethyl-4-{6-[5-(4-trifluoromethyl-phenylamino)-[1,3,4]oxadiazol-2-yl]-1H-benzimidazol-2-yl}-phenol.

[0425] A non-limiting example of a Niemann-Pick C1-like 1 (NPC1-L1) inhibitor that may be used in combination with the compounds of the present disclosure is ezetimibe.

[0426] Apolipoprotein AI is a protein encoded by the APOA1 gene in humans. It plays a special role in lipid metabolism. Apolipoprotein AI is the major protein component of high-density lipoprotein (HDL) in plasma. Chylomicrons secreted by enterocytes also contain ApoA-I, which is rapidly transferred to HDL in the bloodstream. This protein promotes cholesterol flux from tissues to the liver for excretion. It is a cofactor for lecithin-cholesterol acyltransferase (LCAT), which is involved in the formation of many plasma cholesteryl esters. Infusion of apoA-I mutants in humans has been shown to cause regression of atherosclerotic plaques as assessed by intravascular ultrasound; therefore, apoA-I has the ability to both slow the progression and induce regression of atherosclerosis, as well as reduce CVD risk. A non-limiting example of an apoA-I upregulator / inducer is RVX208.

[0427] The ATP-binding cassette transporter, ABCA1 (human transporter subfamily ABCA member 1), also known as cholesterol efflux regulatory protein (CERP), is a protein encoded by the ABCA1 gene in humans. This transporter is a key regulator of cellular cholesterol and phospholipid homeostasis. A non-limiting example of an ABCA1 modulator is probucol. Probucol lowers cholesterol levels in the bloodstream by increasing the rate of LDL catabolism. In addition, probucol can inhibit cholesterol synthesis and delay cholesterol absorption. Probucol is a potent antioxidant, which inhibits the oxidation of cholesterol in LDL; this slows the formation of foam cells, which contribute to atherosclerotic plaques.

[0428] Liver X receptors (LXRs) are members of the nuclear receptor family of transcription factors and are closely related to nuclear receptors such as PPARs, FXRs, and RXRs. Liver X receptors (LXRs) are important regulators of cholesterol, fatty acid, and glucose homeostasis. LXR agonists are effective in treating mouse models of atherosclerosis, diabetes, inflammation, and Alzheimer's disease. Treatment with LXR agonists (including, but not limited to, hypocholamide, T0901317, GW3965, or N,N-dimethyl-3-β-hydroxycholenamide (DMHCA)) lowers serum and hepatic cholesterol levels and inhibits the development of atherosclerosis in mouse disease models. Examples of LXR agonists include, but are not limited to, GW3965 (a synthetic nonsteroidal liver X receptor (LXR) agonist / activator) and T0901317 (a dual LXR, FXR agonist).

[0429] The farnesoid X receptor (FXR), also known as NR1H4 (nuclear receptor subfamily 1, group H, member 4), is a nuclear hormone receptor with activities similar to those seen in other steroid receptors, such as estrogen or progesterone, but more similar in morphology to PPARs, LXRs, and RXRs. Activation of the nuclear receptor FXR is known to improve hyperglycemia and hyperlipidemia. A non-limiting example of an FXR agonist is GW4064 (3-(2,6-dichlorophenyl)-4-(3'-carboxy-2-chlorostilbene-4-yl)oxymethyl-5-isopropylisoxazole).

[0430] Phospholipid transfer protein (PLTP) is a protein encoded by the PLTP gene in humans. This gene encodes one of at least two lipid transfer proteins found in human plasma; the other is CETP. The encoded protein transfers phospholipids from triglyceride-rich lipoproteins to HDL. In addition to regulating HDL particle size, this protein may be involved in cholesterol metabolism. At least two transcript variants of this gene have been found, encoding different isoforms. Because PLTP affects the metabolism of both triglyceride-rich lipoproteins and HDL, modulation of this transfer protein may alter cardiovascular disease risk.

[0431] Fish oil is obtained from the tissues of oily fish. Fish oil contains the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), precursors of eicosanoids known to have numerous health benefits. Fish oil and other omega-3 sources are most highly recommended for the prevention of the following conditions: hypertriglyceridemia, secondary cardiovascular disease, and hypertension. For example, Lovaza® is used in conjunction with a low-fat and low-cholesterol diet to lower very high triglycerides (fats) in the reader's blood. Examples of omega-3 fatty acids that may be used in combination with the compounds of the present disclosure include, but are not limited to, Lovaza® and Vascepa® (ethyl icosapentate).

[0432] Examples of antidiabetic agents that may be used in combination with the compounds of the present disclosure include, but are not limited to, insulin, insulin derivatives and mimetics; insulin secretagogues such as sulfonylureas; insulinotropic sulfonylurea receptor ligands such as meglitinides, e.g., nateglinide and repaglinide; protein tyrosine phosphatase-1B (PTP-1B) inhibitors, including but not limited to PTP-112; GSK3 (glycogen synthase kinase-3) inhibitors, including but not limited to SB-517955, SB-4195052, SB-216763, NN-57-05441, and NN-57-05445; RXR ligands, including but not limited to GW-0791 and AGN-194204; sodium-dependent glucose cotransporter inhibitors, including but not limited to T-1095; glycogen phosphorylase A inhibitors, including R3401; biguanides, including but not limited to metformin; alpha-glucosidase inhibitors, including but not limited to acarbose; GLP-1 (glucagon-like peptide-1), GLP-1 analogs and GLP-1 mimetics, including but not limited to exendin-4; and DPPIV (dipeptidyl peptidase IV) inhibitors, including but not limited to vildagliptin.

[0433] Examples of sulfonylureas include, but are not limited to, tolbutamide, chlorpropamide, tolazamide, acetohexamide, 4-chloro-N-[(1-pyrolidinylamino)carbonyl]-benzenesulfonamide (glycopyramide), glibenclamide (glyburide), gliclazide, 1-butyl-3-methanilylurea, carbutamide, glibonuride, glipizide, gliquidone, glisoxepid, glybuthiazole, glybuzole, glyhexamide, glymidine, glypinamide, phenbutamide, amaryl, and tolylcyclamide, or a pharmaceutically acceptable salt thereof.

[0434] DPP-IV (dipeptidyl peptidase IV) is involved in the inactivation of GLP-1. More specifically, DPP-IV produces a GLP-1 receptor antagonist, thereby shortening the physiological response to GLP-1. GLP-1 is the primary stimulator of pancreatic insulin secretion and has a direct beneficial effect on glucose disposal.

[0435] DPP-IV inhibitors may be peptidic or, preferably, non-peptidic. Examples of DPP-IV inhibitors also include, but are not limited to, those generally and specifically disclosed in WO 98 / 19998, DE 196 16 486 A1, WO 00 / 34241 and WO 95 / 15309, in each case in detail in the compound claims and the final products of the examples, the final products, pharmaceutical formulations and subject matter of the claims being hereby incorporated by reference into the present application.

[0436] GLP-1 (glucagon-like peptide-1) is an insulinotropic protein described, for example, by W. E. Schmidt et al. in Diabetologia, 28, 1985, 704-707 and U.S. Pat. No. 5,705,483. The term "GLP-1 agonist" includes, inter alia, variants and analogs of GLP-1(7-36)NH2 disclosed in U.S. Pat. Nos. 5,120,712, 5,118,666, 5,512,549, WO 91 / 11457, and by C. Orskov et al. in J. Biol. Chem., 264 (1989) 12826. Further examples include GLP-1(7-37) (in which the compound contains Arg at position 37 of the GLP-1(7-36)NH2 molecule). 36 , in which the carboxy-terminal amide functionality is replaced by Gly), and GLN 9 -GLP-1(7-37), D-GLN 9 -GLP-1(7-37), acetyl LYS 9-GLP-1(7-37), LYS 18 -GLP-1(7-37) and, in particular, GLP-1(7-37)OH, VAL 8 -GLP-1(7-37), GLY 8 -GLP-1(7-37), THR 8 -GLP-1(7-37), MET 8 -GLP-1(7-37) and its variants and analogs, including 4-imidazopropionyl-GLP-1. Also preferred is the GLP agonist analog exendin-4, described by Greig, et al. in Diabetologia, 1999, 42, 45-50.

[0437] Also included within the definition of "antidiabetic agent" are insulin sensitizers that restore impaired insulin receptor function, thereby reducing insulin resistance and thereby enhancing insulin sensitivity. Examples include hypoglycemic thiazolidinedione derivatives (e.g., glitazones, (S)-((3,4-dihydro-2-(phenyl-methyl)-2H-1-benzopyran-6-yl)methyl-thiazolidine-2,4-dione (englitazone), 5-{[4-(3-(5-methyl-2-phenyl-4-oxazolyl)-1-oxopropyl)-phenyl]-methyl}-thiazolidine-2,4-dione (darglitazone)). ), 5-{[4-(1-methyl-cyclohexyl)methoxy)-phenyl]methyl}-thiazolidine-2,4-dione (ciglitazone), 5-{[4-(2-(1-indolyl)ethoxy)phenyl]methyl}-thiazolidine-2,4-dione (DRF2189), 5-{4-[2-(5-methyl-2-phenyl-4-oxazolyl)-ethoxy)]benzyl}-thiazolidine-2,4-dione (BM-13.1246), 5-(2-naphthylsulfonyl)-thiazolidine-2,4-dione (AY-31637), bis{4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl}methane (YM268), 5-{4-[2-(5-methyl-2-phenyl-4-oxazolyl)-2-hydroxyethoxy]benzyl}-thiazolidine-2,4-dione (AD-5075), 5-[4-(1-phenyl-1-cyclopropanecarbonylamino)-benzyl]-thiazolidine-2,4-dione (DN-108) 5-{[4-(2-(2,3-dihydroindol-1-yl)ethoxy)phenyl]methyl}-thiazolidine-2,4-dione, 5-[3-(4-chlorophenyl])-2-propynyl]-5-phenylsulfonyl)thiazolidine-2,4-dione, 5-[3-(4-chlorophenyl])-2-propynyl]-5-(4-fluorophenylsulfonyl)thiazolidine-2,4-dione, 5-{[4-(2-(methyl-2-pyridinyl-amino)-ethoxy)phenyl]methyl}-thiazolidine-2,4-dione (rosiglitazone), 5-{[4-(2-(5-ethyl-2-pyridyl)ethoxy)phenyl]-methyl}thiazolidine-2,4-dione (pyridinone) glitazone), 5-{[4-((3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy)-phenyl]-methyl}-thiazolidine-2,4-dione (troglitazone), 5-[6-(2-fluoro-benzyloxy)naphthalen-2-ylmethyl]-thiazolidine-2,4-dione (MCC555), 5-{[2-(2-naphthyl)-benzoxazol-5-yl]-methyl}thiazolidine-2,4-dione (T-174), and 5-(2,4-dioxothiazolidin-5-ylmethyl)-2-methoxy-N-(4-trifluoromethyl-benzyl)benzamide (KRP297)).

[0438] Examples of anti-obesity agents that may be used in combination with the compounds of the present disclosure include, but are not limited to, orlistat, sibutramine, phentermine, and cannabinoid receptor 1 (CB1) antagonists such as rimonabant.

[0439] Examples of peroxisome proliferator-activator receptor agonists that may be used in combination with the compounds of the present disclosure include, but are not limited to, fenofibrate, pioglitazone, rosiglitazone, tesaglitazar, BMS-298585, L-796449, the compounds specifically described in WO 2004 / 103995, i.e., the compounds of Examples 1 to 35 or the compounds specifically listed in claim 21, or the compounds specifically described in WO 03 / 043985, i.e., the compounds of Examples 1 to 7 or the compounds specifically listed in claim 19, and in particular (R)-1-{4-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-benzenesulfonyl}-2,3-dihydro-1H-indole-2-carboxylic acid or a salt thereof.

[0440] Examples of lipid-lowering agents that may be used in combination with the compounds of the present disclosure include, but are not limited to, HMG-CoA reductase inhibitors, squalene synthase inhibitors, LXR agonists, FXR agonists, fibrates, cholesterol absorption inhibitors, nicotinic acid bile acid binding resins, bempedoic acid, nicotinic acid and other GPR109 agonists, and aspirin.

[0441] Examples of antihypertensive agents that may be used in combination with the compounds of the present disclosure include, but are not limited to, loop diuretics; angiotensin-converting enzyme (ACE); inhibitors of the Na-K-ATPase membrane pump; neutral endopeptidase (NEP) inhibitors; ACE / NEP inhibitors; angiotensin II antagonists; renin inhibitors; beta-adrenergic receptor blockers; inotropes; calcium channels; aldosterone receptor antagonists; and aldosterone synthase inhibitors.

[0442] Examples of loop diuretics that may be used in combination with the compounds of the present disclosure include, but are not limited to, ethacrynic acid, furosemide, and torsemide.

[0443] The term "ACE inhibitor" (also called angiotensin-converting enzyme inhibitor) includes molecules that prevent the enzymatic breakdown of angiotensin I to angiotensin II. Such compounds can be used to regulate blood pressure and treat congestive heart failure. Examples include, but are not limited to, alacepril, benazepril, benazeprilat, captopril, ceronapril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, imidapril, lisinopril, moexipril, moveltopril, perindopril, quinapril, ramipril, spirapril, temocapril, and trandolapril, or a pharmaceutically acceptable salt thereof.

[0444] A non-limiting example of an inhibitor of the Na-K-ATPase membrane pump is digoxin.

[0445] The term "NEP inhibitor" refers to a compound that inhibits neutral endopeptidase (NEP). Examples include, but are not limited to, candoxatril, candoxatrilat, dexecadotril, ecadotril, racecadotril, sampatrilat, fasidotril, omapatrilat, gemopatrilat, daglutril, SCH-42495, SCH-32615, UK-447841, AVE-0848, PL-37, and (2R,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester, or a pharmaceutically acceptable salt thereof. NEP inhibitors also include phosphono / biaryl-substituted dipeptide derivatives, as disclosed in U.S. Patent No. 5,155,100. NEP inhibitors also include N-mercaptoacylphenylalanine derivatives as disclosed in WO 2003 / 104200. NEP inhibitors also include dual-acting antihypertensive agents as disclosed in WO 2008 / 133896, WO 2009 / 035543, or WO 2009 / 134741. Other examples include compounds disclosed in U.S. Patent Application Nos. 12 / 788,794; 12 / 788,766; and 12 / 947,029. NEP inhibitors also include compounds disclosed in WO 2010 / 136474, WO 2010 / 136493, WO 2011 / 061271, WO 2012 / 065953, WO 2012 / 065956, WO 2014 / 126979, and WO 2014 / 015965.Other examples of NEP inhibitors are the compounds disclosed in WO2015116786, WO2015116760, WO2014138053, WO2014025891, WO2013184934, WO2013067163, WO2012166389, WO2012166387, WO2012112742, and WO2012082853.

[0446] The term "ACE / NEP inhibitor" refers to a compound that inhibits both angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP). Examples of ACE / NEP inhibitors that may be used in combination with the compounds of the present disclosure include, but are not limited to, omapatrilat, sampatrilat, and fasidotril.

[0447] The class of angiotensin II antagonists or AT1 receptor antagonists includes compounds with various structural features, essentially preferred are non-peptide compounds. Examples of angiotensin II antagonists that may be used in combination with the compounds of the present disclosure include, but are not limited to, valsartan, losartan, candesartan, eprosartan, irbesartan, saprisartan, tasosartan, telmisartan, compounds with the following formulas: E-1477 and ZD-8731. [ka] Or, in either case, a pharmaceutically acceptable salt thereof.

[0448] The term "renin inhibitor" includes ditekiren (chemical name: [1S-[1R,2R,4R(1R,2R)]]-1-[(1,1-dimethylethoxy)carbonyl]-L-prolyl-L-phenylalanyl-N-[2-hydroxy-5-methyl-1-(2-methylpropyl)-4-[[[2-methyl-1-[[(2 Pyridinylmethyl(pyridinylmrthyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-N-α-methyl-L-histidineamide; Tellurakiren (chemical name: [R-(R,S)]-N-(4-morpholinylcarbonyl)-L-phenylalanyl-N-[1-(cyclohexylmethyl)-2-hydroxy-3-(1-methylethoxy)-3-oxopropyl]-S-methyl-L-cysteinamide); Aliskiren (chemical name: (2S,4s,5S,7S)-5-amino-N-(2-carbamoyl-2,2-dimethylethyl)-4-hydroxy-7-{[4-methoxy] ci-3-(3-methoxypropoxy)phenyl]methyl}-8-methyl-2-(propan-2-yl)nonanamide) and Zankylene (chemical name: [1S-[1R[R(R)],2S,3r]]-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-α-[[2-[[(4-methyl-1-piperazinyl)sulfonyl]methyl]-1-oxo-3-phenylpropyl]-amino]-4-thiazolepropanamide), or its hydrochloride salt, or SPP630, SPP635 and SPP800 as developed by Speedel, or RO 66-1132 and RO 66-1168 of formula (A) and (B): [ka] or a pharmaceutically acceptable salt thereof. The term "aliskiren", unless specifically defined, shall be understood to refer to both the free base and a salt thereof, particularly a pharmaceutically acceptable salt thereof, most preferably the hemifumarate salt thereof.

[0449] Examples of beta-adrenergic receptor blockers that may be used in combination with the compounds of the present disclosure include, but are not limited to, acebutolol, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, sotalol, and timolol.

[0450] Examples of inotropic agents that may be used in combination with the compounds of the present disclosure include, but are not limited to, digoxin, dobutamine, and milrinone; inotropic agents as used herein include, for example, dobutamine, isoproterenol, milrinone, amrinone, levosimendan, epinephrine, norepinephrine, isoproterenol, and digoxin.

[0451] Examples of calcium channel blockers that may be used in combination with the compounds of the present disclosure include, but are not limited to, amlodipine, bepridil, diltiazem, felodipine, nicardipine, nimodipine, nifedipine, nisoldipine, and verapamil.

[0452] The aldosterone synthase inhibitor class includes both steroidal and non-steroidal aldosterone synthase inhibitors, with the latter being most preferred. The aldosterone synthase inhibitor class includes compounds with a variety of structural features. Examples of aldosterone synthase inhibitors that can be used in combination with the compounds of the present disclosure include, but are not limited to, compounds of the formula: [ka] and the (+)-enantiomer of the hydrochloride salt of fadrozole (U.S. Pat. Nos. 4,617,307 and 4,889,861), or, where appropriate, pharmaceutically acceptable salts thereof; and compounds and analogs generally and specifically disclosed, for example, in U.S. Patent Application Publication No. 2007 / 0049616, particularly the final products of the compound claims and examples, the subject matter of which is hereby incorporated by reference. Examples of aldosterone synthase inhibitors that can be used in combination with the compounds of the present disclosure include, but are not limited to, 4-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-methylbenzonitrile; 5-(2-chloro-4-cyanophenyl)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazole-5-carboxylic acid (4-methoxybenzyl)methylamide. 4'-Fluoro-6-(6,7,8,9-tetrahydro-5H-imidazo[1,5-a]azepin-5-yl)biphenyl-3-carbonitrile;5-(4-cyano-2-methoxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazole-5-carboxylic acid butyl ester;4-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-2-methoxybenzonitrile;5 -(2-Chloro-4-cyanophenyl)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazole-5-carboxylic acid 4-fluorobenzyl ester;5-(4-cyano-2-trifluoromethoxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazole-5-carboxylic acid methyl ester;5-(4-cyano-2- ... Midazole-5-carboxylic acid 2-isopropoxyethyl ester;4-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-2-methylbenzonitrile;4-(6,7-dihydro-5H-py...

Claims

1. Compounds of formula (I): 【Chemistry 1】 [In the formula: X 1 and X 2 Each independently represents H or (C 1 ~C 6 ) alkyl or X 1 and X 2 together with the carbon atom to which they are attached form =(O); X 3 , X 1 and X 2 are each independently H or (C 1 ~C 6 ) alkyl or X 1 and X 2 When they are combined with the carbon atom to form =(O), it becomes -CH 2 - or X 3 , X 1 and X 2 When they are combined with the carbon atom to form =(O), -O-, -NH- or -N(C 1 ~C 6 ) alkyl-; R 1 (C 6 ~C 10 ) aryl or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are -OR 10 Or -NR 21 R 10 and optionally one or more R 11 is substituted with; R 2 is H, (C 1 ~C 6 ) alkyl, (C 2 ~C 6 ) alkenyl, (C 1 ~C 6 ) haloalkyl, -NR 12 R 13 , (C 3 ~C 7 ) carbocyclyl, (C 3 ~C 7 ) cycloalkenyl, 5- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; (C 6 ~C 10 ) aryl, or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the alkyl optionally contains one or more R 18 and the carbocyclyl, (C 3 ~C 7 Cycloalkenyl, heterocyclyl, aryl and heteroaryl are optionally represented by one or more R 19 is substituted with; R 3 H, D, (C 1 ~C 6 ) alkyl, (C 1 ~C 6 ) alkoxy, (C 1 ~C 6 ) haloalkyl, (C 1 ~C 6 ) haloalkoxy, or (C 1 ~C 6 ) hydroxyalkyl, wherein the alkyl is optionally selected from one or more R 14 is substituted with; R 4 is H or (C 1 ~C 6 ) alkyl; or R 3 and R 4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1 to 3 heteroatoms selected from N, O, and S; R 5 and R 7 are each independently H, D, (C 1 ~C 6 ) alkyl, (C 1 ~C 6 ) alkoxy, (C 1 ~C 6 ) haloalkyl, (C 1 ~C 6 ) haloalkoxy, or (C 1 ~C 6 ) hydroxyalkyl, wherein (C 1 ~C 6 ) alkyl is optionally substituted with one or more D; R 6 (C 1 ~C 6 ) alkyl, (C 1 ~C 6 ) alkoxy, (C 1 ~C 6 ) haloalkyl, (C 1 ~C 6 ) haloalkoxy, or (C 1 ~C 6 ) hydroxyalkyl, wherein the alkyl is optionally selected from the group consisting of (C 1 ~C 6 ) alkoxy, (C 1 ~C 6 ) haloalkoxy, —C(O)(C 1 ~C 6 ) alkyl, —C(O)OH, and —C(O)O(C 1 ~C 6 ) substituted with one or more substituents each independently selected from alkyl; R 8 is H, (C 1 ~C 6 ) alkyl, or (C 1 ~C 6 ) haloalkyl, wherein said alkyl is optionally selected from the group consisting of (C 3 ~C 7 ) carbocyclyl, 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, —NR 16 R 17 and -C(O)NR 16 R 17 substituted with one or more substituents each independently selected from R 9 is a halogen, (C 1 ~C 6 ) alkyl, (C 1 ~C 6 ) alkoxy, (C 1 ~C 6 ) haloalkyl, (C 1 ~C 6 ) haloalkoxy, —OH, or CN; R 10 (C 6 ~C 10 ) aryl or 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally selected from one or more R 22 is substituted with; Each R 11 represents independently at each occurrence a halogen, (C 1 ~C 6 ) alkyl, (C 1 ~C 6 ) alkoxy, (C 1 ~C 6 ) haloalkyl, (C 1 ~C 6 ) haloalkoxy, —OH, or CN; R 12 and R 13 Each independently represents H or (C 1 ~C 6 ) alkyl; Each R 14 is independently expressed for each occurrence as D, NR 15 R 15’ , (C 3 ~C 7 ) carbocyclyl, or a 3- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, wherein said carbocyclyl and heterocyclyl are optionally selected from halogen, (C 1 ~C 6 ) alkyl, (C 1 ~C 6 ) alkoxy, (C 1 ~C 6 ) haloalkyl, and (C 1 ~C 6 ) substituted with one or more substituents each independently selected from haloalkoxy; R 15 and R 15’ Each independently represents H or (C 1 ~C 6 ) alkyl; R 16 and R 17 Each independently represents H or (C 1 ~C 6 ) alkyl, or R 16 and R 17 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocyclyl ring, optionally containing 1-2 additional heteroatoms selected from N, O, and S; Each R 18 is independently calculated for each occurrence, (C 3 ~C 7 ) carbocyclyl, 5- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; (C 6 ~C 10 ) aryl, or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the carbocyclyl, heterocyclyl, aryl, and heteroaryl are optionally joined by one or more R 20 is substituted with; Each R 19 represents independently at each occurrence a halogen, (C 1 ~C 6 ) alkyl, (C 1 ~C 6 ) alkoxy, (C 1 ~C 6 ) haloalkyl, (C 1 ~C 6 ) haloalkoxy, —OH, or CN; or Two R's 19 are taken together and are on adjacent atoms, (C 6 ~C 10 ) aryl, or a 5- or 6-membered heteroaryl ring containing 1 to 3 heteroatoms selected from N, O, and S, wherein said aryl and heteroaryl are optionally selected from halogen, (C 1 ~C 6 ) alkyl, (C 1 ~C 6 ) alkoxy, (C 1 ~C 6 ) haloalkyl, (C 1 ~C 6 ) substituted with one or more substituents each independently selected from haloalkoxy, —OH, and CN; Each R 20 represents independently at each occurrence a halogen, (C 1 ~C 6 ) alkyl, (C 1 ~C 6 ) alkoxy, (C 1 ~C 6 ) haloalkyl, (C 1 ~C 6 ) haloalkoxy, oxo, —OH, or CN; or R 18 When R is carbocyclyl or heterocyclyl, two R 20 when attached to the same carbon atom, they are taken together to form =(O); R 21 is H or (C 1 ~C 6 ) alkyl; Each R 22 represents independently at each occurrence a halogen, (C 1 ~C 6 ) alkyl, (C 1 ~C 6 ) alkoxy, (C 1 ~C 6 ) haloalkyl, (C 1 ~C 6 ) haloalkoxy, —OH, CN, (C 6 ~C 10 ) aryl, or a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally further represented by one or more R 23 is substituted with; Each R 23 represents independently at each occurrence a halogen, (C 1 ~C 6 ) alkyl, (C 1 ~C 6 ) alkoxy, (C 1 ~C 6 ) haloalkyl, (C 1 ~C 6 ) haloalkoxy, -CH 2 (O.C.H. 2 CH 2 ) 1~3 OCH 2 CH 3 , —OH, CN, or a 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, wherein said heterocyclyl is optionally selected from halogen, (C 1 ~C 6 ) alkyl, (C 1 ~C 6 ) alkoxy, (C 1 ~C 6 ) haloalkyl, (C 1 ~C 6 ) haloalkoxy, -OH, -C(O)R 24, -NR 24 C(O)R 25 , -NH 2 , -NH(C 1 ~C 6 ) alkyl, and -N((C 1 ~C 6 ) alkyl) 2 and said alkyl is optionally substituted with one or more substituents each independently selected from -NR 24 R 25 or a 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, and 1 ~C 6 ) alkyl, (C 1 ~C 6 ) alkoxy, (C 1 ~C 6 ) haloalkyl, (C 1 ~C 6 ) Haloalkoxy, -OH, -NH 2 , -NH(C 1 ~C 6 ) alkyl, and -N((C 1 ~C 6 ) alkyl) 2 and R 24 and R 25 Each independently represents H, (C 1 ~C 6 ) alkyl, or 1 to 2 (C 1 ~C 6 ) optionally substituted with alkyl (C 3 ~C 7 ) carbocyclyl; or a pharma- ceutically acceptable salt, hydrate, solvate, stereoisomer, N-oxide, or tautomer thereof.

2. R 4 is H or (C 1 ~C 6 ) alkyl.

3. R 3 and R 4 together with the atoms to which they are attached form a 5- to 7-membered heterocyclyl ring containing 1 to 3 heteroatoms selected from N, O, and S.

4. R 3 and R 4 together with the atoms to which they are attached form a 6-membered heterocyclyl ring containing 1 to 3 heteroatoms selected from N, O, and S.

5. R 5 is H or (C 1 ~C 6 ) alkyl.

6. R 7 is H or (C 1 ~C 6 ) alkyl.

7. R 9 The compound of claim 1 , wherein is a halogen.

8. R 8 However, (C 3 ~C 7 ) carbocyclyl, 4- to 7-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, —NR 16 R 17 and -C(O)NR 16 R 17 (C 1 ~C 6 ) alkyl.

9. R 8 But (C 1 ~C 6 ) alkyl.

10. Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), Formula (If), Formula (Ig), Formula (Ih), or Formula (Ii): 【Chemistry 2】 【Chemistry 3】 2. The compound of claim 1 having the formula:

11. R 1 But, -OR 10 and optionally 1 to 3 R 11 The compound according to any one of claims 1 to 10, which is phenyl or pyridinyl substituted with

12. Formula (Ij), Formula (Ik), Formula (Im), or Formula (Io): 【Chemistry 4】 (wherein x is 0, 1, or 2).

2. The compound of claim 1 having the formula:

13. R 10 But 1 to 3 R 22 13. The compound of any one of claims 1 to 12, which is phenyl or pyridinyl substituted with:

14. (3R,7S,10S,13R)-6-(4-chloro-2-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-3-(pyridin-2-ylmethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7-methyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; 2-(((3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7,12-dimethyl-2,5,8,11-tetraoxo-1,6,9,12-tetraazabicyclo[11.3.1]heptadecan-3-yl)methyl)pyridine 1-oxide; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7-methyl-3-((6-methylpyridin-2-yl)methyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((cyclobutylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(2-(4-(2-((tert-butylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-4-chlorobenzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7-methyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(4-((dimethylamino)methyl)-5-methyl-1H-imidazol-1-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-3-((S)-2,3-dihydro-1H-inden-1-yl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-((6-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)pyridin-3-yl)oxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7-methyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7,12-dimethyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-fluoro-6-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-3-(cyclopropylmethyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-((6-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)pyridin-3-yl)oxy)benzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7,12-dimethyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7,12-dimethyl-3-((6-methylpyridin-2-yl)methyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-fluoro-6-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7,12-dimethyl-3-((6-methylpyridin-2-yl)methyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-fluoro-6-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-3-((R)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-((5-chloro-3-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)pyridin-2-yl)methyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7,12-dimethyl-3-(pyridin-2-ylmethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-3-(pyridin-3-ylmethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7,12-dimethyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7-methyl-3-(pyridin-2-ylmethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7,12-dimethyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7-methyl-3-(pyridin-3-ylmethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-((6-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)pyridin-3-yl)oxy)benzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7,12-dimethyl-3-((6-methylpyridin-2-yl)methyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-3-fluorobenzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-3-ethyl-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-((6-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)pyridin-3-yl)oxy)benzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7,12-dimethyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(2-(4-(2-(azetidin-1-ylmethyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-4-chloro-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-((5-chloro-3-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)pyridin-2-yl)methyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7-methyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-((difluoromethoxy)methyl)-7-methyl-3-(pyridin-2-ylmethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-((5-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)pyridin-2-yl)oxy)benzyl)-13-(4-chlorobenzyl)-3-((R)-2,3-dihydro-1H-inden-1-yl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-((5-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)pyridin-2-yl)oxy)benzyl)-13-(4-chlorobenzyl)-3-((S)-2,3-dihydro-1H-inden-1-yl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7,12-dimethyl-3-(pyridin-2-ylmethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(2-(4-(2-(azetidin-1-ylmethyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-4-chlorobenzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7-methyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-3-(2,6-difluorobenzyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7-methyl-3-(oxazol-2-ylmethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-(2,2,2-trifluoroethoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7,12-dimethyl-3-(2,4,6-trifluorobenzyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7,12-dimethyl-3-((6-methylpyridin-2-yl)methyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-fluoro-6-(4-(5-methyl-4-(pyrrolidin-1-ylmethyl)-1H-imidazol-1-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-((E)-but-2-en-1-yl)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-3-((6-methylpyridin-2-yl)methyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-3-(cyclopropylmethyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)-3-fluorophenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7-methyl-3-((1-methyl-6-oxo-1,6-dihydropyridin-2-yl)methyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((cyclobutylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7-methyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-3-(2,4,6-trifluorobenzyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(1-methyl-2-(morpholinomethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-3-(pyridin-3-ylmethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-3-(2,3,4-trifluorobenzyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-3-((S)-2,3-dihydro-1H-inden-1-yl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-3-propyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-((6-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)pyridin-3-yl)oxy)benzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7,12-dimethyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-5-fluorobenzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-13-(4-chlorobenzyl)-3-((S)-2,3-dihydro-1H-inden-1-yl)-6-(2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(5-((dimethylamino)methyl)-4-methyl-4H-1,2,4-triazol-3-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7,12-dimethyl-3-(pyridin-2-ylmethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-3-(2,2-difluoroethyl)-10-(hydroxymethyl)-7-methyl-1,4,6,9,12-pentaazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(2-(((S)-3-hydroxypyrrolidin-1-yl)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-1,4,6,9,12-pentaazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(2-((4-hydroxypiperidin-1-yl)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-3-(4-(trifluoromethyl)benzyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-3-ethyl-10-(methoxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-((S)-1-hydroxyethyl)-7-methyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7,12-dimethyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; 2-(((3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-2,5,8,11-tetraoxo-1,6,9,12-tetraazabicyclo[11.3.1]heptadecan-3-yl)methyl)pyridine 1-oxide; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-3-isopropyl-7-methyl-1,4,6,9,12-pentaazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-3-((R)-2,3-dihydro-1H-inden-1-yl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(1-methyl-2-(1-methylazetidin-3-yl)-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-3-((S)-2,3-dihydro-1H-inden-1-yl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((R)-1-(dimethylamino)ethyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-3-((S)-2,3-dihydro-1H-inden-1-yl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-((6-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)pyridin-3-yl)oxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7,12-dimethyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(2-(((S)-3-(dimethylamino)pyrrolidin-1-yl)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-13-(4-chlorobenzyl)-3-((S)-2,3-dihydro-1H-inden-1-yl)-6-(2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-4-fluorobenzyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-13-(4-chlorobenzyl)-3-((S)-2,3-dihydro-1H-inden-1-yl)-6-(2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-5-fluorobenzyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-3-((S)-2,3-dihydro-1H-inden-1-yl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-13-(4-chlorobenzyl)-6-(2,4-difluoro-6-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(1-methyl-2-((4-methylpiperazin-1-yl)methyl)-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(1-methyl-2-(1-methyl-2,5-dihydro-1H-pyrrol-3-yl)-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-3-((S)-2,3-dihydro-1H-inden-1-yl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-4-oxa-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7,12-dimethyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-3-(3-(trifluoromethyl)benzyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (2S,5S,8R,12S)-1-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-8-(4-chlorobenzyl)-5-(hydroxymethyl)-2,7,10-trimethyl-12-((1R,3S)-3-methyl-2,3-dihydro-1H-inden-1-yl)-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7,12-dimethyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-3-((S)-2,3-dihydro-1H-inden-1-yl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-((5-chloro-3-((6-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)pyridin-3-yl)oxy)pyridin-2-yl)methyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7,12-dimethyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (2S,5S,8R,12S)-1-(4-chloro-2-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-8-(4-chlorobenzyl)-12-((R)-2,3-dihydro-1H-inden-1-yl)-5-(hydroxymethyl)-2,7,10-trimethyl-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)-2-fluorophenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-ethyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (2S,5S,8R,12R)-12-benzyl-1-(4-chloro-2-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-8-(4-chlorobenzyl)-5-(hydroxymethyl)-2,7-dimethyl-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (3S,7S,10S,13R)-13-(4-chlorobenzyl)-3-((S)-2,3-dihydro-1H-inden-1-yl)-6-(2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-4-(trifluoromethyl)benzyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (2S,5S,8R,12S)-1-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-8-(4-chlorobenzyl)-12-((R)-2,3-dihydro-1H-inden-1-yl)-5-(hydroxymethyl)-2,7,10-trimethyl-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (2S,5S,8R,12R)-12-benzyl-1-(4-chloro-2-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-8-(4-chlorobenzyl)-5-(methoxymethyl)-2,7-dimethyl-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (2S,5S,8R,12S)-1-(4-chloro-2-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-8-(4-chlorobenzyl)-5-(hydroxymethyl)-2,7,10-trimethyl-12-((1R,3S)-3-methyl-2,3-dihydro-1H-inden-1-yl)-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-((6-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)pyridin-3-yl)oxy)benzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7,12-dimethyl-3-(pyridin-2-ylmethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-3-((S)-2,3-dihydro-1H-inden-1-yl)-10-(methoxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-3-((R)-2,3-dihydro-1H-inden-1-yl)-10-(methoxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-((R)-1-hydroxyethyl)-7-methyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-13-(4-chlorobenzyl)-6-(2,4-dichloro-6-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-3,7,12-trimethyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,10S,13R)-6-(5-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-3-((S)-2,3-dihydro-1H-inden-1-yl)-10-(hydroxymethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-3-((S)-2,3-dihydro-1H-inden-1-yl)-10-(hydroxymethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (2S,5S,8R,12S)-1-(4-chloro-2-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-8-(4-chlorobenzyl)-12-((R)-2,3-dihydro-1H-inden-1-yl)-5-(methoxymethyl)-2,7,10-trimethyl-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (2S,5S,8R,12S)-1-(4-chloro-2-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-8-(4-chlorobenzyl)-12-((R)-2,3-dihydrobenzofuran-3-yl)-5-(hydroxymethyl)-2,7,10-trimethyl-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (2S,5S,8R,12S)-1-(4-chloro-2-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-8-(4-chlorobenzyl)-5-(hydroxymethyl)-12-((R)-7-methoxy-2,3-dihydrobenzofuran-3-yl)-2,7,10-trimethyl-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (3S,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(2-((2-(2-ethoxyethoxy)ethoxy)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-1,4,6,9,12-pentaazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-7-(2-fluoroethyl)-10-(methoxymethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (2S,5S,8R,12R)-12-benzyl-1-(4-chloro-2-(3,5-difluoro-4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-8-(4-chlorobenzyl)-5-(hydroxymethyl)-2,7,10-trimethyl-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (2S,5S,8R,12S)-1-(4-chloro-2-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-8-(4-chlorobenzyl)-5-(hydroxymethyl)-2,7,10-trimethyl-12-((R)-1-phenylethyl)-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (2S,5S,8R,12R)-12-benzyl-1-(4-chloro-2-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-8-(4-chlorobenzyl)-5-(hydroxymethyl)-2,7,10-trimethyl-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-((S)-1-hydroxyethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (2S,5S,8R,12S)-1-(4-chloro-2-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-8-(4-chlorobenzyl)-12-((R)-7-methoxy-2,3-dihydrobenzofuran-3-yl)-5-(methoxymethyl)-2,7,10-trimethyl-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (2S,5S,8R,12S)-1-(4-chloro-2-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-8-(4-chlorobenzyl)-12-((R)-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl)-5-(methoxymethyl)-2,7,10-trimethyl-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (2S,5S,8R,12R)-1-(4-chloro-2-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)-6-(2,2,2-trifluoroethoxy)benzyl)-8-(4-chlorobenzyl)-12-ethyl-5-(hydroxymethyl)-2,7-dimethyl-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (2S,5S,8R,12S)-1-(4-chloro-2-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-8-(4-chlorobenzyl)-10-(3,3-difluoropropyl)-12-((R)-2,3-dihydro-1H-inden-1-yl)-5-(methoxymethyl)-2,7-dimethyl-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (2S,5S,8R,12R)-12-benzyl-1-(4-chloro-2-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-8-(4-chlorobenzyl)-5-(methoxymethyl)-2,7,10-trimethyl-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (2S,5S,8R,12S)-1-(4-chloro-2-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-8-(4-chlorobenzyl)-12-((R)-2,3-dihydro-1H-inden-1-yl)-5-(methoxymethyl)-2,7-dimethyl-10-((1-methylcyclopropyl)methyl)-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (2S,5S,8R,12R)-12-benzyl-1-(4-chloro-2-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-8-(4-chlorobenzyl)-10-(3-(dimethylamino)propyl)-5-(methoxymethyl)-2,7-dimethyl-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (2S,5S,8R,12R)-12-benzyl-1-(4-chloro-2-(3,5-difluoro-4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-8-(4-chlorobenzyl)-5-(methoxymethyl)-2,7,10-trimethyl-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (2S,5S,8S,12S)-8-(4-chlorobenzyl)-12-((S)-2,3-dihydro-1H-inden-1-yl)-1-(2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-4-ethylbenzyl)-5-(hydroxymethyl)-2,7,10-trimethyl-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (2S,5S,8R,12S)-8-(4-chlorobenzyl)-12-((S)-2,3-dihydro-1H-inden-1-yl)-1-(2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-4-ethylbenzyl)-5-(hydroxymethyl)-2,7,10-trimethyl-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,8,11-trione; (2S,5R,8R,12S)-8-(4-chlorobenzyl)-12-((S)-2,3-dihydro-1H-inden-1-yl)-1-(2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-4-ethylbenzyl)-5-(hydroxymethyl)-2,7,10-trimethyl-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (3R,7S,10R,13R)-3-benzyl-6-(4-chloro-2-((6-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)pyridin-3-yl)oxy)benzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,10S,13R)-13-(4-chlorobenzyl)-3-((S)-2,3-dihydro-1H-inden-1-yl)-6-(4-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-2-fluorobenzyl)-10-(hydroxymethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-13-(4-chlorobenzyl)-3-((S)-2,3-dihydro-1H-inden-1-yl)-6-(4-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-2-fluorobenzyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (2S,5S,8R,12R)-1-(4-chloro-2-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-8-(4-chlorobenzyl)-12-ethyl-5-(hydroxymethyl)-2,7-dimethyl-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (2S,5S,8R,12S)-1-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-8-(4-chlorobenzyl)-12-((R)-2,3-dihydro-1H-inden-1-yl)-5-(methoxymethyl)-7,10-dimethyl-2-(2-morpholinoethyl)-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (2S)—N-((3R,8S,11R)-3-benzyl-11-(4-chlorobenzyl)-10-methyl-2,5,9-trioxo-6-oxa-1,10-diazabicyclo[9.3.1]pentadecan-8-yl)-2-((4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)amino)propanamide; (2S,5S,8R,12S)-1-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-8-(4-chlorobenzyl)-12-((R)-2,3-dihydro-1H-inden-1-yl)-5-(methoxymethyl)-7,10-dimethyl-2-(3-morpholinopropyl)-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (2S,5S,8R,12R)-1-(4-chloro-2-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-8-(4-chlorobenzyl)-12-ethyl-5-(hydroxymethyl)-2,7,10-trimethyl-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (2S,5S,8R,12R)-12-benzyl-1-(4-chloro-2-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-8-(4-chlorobenzyl)-2,7,10-trimethyl-5-(2-oxopropyl)-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (2S)—N-((3S,8R,11R)-8-benzyl-11-(4-chlorobenzyl)-10-methyl-2,6,9-trioxo-5-oxa-1,10-diazabicyclo[9.3.1]pentadecan-3-yl)-2-((4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)amino)propanamide; (2S,5S,8R,12S)-1-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-8-(4-chlorobenzyl)-12-((R)-2,3-dihydro-1H-inden-1-yl)-5-(methoxymethyl)-7,10-dimethyl-2-(4-morpholinobutyl)-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (2S,5S,8R,12S)-2-(3-(azetidin-1-yl)-3-oxopropyl)-1-(4-chloro-2-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-8-(4-chlorobenzyl)-12-((R)-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl)-5-(methoxymethyl)-7,10-dimethyl-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-3-isopropyl-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (2S,5S,8R,12R)-1-(4-chloro-2-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-8-(4-chlorobenzyl)-12-(dimethylamino)-5-(methoxymethyl)-2,7,10-trimethyl-1,4,7,10-tetraazacyclotetradecane-3,6,11,14-tetraone; 2-((2S,5S,8R,12R)-12-benzyl-1-(4-chloro-2-(4-(1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-imidazol-5-yl)phenoxy)benzyl)-8-(4-chlorobenzyl)-2,7,10-trimethyl-3,6,11,14-tetraoxo-1,4,7,10-tetraazacyclotetradecan-5-yl)acetic acid; (3S,7S,10S,13R)-6-(2-(4-(2-((tert-butylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-4-chloro-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7,12-dimethyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(2-(4-(2-((tert-butyl(methyl)amino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-4-chloro-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7-methyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(2-(4-(2-((tert-butylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-4-chloro-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7-methyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((cyclobutyl(methyl)amino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-3-cyclobutyl-10-(methoxymethyl)-7,12-dimethyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(2-(4-(2-((tert-butyl(methyl)amino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-4-chloro-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7,12-dimethyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(2-(4-(2-((tert-butylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-4-chloro-6-fluorobenzyl)-13-(4-chlorobenzyl)-3-(cyclopropylmethyl)-10-(methoxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(2-(4-(2-((tert-butyl(methyl)amino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-4-chlorobenzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-3-((1-methylcyclopropyl)methyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-3-(cyclopropylmethyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-3-(2,2-difluoropropyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(2-(4-(2-((tert-butylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-4-chlorobenzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(2-(4-(2-((tert-butylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-4-chlorobenzyl)-13-(4-chlorobenzyl)-3-(cyclopropylmethyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(2-(4-(2-((tert-butylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-4-chlorobenzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(1-methyl-2-((methylamino)methyl)-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7,12-dimethyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((ethyl(1-methylcyclopropyl)amino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7-methyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((cyclobutylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-3-(cyclopropylmethyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(2-(4-(2-((tert-butylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-4-chloro-6-fluorobenzyl)-13-(4-chlorobenzyl)-3-(cyclopropylmethyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-3-(cyclobutylmethyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7-methyl-4-oxa-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(2-(4-(2-(azetidin-1-ylmethyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-4-chloro-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7,12-dimethyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-3-(2,2-difluoropropyl)-10-(methoxymethyl)-7,12-dimethyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-3-benzyl-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7,12-dimethyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((cyclobutyl(methyl)amino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7-methyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-3-(3,3-difluorocyclobutyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(2-(4-(2-((tert-butyl(methyl)amino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-4-chlorobenzyl)-13-(4-chlorobenzyl)-3-(cyclopropylmethyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(2-(4-(2-((tert-butyl(methyl)amino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-4-chloro-6-fluorobenzyl)-13-(4-chlorobenzyl)-3-(cyclopropylmethyl)-10-(hydroxymethyl)-7-methyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-3-(3,3-difluorocyclobutyl)-10-(hydroxymethyl)-7,12-dimethyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(2-(4-(2-((tert-butylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-4-chloro-6-fluorobenzyl)-13-(4-chlorobenzyl)-3-(3,3-difluorocyclobutyl)-10-(methoxymethyl)-7,12-dimethyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(2-(4-(2-(aminomethyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-4-chloro-6-fluorobenzyl)-13-(4-chlorobenzyl)-3-(3,3-difluorocyclobutyl)-10-(methoxymethyl)-7,12-dimethyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-fluoro-6-(4-(1-methyl-2-((methylamino)methyl)-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7,12-dimethyl-3-((6-methylpyridin-2-yl)methyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; 2-(((3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7,12-dimethyl-2,5,8,11-tetraoxo-1,6,9,12-tetraazabicyclo[11.3.1]heptadecan-3-yl)methyl)-6-methylpyridine 1-oxide; (3S,7S,10S,13R)-6-(2-(4-(2-((tert-butyl(methyl)amino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-4-chloro-6-fluorobenzyl)-13-(4-chlorobenzyl)-3-(3,3-difluorocyclobutyl)-10-(methoxymethyl)-7,12-dimethyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3R,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7,12-dimethyl-3-((6-methylpyridin-2-yl)methyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-((6-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)pyridin-3-yl)oxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-3-(3,3-difluorocyclobutyl)-10-(methoxymethyl)-7,12-dimethyl-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-fluoro-6-(4-(1-methyl-2-((methylamino)methyl)-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7,12-dimethyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-((6-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)pyridin-3-yl)oxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7,12-dimethyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7,12-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-((difluoromethoxy)methyl)-7,12-dimethyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7R,10S,13R)-6-(4-chloro-2-((6-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)pyridin-3-yl)oxy)-6-fluorobenzyl)-13-(4-chlorobenzyl)-10-(methoxymethyl)-7,12-dimethyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; (3S,7S,10S,13R)-6-(4-chloro-2-fluoro-6-(4-(1-methyl-2-((methylamino)methyl)-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-7,12-dimethyl-3-(2,2,2-trifluoroethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; and 2. The compound according to claim 1, selected from: (3R,7S,10S,13R)-7-(2-aminoethyl)-3-benzyl-6-(4-chloro-2-(4-(2-((dimethylamino)methyl)-1-methyl-1H-imidazol-5-yl)phenoxy)benzyl)-13-(4-chlorobenzyl)-10-(hydroxymethyl)-1,6,9,12-tetraazabicyclo[11.3.1]heptadecane-2,5,8,11-tetraone; or a pharma- ceutically acceptable salt, hydrate, solvate, stereoisomer, N-oxide, or tautomer thereof.

15. 15. A compound according to any one of claims 1 to 14, or a pharma- ceutically acceptable salt thereof, for use in the treatment of a PCSK9-mediated disease or disorder.

16. 15. The compound of any one of claims 1 to 14, or a pharma- ceutically acceptable salt thereof, for use in the treatment of a disease or disorder selected from hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral vascular disease, vascular inflammation, and xanthomas.

Citation Information

Patent Citations

  • Compound, and medical composition and use thereof

    CN108239073A

  • Compounds for the treatment of dyslipidemia and related diseases

    US20120252796A1